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Introduction: Pyrazinamide is an integral component of anti-tuberculosis therapy as it has contributed 
to the shortening of treatment. Pyrazinamidase, encoded by pncA, activates pyrazinamide, with 
mutations in pncA being the primary mechanism of resistance topyrazinamide. Defining the full 
repertoire of resistance conferring mutations, which is still unknown, is critical to developing a 
genotypic diagnostic assay and optimizing individualised regimens for more favourable treatment 
outcomes.  
 
Methodology: Random PCR mutagenesis and cloning were used to generate and express apncA mutant 
library harbouring single nucleotide polymorphisms in a pncA-null strain of M. tuberculosis. We 
screened our library in vitro and in vivo against pyrazinamide,and sequencedrecovered libraries to 
determine the enrichment of mutant clones during selection to predict pyrazinamide susceptibility. 
Isogenic pncA mutants underwent phenotypic drug susceptibility testing to validate our screen 
predictions. Proteomics and a modified Wayne’s enzymatic assay were utilized to elucidate the 
molecular basis of pyrazinamide resistance in selected isogenic pncA mutants. 
 
Results: After provisional analysis, predictions for >85% of all possible mutations at the amino acid 
level were made, with 411 and 357 mutations predicted to result in pyrazinamide resistant and 
susceptible phenotypes respectively, and 374 mutants being neither enriched nor depleted. Drug 
susceptibility testing of isogenic pncA mutants showed 100% and 92.86% agreement with provisional 
screen predictions for resistance and susceptibility respectively, with unselected mutants being 
classified as intermediate phenotype and concluded to be susceptible. Proteomics and an enzyme assay 
on selected isogenic mutants revealed reduction of pyrazinamidase and/or its enzymatic function were 
mechanisms of conferring resistance to pyrazinamide. 
 
Conclusion: Random mutagenesis combined with deep-sequencing of isogenic libraries is a promising 
method of simultaneously evaluating multiple SNPs for their ability to confer drug resistant phenotypes, 
and allowed us to provisionally predict phenotypes for 1142 pncA mutants. Subject to completion of 
data analysis, this list may serve as a reference for interpreting sequences/mutations in a genotypic 
based diagnostic assay. In addition to contributing knowledge to the understanding of pyrazinamide 
activity and confirming disruption of the enzymatic activity of pyrazinamidase by selected mutations 
in pncA,  reduction in pyrazinamidase abundance through intragenic pncA mutations was identified as 
a mechanism of pyrazinamide resistance.
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Chapter 1: Introduction 
 
Tuberculosis (TB), caused by the bacterial organism Mycobacterium tuberculosis (M. tuberculosis), 
remains a massive public health threat causing annually as estimated 9.6 million new cases and 1.5 
million deaths1. Pyrazinamide remains a cornerstone of not only current, but potential future treatment 
regimens 2-4, particularly for drug susceptible tuberculosis, as in combination with rifampicin, it allowed 
for the shortening of treatment duration down to six months5-9. In light of the emergence of drug resistant 
tuberculosis, early detection of this resistance would allow for the customization of treatment regimens 
and more favourable patient outcomes.  
 
With developments in medical research and technology, there has been a drive towards faster, genetic 
based diagnostic assays for the detection of drug resistance. This advancement has led to the 
endorsement of Nucleic Acid Amplification Tests (NAAT) for the detection of TB infection and drug 
resistance10. Examples of such are the GeneXpert MTB/RIF (Cepheid, USA) which allows for detection 
of rifampicin resistance, and the Hain MDRplus line probe assay (Hain Lifescience, Germany) which 
allows for the simultaneous detection of rifampicin and isoniazid resistance. The basis of these tests 
however, is that they target specific mutations in defined genes that have been well characterized and 
shown to confer resistance11-18. These tests generate drug susceptibility results within 24-48 hours, 
whereas the conventional phenotypic drug susceptibility tests (dependent on isolating and growing 
M.tuberculosis) can take six to eight weeks. 
 
Phenotypic drug susceptibility testing to pyrazinamide is notoriously challenging and unreliable 19-24. 
These factors coupled with the high commercial cost, need for specialised biosafety facilities and trained 
laboratory staff, means that phenotypic drug susceptibility testing to pyrazinamide is rarely performed 
in many settings24 nor recommended unless in the management of drug resistant tuberculosis 25-27. Given 
the essentiality of pyrazinamide in TB chemotherapy, and the alarming emergence and prevalence of 
drug resistant TB, the introduction and implementation of a rapid, genotypic based assay for detecting 
pyrazinamide resistance is a priority. 
 
Mutations in the pncA gene of M. tuberculosis have been shown to be the primary driver of genetic 
resistance to pyrazinamide 24,28-33, however it is still unclear which specific mutations actually confer 
resistance as mutations have previously been identified along the full length of the 561 nucleotidepncA 
gene24,31-33. Initially it was thought that any  non-synonymous mutation in pncA must have been selected 
by pyrazinamide treatment and would therefore confer resistance, but some mutations have been shown 
to have no effect on drug resistance 34. In addition there are a substantial number of mutations that have 
been associated with both a resistant and susceptible phenotype. A comprehensive list of mutations 
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conferring resistance to pyrazinamide is crucial to the implementation of any genotypic diagnostic 
assay, and various approaches have been proposed35-37. 
 
Molecular biology tools such as site directed mutagenesis38and single-strand recombineering 39-41 have 
been developed, which have allowed for introduction of single mutations into genes in an isogenic 
background of the bacteria. These tools allowed for more rigorous and reliable testing of associations 
between specific mutations and drug resistance. In the case of pncA however, these techniques would 
be laborious and time consuming as it require the generation of 1683 separate mutant strains, thus a 
more efficient and feasible approach is required to comprehensively study the phenotypic consequences 
of mutations inpncA. 
 
This thesis details our unbiased approach to generate a complex library of pncA single point mutations 
in an isogenic strain of M. tuberculosis where the endogenous copy of pncA has been disrupted by the 
insertion of a hygromycin resistance cassette, and then to screen this library to fully characterize the 
full repertoire of resistance conferring mutations. 
 
The remainder of this first introductory chapter serves to highlight the history and importance of 
pyrazinamide in tuberculosis chemotherapy, our current knowledge on the action of pyrazinamide in 
tuberculosis chemotherapy as well as the gaps in current knowledge, and the difficulties associated with 
drug susceptibility testing for pyrazinamide. This chapter includes a problem statement, research 
rationale, and the specific aims and objectives of our work. Chapter two encompasses the methodologies 
used in generating our pncA mutant library, screening assays to determine mutations conferring 
pyrazinamide resistance, and in elucidating the mechanisms of resistance. Chapter three is a 
representation of the results obtained and is followed by a discussion of our findings, limitations of our 
work, and concluding remarks.  
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1.1. Role of pyrazinamide in tuberculosis chemotherapy 
Although pyrazinamide is an essential cornerstone of the current treatment regimens, particularly drug 
susceptible tuberculosis, prior to the 1970’s it was mainly utilized as a second-line TB agent for the 
treatment of drug resistant TB or in cases of relapse, due to hepatotoxic side-effects associated with a 
high dose and combination with isoniazid 42,43,44,45,46. The discovery of pyrazinamide as an anti-
tuberculosis agent was different from many other currently used tuberculosis drugs. Soon after its 
discovery it was tested in vivo and shown to have activity. When subsequent in vitro testing was carried 
out, no activity was detected, meaning it would not have been identified in the contemporary approach 
of using in vitro screens as a triage for taking compounds into animal models 9.  
 
1.1.1. Early observations of pyrazinamide in tuberculosis chemotherapy 
First synthesized in 1936 48, pyrazinamide’s use for the treatment of tuberculosis was discovered after 
the initial observation of the anti-tuberculosis effects of nicotinamide 49,50. This work was followed up 
by the testing of nicotinamide analoguesin mouse and guinea pig models of tuberculosis treatment, 
where pyrazinamide was found to be a highly active analogue of nicotinamide against TB51-54. 
Pyrazinamide was tested as a single treatment agent in human trials where it showed sputum conversion 
after four months, however this finding was overshadowed by the later reactivation of the disease 
termed as relapse55. It showed more promising results as a sterilizing agent (the ability to kill “semi-
dormant” or non/slow-replicating persister bacterial populations which are though to lead to relapse) 
when combined with isoniazid42,56-58. Combinations with streptomycin and para-aminosalicylic acid 




Figure 1: Structures of nicotinamide and nicotinamide analogues60. 
 
This result was mirrored when it was shown that almost all other singular or paired combination 
treatment regimens, containing streptomycin, isoniazid, para-aminosalicylic acid, and oxytetracycline, 
tested in a mouse model failed to eradicate TB infection, whereas a longer term “repression” of the 
infection (long period of non-culturability of bacteria after cessation of treatment, now known as the 
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Cornell model of TB dormancy) was observed when isoniazid was used in combination with 
pyrazinamide 61-64. This finding supported the idea that pyrazinamide was able to target a so-called 
“persistent” population of bacteria, unaffected by other drugs. Although the findings of regimens 
combining streptomycin with pyrazinamide in retreatment patients were unsatisfactory due to relapses, 
it was still concluded that the addition of pyrazinamide was beneficial 44. Later in vitro experimentation 
suggested that intermittent use of pyrazinamide produced a lag in growth of the bacteria making it 
suitable for tuberculosis chemotherapy 65.  
 
1.1.2. Pyrazinamide in shortening treatment duration for drug susceptible tuberculosis 
Initial findings in further human trials testing combination treatments with isoniazid, streptomycin, 
rifampicin and thiacetazone 66-69 showed that inclusion of pyrazinamide in experimental regimens 
proved superior for drug susceptible TB, reducing the time to negative culture conversion and relapse 
rates. This finding was corroborated with the findings that the addition of rifampicin or pyrazinamide 
to regimens drastically reduced the necessary treatment duration and rate of relapse in a mouse model 
5. Pyrazinamide and rifampicin were then classified as strong “sterilizing” agents with potential for TB 
treatment5,45. 
 
Pyrazinamide’s use in the treatment of tuberculosis was cemented following several human clinical 
trials specifically testing short-course treatment regimens carried out over the course of three decades 
8,70-80. It was demonstrated that when either rifampicin or pyrazinamide was added to chemotherapy 
regimens, curative treatment duration could be shortened from over twelve months down to nine 
months. If rifampicin and pyrazinamide were utilized together in combinatory regimens, treatment 
could be further reduced to six months, with equivalent or lower rates of relapse6,81-85. This effect was 
attributed to their synergisticrelationship and ability to target slow or non-replicating bacteria, which 
would be unaffected by isoniazid 7,59.  
 
Strangely it was also found that there was no additive benefit to retaining pyrazinamide through the full 
six months of the short-course treatmentin human trials and murine treatment models 73,77,80,86,87, despite 
its potency in sterilization. The combination of all the above mentioned historical findings was pivotal 
in leading to the currently recommended short-course regimen for drug-susceptible TB of a two month 
intensive phase consisting of rifampicin, isoniazid, pyrazinamide and ethambutol for two months, 
followed by a continuation phase of isoniazid and rifampicin for four months 88,89.In the cases of central 
nervous system or bone and joint infections longer therapy (including pyrazinamide) is recommended.  
1.1.3. Pyrazinamide in the treatment of drug resistant tuberculosis 
The crucial activity of pyrazinamide in the treatment of drug-susceptible TB means it has traditionally 
been retained in regimens for the treatment of multi drug resistant (MDR) and extensively drug resistant 
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(XDR) TB, even in the absence of drug susceptibility testing. Although direct evidence of the role of 
pyrazinamide in MDR- and XDR-TB treatment was initially scarce, results from a community-based 
therapy for the treatment of MDR-TB highlighted the inclusion of pyrazinamide in treatment regimens 
as a factor strongly associated with more favourable treatment outcomes 90. This was further 
substantiated by a study in Hong-Kong where it was found that retention of pyrazinamide in 
fluoroquinolone-based MDR-TB regimens resulted in higher cure or treatment completion, and early 
culture conversion 4. Separate trials carried out in Bangladesh 91-93 and Cameroon 94showed highly 
encouraging results in the shortening of MDR-TB treatment duration down to nine to twelve months, 
with both trials including pyrazinamide in the treatment regimens. The WHO now recommends that in 
addition to using four core second line drugs, pyrazinamide should also be routinely utilized as an add-
on agent unless resistance is confirmed from a reliable drug susceptibility test 26,27,89. This applies to 
both the shorter nine to twelve month, and conventional eighteen to twenty-four month regimens for 
the treatment of MDR-TB. 
 
1.1.4. Pyrazinamide in new experimental tuberculosis treatment regimens 
In addition to its use in the treatment of drug-susceptible and drug-resistant TB, pyrazinamide is also a 
crucial component of new experimental regimens, aimed at increasing the efficacy and shortening the 
duration of treatment. Over the last decade, pyrazinamide has been found to have an additive or 
synergistic effect in both animal and human studies when combined with the diarylquinolone, 
bedaquiline 95-101 or the nitroimidazo-oxazine, pretomanid 2,99-103. Pyrazinamide also showed 
effectiveness in reducing the time required for culture negativity and relapse rates in murine treatment 
models when used in combined with rifapentine and moxifloxacin 104. It also displayed efficacy in 
reducing bacterial CFU burden in human 101 and murine 105 EBA studies when included in clofazimine 
containing regimens. In general experimental regimens testing new and/or repurposed drugs in different 
combinations prove less effective in murine and human treatment models when pyrazinamide is 
excluded 95,96,98,99,101-103,106. These experimental findings highlights the importance of pyrazinamide as a 
sterilizing drug and the need to include it in experimental regimens to shorten the duration of TB 
treatment below six months. It is likely a rapid pyrazinamide susceptibility test will be needed to screen 
patients before they start these novel regimens. 
 
 
1.2. The idiosyncratic nature of pyrazinamide 
Despite its unequivocal essentiality in tuberculosis chemotherapy, pyrazinamide remains a strange and 
mysterious drug with controversy and debate following almost every discovery and gaps still remaining 




1.2.1. Entry of pyrazinamide into bacterial cells 
Pyrazinamide is believed to enter the cell through passive diffusion 107,108. Experimental evidence has 
suggested that the entry may be facilitated through an adenosine triphosphate (ATP) dependent 
transport system 109 as shown through competitive inhibition of uptake of [14C]-pyrazinamide by 
unlabelled pyrazinamide and reduction in the uptake of [14C]-pyrazinamide under low temperature 
conditions which abolish active uptake systems. In addition, the authors suggested that the proposed 
transporter was located in the plasma membrane since the addition of arsenate had no effect on 
pyrazinamidase activity but resulted in a reduction of the initial uptake of pyrazinamide, and that a 
mechanism of resistance to pyrazinamide was the failure of strains to take up the drug. The proposed 
transporter however remains unidentified. 
 
1.2.2. Activation of pyrazinamide and biological role of pyrazinamidase 
It was originally though that pyrazinamide was the active drug moiety, which was hydrolysed and 
rendered ineffective 110. We now know pyrazinamide is a pro-drug, which requires conversion to its 
active form, pyrazinoic acid (POA) by the enzyme, pyrazinamidase (PZase or PncA) within the bacterial 
cytoplasm 107. The unique susceptibility of M.tuberculosis is believed to be due to a functional 
pyrazinamidase and inefficient efflux of pyrazinamide/POA 9,107. There has also been evidence 
produced that there is host-mediated activation of pyrazinamide to POA 111,112.  
 
Figure 2: Conversion of nicotinamide/pyrazinamide to respective acid derivatives. 
 
Pyrazinamidase, or nicotinamidase as it is also known, is responsible for the hydrolysis of nicotinamide 
to nicotinic acid which can then be utilized in the generation of nicotinamide adenine dinucleotide 
(NAD+) through the salvage or recycling Preiss-Handler  pathway 113. This was initially believed not to 
be the case in M. tuberculosis due to the deficiency of a nicotinic acid phosphoribosyltransferase 
enzyme 114.  Two putative phosphoribosyltransferase enzymes (PncB1 and PncB2) have since been 
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identified 115, leading to the conclusion that M. tuberculosis can utilize the scavenging/recycling 
pathway 287. 
 
1.2.3. Activity of pyrazinamide against replicating and non-replicating bacteria 
Despite its potent sterilizing activity in vivo, pyrazinamide is considered a poor bactericidal drug in 
vitro as it was shown that even concentrations 50x higher than the minimum inhibitory concentration 
(MIC), were unable to kill more than 76% of the bacterial population 116. It therefore cannot be assigned 
a minimum bactericidal concentration (MBC). Pyrazinamide has more potent activity against semi-
dormant or slow/non-replicating persisters than actively replicating bacteria. It has been shown that 
pyrazinamide was more bactericidal against stationary-phase cultures than log-phase cultures 21,117 and 
against rifampicin-tolerant cultures 117. In the latter metabolic activity of the bacteria was shown to be 
low, by lower incorporation of [3H] uridine into ribonucleic acid (RNA) by viable cells. More recently, 
a group showed that pyrazinamide may have equivalent in vitro bactericidal activity against fast and 
slow growing bacilli when pyrazinamide concentration is higher than 250µg/mL 118. Pyrazinamide’s 
MIC against susceptible M. tuberculosis in vitro has been shown to be between 6.25µg/mL and 
50µg/mL at a pH of 5.5 9,119-121. 
 
1.2.4. Pyrazinamide and external acidic environments 
It is widely believed that pyrazinamide requires an acidic environment to be active against susceptible 
Mycobacterial species. This has been demonstrated in vitro where culture conditions require 
acidification to between pH 4.8 and pH 6.0 in order for pyrazinamide to be active against M. 
tuberculosis 65,116,119,122,123. There islittle to no activity at near-neutral pH in standard culture 
conditions124-126. It is worth noting that lower pH (pH4.8 to 5.5) culture conditions may inhibit the 
growth of the bacteria 65,120,122,123 which has made it difficult to precisely define the role of acid in the 
action of pyrazinamide. The MIC of pyrazinamide is however dependent on the pH of the media being 
utilized, with increases in MIC values being observed as the pH moves from acidic closer to neutral 
21,116,127. Interestingly, the expression of pyrazinamidase does not appear to induced by acid stress 128 
with the optimal range for enzyme function being between pH 6 and pH 8 when utilizing nicotinamide 
as a substrate with purified M. tuberculosis pyrazinamidase 129.  
 
1.2.5. Factors affecting pyrazinamide activity 
It is less appreciated that many external environmental factors other than acid can also enhance the 
activity of pyrazinamide. M. tuberculosis subjected to  anaerobic or microaerobic conditions 130, 
nutrient-starvation 128,131, low incubation temperature 132,133, inhibitors of the M. tuberculosis respiratory 
machinery and compounds which disrupt membrane potential and energetics 108,130,134,135, the efflux 
pump inhibitor reserpine 21,107, ultraviolet light  and some weak acids 131,134, as well as aspirin and 
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ibuprofen 136 is more susceptible to pyrazinamide.  Pyrazinamidase is a metalloenzyme with various 
metal co-factors influencing activity 137, with iron in particular being shown to magnify the effect of 
pyrazinamide and pyrazinoic acid in vitro138. It is interesting that certain conditions such as lower 
incubation temperature 133, efflux pump inhibitors 21,107 and ectopic over-expression of the 
pyrazinamidase enzyme 128,139 appear to nullify pyrazinamide reliance on an external acidic environment 
for in vitroactivity. This is highly suggestive that an acidic external environment may not influence 
pyrazinamide activity directly, but along with other external stress conditions, it induce metabolic 
changes which renders pyrazinamide more active. One possibility is that acid increasesthe accumulation 
of POA.  
 
1.2.6. Intracellular activity of pyrazinamide 
It has been proposed that pyrazinamide is active within macrophages due to an internal acidic 
environment 5,7.  However there have been mixed reports on the activity of pyrazinamide within 
macrophages obtained from humans or animals using in vitro culture systems. Some authors report slow 
bactericidal activity or mostly bacteriostatic (inhibition of growth of bacteria) activity against 
intracellular bacteria 28,122,126,140-142, while other groups have demonstrated no activity of pyrazinamide 
in macrophage treatment models 143-146.  It is interesting that chloroquine, an anti-malarial agent which 
raises phagolysosome pH, had no detrimental effect on pyrazinamide activity in macrophages, although 
chloroquine did itself show activity against M. tuberculosis147. In addition, it is well known that M. 
tuberculosis can inhibitphagosome-lysosome fusion which is required for acidification 148,149, and that 
organelles within macrophages may only be neutral or slightly acidic 150,151. 
 
1.2.7. Pyrazinamide activity in vivo 
If pyrazinamide is predominantly active against semi-dormant or non-replicating persister bacilli 7,123, 
it would be expected that pyrazinamide should be more active during the continuation phase of 
treatment rather than the intensive phase. Early bactericidal activity (EBA) and extended EBA studies 
in human as a measure of the effectiveness of anti-tuberculosis drugs in chemotherapy 59,100,101,152-157 
have shown that pyrazinamide has very little activity within the first two weeks of treatment. 
Furthermore Phase 3 studies have demonstrated activity is not extended beyond 2 months 73,77,80. This 
is supported by similar findings from murine treatment models 5,86,87,158,159. This anomaly has been put 
down to a reduction in acidic environments as inflammation due to the infection subsides 5,7. 
 
 
1.3. Proposed targets/mechanisms of action of pyrazinamide/POA 
Despite extensive research, the precise mechanism/s of action of pyrazinamide remains elusive 9,46,60. 
Researchers have proposed different cellular targets and mechanisms of action for pyrazinamide, and 
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there is some suggestion that the drug may have pleiotropic activity, exerting it effect/s on multiple 
pathways or systems 9,60,128,160-162 rather than a single cellular target, as is the case with many other anti-
tuberculosis agents. 
 
1.3.1. Panthothenate and coenzyme A synthesis 
Pyrazinamide has recently been implicated in the inhibition of panthothenate and coenzyme A (CoA) 
biosynthesis 163. panD encodes for aspartate decarboxylase, which is required for the synthesis of β-
alanine (a pre-cursor to panthothenate, which itself is a pre-cursor for CoA) from L-aspartate 164. It was 
subsequently shown that POA but not pyrazinamide had an inhibitory effect on aspartate decarboxylase 
activity, overexpression of panD conferred resistance to pyrazinamide 165, andsupplementation with β-
alanine 165, panthothenate 162,165 or panthetheine 162 reduced susceptibility to POA. In addition, POA was 
shown to deplete CoA, with mutations in panD abrogating this depletion 166.Molecular docking analysis 
of crystal structures have confirmed potential interaction between a PanD and POA 167. There has 
however been some suggestion that PanD and therefore panthothenate synthesis itself may not be the 
direct target after it was found that panthetheine supplementation of a panCD auxotrophic strain did not 
abrogate susceptibility to pyrazinamide as would be expected 162. 
 
1.3.2. trans-Translation 
It was also proposed that POA inhibits trans-translation 168 via binding to the C-terminal end of 
ribosomal protein S1 (RpsA). trans-Translation is an essential process mediated by transfer-messenger 
ribonucleic acid (tmRNA) and a small basic protein B that rescues and recycles stalled ribosomes during 
the process of translation. This is achieved by tagging the stalled protein and releasing messenger RNA 
(mRNA) for degradation 169. The process is believed to be dispensable during normal growth, but 
critical during stress conditions 169,170. Inhibition of trans-translation may result in an accumulation of 
toxic peptide waste and a shortage in free ribosomes leading to an arrest in translation and eventually 
cell death. Crystal structure analysis supported POA binding to the C-terminus residues of RpsA, which 
are believed to be the binding sites of the tmRNA 171. This hypothesis has been challenged because 
mutations of ssrAor a deletion of SmpB (which encode the tmRNA and small basic protein B 
respectively in M. tuberculosis), which result in a defective trans-translational response, have no effect 
on pyrazinamide susceptibility 172. 
 
1.3.3. Intracellular acidification, membrane potential and cellular energy state 
One of the earliest proposed mechanisms of action for pyrazinamide was based on the drug’s 
requirement for an external acidic environment for in vitro activity.  It was proposed that POA produced 
through catalytic hydrolysis of pyrazinamide exited bacterial cells through diffusion and an as yet 
unidentified efflux mechanism. In an externally acidic environment, negatively charged POA would 
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become protonated to form an uncharged conjugate, HPOA, which could then easily permeate back into 
the bacterial cell where the conjugated form would dissociate to release a proton and POA. This cycle 
would continue until an equilibrium is reached, which is believed to result in accumulation of POA and 
intracellular acidification, ultimately inhibiting vital enzymatic functions leading to death 9,107. Indeed 
it has been shown that an external acidic environment does facilitate intracellular accumulation of POA 
107, but it has been difficult to demonstratea decrease in intracellular pH 107,128.  
 
In keeping with the hypotheses that POA is cyclically shuttled and eventually accumulated 
intracellularly, it was suggested that protonated POA re-entering the cells potentially impaired 
membrane transport (as demonstrated by the reduced uptake of radiolabelled precursors of RNA and 
protein synthesis) and disrupted membrane potential 9,108. Lower membrane potential was reported in 
old non-replicating cells versus replicating cells, and in cells exposed to an acidic environment, with 
POA causing a further reduction in membrane potential in older bacteria. POA-mediated lowering of 
membrane potential could cause a reduction in ATP synthesis leading to a depletion of cellular energy 
reserves and reduced viability. Cells with diminished membrane potential as in the case of non-
replicating and acid-exposed cells would therefore be particularly vulnerable to pyrazinamide. 
 
The observation of a reduction in proton motive force (PMF) and inhibition of ATP synthesis using 
membrane vesicles, and depletion of cellular ATP reserves in a whole cell assay by POA in a dose 
dependent manner supported the idea that a reduction in membrane potential was central to the 
mechanism of action of pyrazinamide173. It would also explain the reduced uptake of essential 
metabolites through impaired membrane transport108, and is consistent with the observations that 
pyrazinamide’s activity is potentiated by cellular respiratory inhibitors. However a recent report found 
no reduction in membrane potential in a whole cell assay at an acidic pH of 5.5 with POA treatment 128.  
 
1.3.4. NAD+ biosynthesis 
Another proposed mechanism of action of pyrazinamide was the inhibition of de novo NAD+ 
biosynthesis. By assaying for production of nicotinic acid mononucleotide (NaMN), it was found that 
both pyrazinamide and POA inhibited the catalytic capacity of quinolic acid phosphoribosyltransferase 
(QAPRTase encoded for by nadC). Molecular docking analysis revealed that pyrazinamide could 
potentially competitively bind to the QAPRTase enzyme thus preventing the synthesis of nicotinic acid 
mononucleotide from quinolic acid (a structural analogue of pyrazinamide and the substrate for 
QAPRTase) and 5-phosphoribosyl-1-pyrophosphate174. It is unlikely that NAD+ biosynthesis is the 
unique intracellular target of pyrazinamide given the discovery of the two putative 
phosphoribosyltransferase enzymes (PncB1 and PncB2) which suggests that the organism can switch 
between the de novo synthesis and the recycling/scavenging Preiss-Handler pathways for the generation 
of NAD+115. However this mechanism cannot be ruled out as we do not fully understand the interactions 
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between these pathways in an in vivo setting. Indeed it is plausible that in a nutrient starved environment 
where scavenging and recycling is limited or non-existent, obstruction of the de novo synthesis pathway 
through POA inhibition of the QAPRTase catalytic function may be detrimental to the organism. 
Competitive binding and inhibition of the QAPRTase enzyme by pyrazinamide itself however would 
be highly unlikely as strains lacking a functional pyrazinamidase should remain susceptible to 
pyrazinamide.  
 
1.3.5. Fatty acid synthesis 
Fatty acid synthase I (FAS-I) of M. tuberculosishas also been proposed as a target, after it was found 
that over-expression of the fasI gene from Mycobacterium avium, M. tuberculosis and Mycobacterium 
bovis BCG all resulted in resistance to the pyrazinamide analogue 5-Cl-PZA in Mycobacterium 
smegmatis 175. The authors went on to report inhibition of FAS-I activity in Mycobacterium smegmatis 
and M. tuberculosis by 5-Cl-PZA, as well by pyrazinamide and POA in M. tuberculosis at an acidic pH 
(pH 6.0), but no effect on FAS-I by pyrazinamide and POA at pH 6.8. In addition they showed no effect 
on FAS-I in M. bovis BCG with pyrazinamide but inhibition with POA, consistent with previous 
findings that M. bovis BCG is inherently resistant to pyrazinamide as it lacks a functional 
pyrazinamidase enzyme 176,177. The author’s findings on inhibition of FAS-I was corroborated by similar 
observations using pyrazinamide, POA or closely related structural derivatives 178,179. It was proposed 
that pyrazinamide and other analogues reversibly bound to M. tuberculosis FAS-I, with pyrazinamide 
competitively inhibiting the binding of dihydronicotinamide-adenine dinucleotide phosphate 
(NADPH). POA was thought to have a different biological effect as it did not competitively displace 
pyrazinamide 180,181.  
 
As in the case of the hypothesis of pyrazinamide binding the QAPRTase enzyme, it would be unlikely 
that FAS-I is the single, direct target of pyrazinamide, as susceptibility to pyrazinamide would be 
retained in strains lacking a functional pyrazinamidase enzyme. It is worth noting that the 
concentrations of pyrazinamide and POA utilized in the abovementioned experiments were well above 
the MIC for drug susceptible M. tuberculosis, and concentrations observed in a pharmocokinetic study 
9,182. The proposed mechanism of direct FAS-I inhibition by pyrazinamide and POA has been questioned 
after findings that pyrazinamide and POA showed no inhibitory effect on fatty acid synthesis mediated 
through FAS-I in experiments using whole cell and whole cell lysates ofM. tuberculosis and M. 
smegmatis, and purified M. smegmatis FAS-I 160. The authors suggested that any effect on fatty acid 
synthesis was indirect and rather a response to inorganic acid stress. Indeed it is plausible that fatty acid 
synthesis is affected in an indirect manner given that fatty acid synthesis is dependent on CoA, which 




1.3.6. Immune modulation 
Pyrazinamide has also been implicated in potentially having a role in host immune modulation during 
the course of treatment. It has been shown that pyrazinamide treatment significantly reduced the release 
of pro-inflammatory cytokines and chemokines in a murine model of infection 183, and that 
pyrazinamide promoted autophagy and phagosomal maturation 184. It is also interesting to note that 
pyrazinamide induced a pro-inflammatory in response to Leishmania major infection in vivo47.  More 
recently it has been proposed that pyrazinamide may act as an anti-virulence agent by affecting 
phthiocerol dimycoserate (PDIM) synthesis166. Further investigation is however required given the 
findings of Grosset and colleagues in immune-competent and immune-deficient murine treatment 





Figure 3: Summary of proposed targets/mechanisms of action of pyrazinamide. Blue boxes highlight 
potentially passive import through diffusion. Yellow box indicates potentially passive export through diffusion. 
Copper boxes highlight potentially energy dependant transporters. Grey arrows indicate proposed cycling 
hypothesis 9,107. Purple arrow indicate potential host activiation of pyrazinamide 111,112. Green arrow indicates 
potential host immune modulation by pyrazinamide 184. Solid black circles indicate postulated targets of 
pyrazinoic acid. PZA = pyrazinamide, POA- = negatively charged pyrazinoic acid, PZase = pyrazinamidase, H+ 
= proton, HPOA = protonated pyrazinoic acid, PMF = Proton Motive Force, ATP = Adenosine Tri-Phosphate, 
Mas = Mycocerosic acid synthase, Ppsa-E = Phenolphthiocerol synthesis type-I polyketidesynthase, PDIM = 
Phthiocerol dimycoserate, NadC = Quinolic acid phosphoribosyltransferase, NAD+ = Nicotinamide Adenine 
Dinucleotide, RpsA = Ribosmal Protein S1, PanD = Aspartate Decarboxylase, CoA = Co-enzyme A, FAS-I = 
Fatty Acid Synthase-I. 
 
 
1.4. Genetic mechanisms of resistance to pyrazinamide 
It is estimated that 16.2% of all TB cases harbour resistance to pyrazinamide with the pooled prevalence 
of pyrazinamide resistance in MDR-TB cases being around 60.5% 24, although this number may be as 
high as 85% in certain regions 185,186, and as high as 93% in fluoroquinolone resistant MDR-TB cases 
187. Although multiple mechanisms of resistance to pyrazinamide have been suggested, related to 
recently proposed modes of action, the primary mechanism of resistance is analogous to that of the drug 
isoniazid, which is also an analogue of nicotinamide. Isoniazid is a pro-drug which requires intracellular 
conversion to its active form, by the catalase-peroxidase (encoded by the katG gene) of M. tuberculosis. 
Mutations in katG which cause loss of enzymatic conversion of isoniazid are the primary mechanism 
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of high level resistance in clinical isolates 12,17,18,188-191. Similarly mutations within pncA, encoding for 
the pyrazinamidase, that result in loss or reduction of pyrazinamide activation are associated with 
primary high level resistance 20,177,192-195. 
 
1.4.1. Mutations in M. tuberculosis pncA 
A breakthrough finding in understanding the molecular basis of resistance to pyrazinamide was the 
identification of the 561 nucleotide pncA gene in M. tuberculosis. It was discovered that pyrazinamidase 
activity and susceptibility to pyrazinamide could be restored in M. bovis BCG and pyrazinamide 
resistant strains of M. tuberculosis by complementation with wild type pncA from M. tuberculosis28. 
Subsequently it was shown that resistance to pyrazinamide could be conferred via intragenic non-
synonymous single nucleotide polymorphisms and frameshift mutations or mutations in the putative 
promoter region of pncA resulting in a decrease or loss of pyrazinamidase activity 28,29,195-201. M. bovis 
and M. bovis BCGboth carry a non-synonymous single nucleotide polymorphism (histidine to aspartic 
acid substitution at codon 57 - H57D) in the pncA gene and are intrinsically resistant to pyrazinamide28.  
 
Given that pyrazinamidase is part of the NAD+ salvage pathway in TB which may be dispensable due 
to the presence of a de novo synthesis pathway for NAD+, it is likely that loss of function mutations in 
pncA do not result in loss of fitness 162. This idea is supported by the fact that pncA is a non-essential 
gene in M. tuberculosis202-206and loss of pyrazinamidase activity in M. bovis does not affect virulence 
in animal hosts. The diversity of mutations which can occur along the full length of the gene 207 is unlike 
resistance to isoniazid where a single substitution in katG (S315T) accounts for the vast majority of 
mutations 191. This is because the S315T mutation results in an enzyme that retains some catalase 
activity whilst losing the ability to activate isoniazid 208. The absence of a similar dominant substitution 
that retains enzymatic activity with loss of drug activation also suggests that pyrazinamidase is not 
essential for full virulence in humans. There is some noticeable clustering of mutations at residues 3-
17, 61-85, and 132-143 29,32,33 believed to be residues related to the catalytic site of the enzyme, the 
metal co-ordinating sites, or essential to the structure of the enzymatic core 31,129,209-213. Mutations also 
occur outside of these regions indicating a more complex relationship between mutations and enzymatic 
function. 
 
Investigations into associating specific pncA genotypes to resistant phenotypes have so far been carried 
mainly by sequencing of clinical isolates of M. tuberculosis with resistance to pyrazinamide (identified 
by phenotypic drug susceptibility testing or measurement of pyrazinamidase activity as a proxy for 
pyrazinamide resistance). Some studies have alsoderived spontaneous resistant mutants to 
pyrazinamide or POA. The proportion of pyrazinamide resistance based on intragenic mutations in pncA 
or in its promoter is between 70% and 97% depending on geographic location 29,31,32,195-198,200,214-220. 
Unexplained resistance (pyrazinamide resistance without the occurrence of mutations in pncA or its 
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promoter) is often attributed to errors in pyrazinamide drug susceptibility testing 19, although alternate 
resistance conferring mutations may occur. In addition polymorphisms in pncA which do not confer 
resistance to pyrazinamide have been identified34,220. 
 
To date, the most comprehensive attempt to associate pncA mutant genotypes to pyrazinamide resistant 
phenotypes was a multi-centre study which sequenced the pncA gene and promoter from 843 
pyrazinamide resistant and 1107 pyrazinamide susceptible clinical isolates resulting in the identification 
of 239 mutations believed to confer resistance to pyrazinamide 32. In addition, two systematic reviews 
were recently undertaken in an attempt to correlate the association between mutations in pncA and 
clinical pyrazinamide resistance 24,33, and identified 641 and 608 unique mutations in pncA and/or its 
promoter region respectively, which are believed to confer resistance to pyrazinamide.These mutations 
include single nucleotide polymorphisms, insertions and deletions. Indeed the wide body of data that 
currently exists is useful in our attempts to do genotype-phenotype associations, however these data-
sets may be skewed through the identification of pyrazinamide resistant clinical isolates, which is 
drastically influenced by drug susceptibility testing and by the inherent genetic diversity of the isolates. 
There has been no literature produced where pncA mutants have been introduced and tested in an 
isogenic mycobacterial background to concretely associate the genotypes with pyrazinamide resistance, 
with the only expression of mutants (albeit a small subset) being undertaken in Escherichia coli (E. 
coli) to purify the pyrazinamidase in order to study enzyme activity in relation to resistance 201,221.  
 
1.4.2. Mutations in M. tuberculosis rpsA 
Mutations in rpsA have been suggested as an alternate mechanism for pyrazinamide resistance in M. 
tuberculosis as RpsA has been proposed as a target for the drug 168. It has been shown that ectopic over-
expression of rpsA does confer resistance to pyrazinamide, and POA binding to the C-terminus of RpsA 
was abolished in a “low-level” pyrazinamide resistant clinical isolate (MIC = 200-300µg/mL) with no 
mutations in pncA, but a deletion of codon 438 of rpsA168. Subsequent sequencing and analysis of 
clinical isolates has however yielded mixed results. While some groups have identified non-
synonymous rpsA mutations in pyrazinamide resistant, wild typepncA (pncAWT) clinical isolates 222, 
there have also been non-synonymous rpsA mutations identified in pyrazinamide susceptible pncAWT 
clinical isolates 223. Additionally there still remain pyrazinamide resistant pncAWT clinical isolates with 
no rpsA mutations 220,223-226. It is worth noting that Gu and colleagues identified 26 pyrazinamide 
resistant and 6 pyrazinamide susceptible isolates containing mutations diversely located throughout 
rpsA (and not restricted the the C-terminal end as suggested by Shi and colleagues). However it was not 
clear if the isolates also contained mutations in pncA or not. It is also interesting that a variety of rpsA 
mutations have also been identified in the intrinsically pyrazinamide resistant Mycobacterium canetti 
(M. canetti), which has a synonymous pncA mutation believed not to affect pyrazinamidase activity, as 
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well as a panD mutation227,228. It is therefore unclear whether mutations in rpsA plays any role in 
conferring resistance in a clinical setting. 
 
1.4.3. Mutations in M. tuberculosispanD 
The role of panD in M. tuberculosis pyrazinamide resistance was proposed after Zhang and colleagues 
isolated and whole genome sequenced five in vitro selected pyrazinamide resistant mutants lacking 
mutations in pncA and rpsA, which resulted in the identification of mutations in the panD gene of M. 
tuberculosis163.It was then shown that a pyrazinamide resistant clinical isolate as well as M. canetti also 
harboured mutations in panD. Subsequent work derived 30 in vitro selected pyrazinoic acid resistant 
mutants with seven different panD mutations, and showed that ectopic over-expression of either wild 
type or mutated panD conferred resistance to POA and resulted in a 3-fold increase in pyrazinamide 
MIC 165. Apart from the isolate tested by Zhang and colleagues, there have been no further clinical 
isolates identified with panD mutations so it is unclear if this mechanism of resistance is important 
clinically220. 
 
1.4.4. Potential alternate resistance conferring mechanisms 
Loss of function frameshift mutations within the mas and ppsA-E genes have also been proposed as a 
potential resistance conferring mechanism to pyrazinamide and POA.These mutants were only derived 
in the absence of glycerol in vitro 166. These genes are required for PDIM synthesis which has been 
shown to be dispensable in vitro 203,205,229,230 but results in attenuation when lost in vivo 204,231,232. Loss 
of PDIM synthesis has occurred spontaneously during in vitro passage and no mutations in these two 
genes have yet been identified in clinical isolates 233,234, so it seems unlikely that this pathway constitutes 
a clinically relevant resistance mechanism.  
 
M. smegmatis has two functional pyrazinamidase enzymes, PncA and PzaA, which can confer 
susceptibility to pyrazinamide 202,235,236, but this organism is intrinsically resistant to pyrazinamide, 
which is thought to be due to an as yet unidentified efflux transporter of POA107. Given that 
pyrazinamide and POA activity are enhanced by efflux pump inhibitors, investigation into drug efflux 




1.5. Drug susceptibility testing 
Drug susceptibility testing (DST) for M. tuberculosis can be broadly divided into phenotypic and 
genotypic based tests, and is essential in clinical settings to identify resistance to antibiotics utilized in 
the treatment of TB in order to ensure the curing of patients, as well as to reduce or prevent the 
17 
 
transmission of TB and further emergence of drug resistance. Phenotypic drug susceptibility testing is 
based on measurements of viability such as growth inhibition on solid or in liquid culture media, or the 
production of metabolites or substrates, in response to drug treatment. Genotypic assays are based on 
the detection or identification of genetic mutations within genes known to result in a drug resistant 
phenotype 237. 
 
1.5.1. Phenotypic drug susceptibility testing for pyrazinamide resistance 
Phenotypic drug susceptibility testing for pyrazinamide is complicated, technically challenging and at 
times unreliable 19,21,23,238,239. Initial attempts at pyrazinamide susceptibility testing on solid media 
proved difficult primarily due to the requirement of acidity and the presence of culture supplements 
which impaired the growth of mycobacteria. A lack of growth inhibition when a dense inoculum was 
used was also observed and believed to be due to localized neutralization of pyrazinamide in the media 
119,240-245. Also the need to prepare the media in house as no commercially available alternate options 
has made reproducibility a problem120,245,246.  
 
Adaptations and modifications to solid agar testing for improved detection of pyrazinamide resistance 
have been tested 120,193,241,242,245,247. Solid media testing is currently not recommended by the WHO with 
susceptibility testing in liquid media being the preferred method 25-27.  
 
Liquid based pyrazinamide susceptibility testing has mainly been carried out in the discontinued 
radiometric Bactec 460TB system and the currently available Bactec MGIT 960 PZA system (Becton 
Dickinson and company, USA) at pH 6.0 and pH 5.9 respectively using a 100µg/mL critical 
concentration. These commercial assays are expensive, and require trained laboratory personnel and 
specialized biosafety level III (BSL-III) facilities 248-250 so they have not been widely used in resource 
poor settings. Although standardized, these systems have a significant false-resistance rate and suffer 
from lack of reproducibility19-23,238,239,251-258. Testing outcomes have been shown to be influenced by 
conditions such as acidification of the media, inoculum size, growth phase dependency and additives 
such bovine serum albumin (BSA) and polyoxyethylene stearate (POES) 21,65,119,259,260. It is worth noting 
that susceptibility testing to pyrazinamide is not included in the WHO yearly proficiency testing 23 and 
there has been some suggestion that the critical concentration for pyrazinamide susceptibility testing 
should be increased 21,121,198,261. 
 
1.5.2. Alternate methods for detection of pyrazinamide resistance 
Methods have also been developed to detect the loss of pyrazinamidase activity as a marker for loss of 
function mutations in pncA. The Wayne assay 262 is a colorometric assay based on the reaction of POA 
with ferrous ammonium sulphate. Mutations in pncA causing loss of pyrazinamidase activity result in 
no colour change of the ferrous ammonium sulphate (negative result) since no POA is available to 
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complex with the ferrous iron, whereas, a functional pyrazinamidase converting pyrazinamide to POA 
causes the development of a pink/red colour upon addition of ferrous ammonium sulphate due to the 
formation of a complex between POA and the ferrous iron.  
 
The method was originally carried out by adding ferrous ammonium sulphate to LJ media on which the 
bacteria was grown in the presence of pyrazinamide and looking for the development of a pink/red 
coloured band on the media. Despite being a good indicator of loss of pyrazinamidase function and 
therefore pyrazinamide resistance, the assay is highly subjective, has poor sensitivity and may also 
predict false resistance and susceptibility 22,193,260. The method has however been adapted over the years 
to be used with liquid culture systems leading to the development of a more quantitative assay which 
can be combined with spectrophotometry 263.  
 
Additional methods such as microscopic observation drug susceptibility or MODS 264 flow cytometry 
265 viability indicators 266,267, a PCR amplified and in vitro synthesized pyrazinamidase assay 268,269 and 
colometric methods substituting pyrazinamide with nicotinamide 270,271  have also been developed for 
use in pyrazinamide susceptibility testing but have not gained much traction. 
 
1.5.3. Genotypic susceptibility testing for pyrazinamide resistance 
The use of genotypic based methods or nucleic acid amplification tests (NAAT such as the GeneXpert 
MTB/RIF (Cepheid, Sunnyvale, CA, USA) and MTBDRplus (Hain Lifescience, Nehren, Germany) 
have been endorsed for use by the WHO as these tests have allowed more rapid time-to-diagnosis of M. 
tuberculosis and potential drug resistance to rifampicin and isoniazid which allows for more timely 
intervention with regards to selection of treatment regimens 10. The GeneXpert MTB/RIF relies on the 
polymerase chain reaction (PCR) amplification and overlapping molecular beacon detection of 
mutations within an 81 base pair region of the M. tuberculosis rpoB gene known as the rifampicin 
resistance determining region (RRDR) for identification of rifampicin resistance 11 in under two hours 
excluding sample preparation 272, while the MTBDRplus is based on PCR amplification and 
hybridization of complementary  fragments to a line probe strip for the detection of mutations within 
the RRDR for identification of rifampicin resistance, as well as specific mutations within katG and the 
promoter region of inhA 188,273-275 for determination of isoniazid resistance, in 6 to 48 hours 276-278. A 
line-probe assay for pyrazinamide has been developed 36,279,280 but has not yet been fully evaluated 
clinically. However such tests will only be able to determine if a mutation is present within pncA and 
will not be able to distinguish between resistance conferring and non-conferring mutations.   
 
Genotypic susceptibility testing for pyrazinamidebased on PCR amplification and sequencing of the 
full length of pncA and its promoter 29,32,197,225,281 or through whole genome sequencing 282 is an alternate 
approach that has the advantage of being able to detect specific mutations. For example, it is possible 
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to detect mutations in pncA directly from clinical specimens (sputum samples) in under 48 hours using 
PCR and sequencing 37. 
 
Genotypic testing approaches require that the genotype-phenotype relationship of all pncA mutations is 
known, and limitations in susceptibility testing has made this challenging. Genotypic methods could be 
expanded to include rpsA and panD, however their role in improving susceptibility testing to 
pyrazinamide requires further evaluation 220,222,223,225,283. 
 
 
1.6. Problem Statement 
Emergence of drug resistant tuberculosis has compromised TB control. Rapid genetic based assays for 
detection of drug resistance will allow for individualized treatment regimens and improve patient 
outcomes. The development of a genetic based test requires detailed knowledge of all the mutations 
that can confer drug resistance. In the case of pyrazinamide, this knowledge is lacking. 
 
 
1.7. Research Rationale 
Mutations within M. tuberculosis pncAare the primary mechanism of resistance to pyrazinamide and 
need to be analysed in a rapid genetic test for pyrazinamide resistance. The diversity of pncA mutations, 
the occurrence of mutations in pncA that do not confer resistance, and the variability of phenotypic drug 
susceptibility testing means that the genotype-to-phenotype associations of pncA mutations need to be 
accurately defined to develop a genetic based diagnostic assay for detection of pyrazinamide resistance. 
Current knowledge of resistance conferring mutations is incomplete and based on sequencing of clinical 
isolates. A comprehensive screen of the full repertoire of pncA mutants in an isogenic background 




Our study aims to generate a pool of isogenic M. tuberculosis clones, each harbouring a single 
nucleotide polymorphism representing every possible PncA mutation. We then intend to use in vitro 




 Using PCR random mutagenesis to generate a mutant library of the M. tuberculosispncA gene 
containing every possible single nucleotide polymorphism (SNP). 
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 Transform the pncA mutant library into an isogenic M. tuberculosis strain which has an 
insertionally inactivated pncA. 
 Develop and optimize an in vitro phenotypic drug screen using pyrazinamide to select for 
bacterial clones containing pncA mutations which confer resistance. 
 Phenotypically screen thepncA mutant library in a murine model using pyrazinamide 
monotherapy to select for bacterial clones containing pncA mutations which confer resistance. 
 Use conventional phenotypic drug susceptibility testing to validate if selected pncA mutants 
confer resistance to pyrazinamide. 
 Use quantitative mass spectrometry and enzymatic assays to investigate the structural basis by 




Chapter 2: Materials and Methods 
 
2.1. Bacterial strains, media and materials 
We used E. coli DH5α (a gift from the Rubin lab at the Harvard School of Public Health, and M. 
tuberculosis H37Rv (sAY101) and H37RvΔpncA (a gift from Dr. Valerie Mizrahi and Dr. Helena 
Boshoff 202) in this study. All plasmids and strains utilized and generated through the course of this 
work are listed in supplementary table 1 and supplementary table 2 respectively. Unless otherwise 
specified, M. tuberculosis were grown either in 7H9 broth or on 7H10/7H11 agar while E. coli DH5α 
was grown in LB broth or on LB agar. All media formulations are provided in the Appendix section of 
this dissertation. Zeocin (R25001, Thermo Fisher Scientific, USA) was used at 50 µg/mL and 20 µg/mL 
for E. coli and M. tuberculosis, respectively. Hygromcyin B (H0654, Sigma Aldrich, USA) was used at 
50 µg/mL for M. tuberculosis. For storage of strains as stocks or titres, E. coliand M. tuberculosis strains 
were grown to O.D.600 ≈ 1.2 and stored in 1mL aliquots at -80°C. Pyrazinamide (P7136, Sigma Aldrich, 
USA) and pyrazinoic acid (P56100, Sigma Aldrich, USA) stocks of 40mg/mL and 100mg/mL were 
prepared in water and DMSO (D8418, Sigma Aldrich, USA) respectively. All strains were grown at 
37°C. All DNA oligonucleotides for PCR amplification were purchased from Integrated DNA 
Technologies (USA) and are listed in supplementary table 3. Other reagents and materials catalogue 
numbers and suppliers will be specified where required. 
 
2.2. Basic methodologies 
Due to the standardised nature of the primary molecular biology tools utilized in generating our control 
strains, as well as our pncA mutant library, the principal methodologies, standard reaction 
concentrations and conditions will be detailed initially in the section below, with any specific changes 
to protocol being detailed where relevant.Examples of reaction volumes and cycling conditions are 
represented below the relevant methods. 
 
2.2.1 PCR amplification 
All PCR amplification reactions with the exception of the error-prone mutagenesis PCR (which will be 
detailed in section 2.4.) were carried out in a standardized manner using KOD Hot Start 
DNAPolymerase (71086-3, Merck-Millipore, USA). The volume of DNA template for added to 
reactions for PCR amplification varied between 0.4 uL for amplification from plasmid DNA to 2.5 µL 
for amplification from Hain GenoLyse DNA extractions. Reactions were carried out in 50µL volumes 
with reagents at the following final concentrations: 1x PCR Buffer, 5% DMSO, 0.4mM each dNTP, 
0.5µM forward primer, 0.5µM reverse primer, 1 unit of KOD Taq polymerase and nuclease free water 
(129114, Qiagen, Germany) up to the final 50 µL reaction volume. PCR reaction started with a 2 minute 
incubation at 94°C for denaturation of DNA and activation of the polymerase. Cycling started with a 
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15 second incubation at 98°C, followed by 30 second annealing and extension at 68°C. Cycling 
annealing temperatures and cycling extension times are unique to the primer pairs utilized and size of 
the PCR product being amplified respectively and will be specified where necessary. Final extension 
was carried out at 68°C for 5 minutes. Cycling extension time was kept standard at 1 minute for PCR 
products less than 1kb, with 30 second added on to the extension time for every additional 500 base 
pairs to be amplified. 
DNA template Variable 
2x KOD PCR buffer 25 µL 
dNTPs (2mM each) 10 µL 
DMSO 2.5 µL 
Forward primer (10µM) 2.5 µL 
Reverse primer (10µM) 2.5 µL 
KOD Hot Start DNA polymerase (1u/µL) 1 µL 
Nuclease free water Up to 50 µL 
Total 50 µL 
 
94°C 2 minutes  
98°C 15 seconds 
x 40 cycles *°C 30 seconds 
68°C 1minute/kb, 30 sec/0.5kb thereafter 
68°C 5 minutes  
4°C Hold  
 
2.2.2.  Restriction Digests and dephosphorylation 
All restriction digests were carried out in a standardized manner using restriction enzymes purchased 
from New England Biolabs. Reactions were carried out in a 50 µL reaction volume containing the 
following at their final concentrations: 2µg of vector/PCR product, 1x digest buffer (NEB supplied 
buffer specific to enzymes), 1x BSA (NEB supplied 100x stock), 50-100 units of Restriction Enzyme/s 
(no more than 5 µL or 10% of total reaction volume), and nuclease free water up to 50 µL. In the case 
of double digests, an appropriate digest buffer was selected using the NEB guide and concentration of 
enzyme was adjusted according to the compatibility of restriction enzymes to the digest buffer. 
Restriction digests were carried out at 37°C over-night. Dephosphorylation was carried out by adding 
2 units of Alkaline Phosphatase (EF0651, Thermo Fisher Scientific, USA) to post-digested reactions 
and incubating at 37°C for 30 minutes followed by enzyme inactivation at 75°C for 10 minutes. 
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DNA (2 µg) Variable 
10x Digest Buffer 5 µL 
100x BSA 0.5 µL 
Enzyme 1 2.4 µL 
Enzyme 2 2.4 µL 
Nuclease free water Up to 50 µL 
Total 50 µL 
 
2.2.3. Purification of PCR and restriction digest products 
All purification of PCR and restriction digest products was performed by spin-column purification 
following gel extraction. Briefly, all products were run on a 0.9% agarose gel prepared with 1x TAE 
buffer. Gel electrophoresis was carried out at a constant 150V for 30 minutes at 400mA. Products of 
appropriate sizes were visualized and excised using the Bio-Rad ChemiDoc MP Imaging system for 
UV translumination. Gel slices were then dissolved and DNA purified using the QIAquick Gel 
Extraction Kit (28706, Qiagen, Germany), as per manufacturers recommended protocol with the 
exception that purified products were eluted in nuclease free water rather than the provide elution buffer. 
 
2.2.4. Ligation and dialyzation 
Ligation reactions were performed under standardized conditions using T4 DNA Ligase (Thermo 
Scientific, EL0011). Reactions were carried out in a 20 µL total volume containing 50ng of vector 
DNA, 1x supplied Ligase Buffer, 1 Weiss unit of T4 DNA ligase, 10:1 molar ratio of insert DNA 
(calculated using online resource: http://www.insilico.uni-duesseldorf.de/Lig_Input.html) and nuclease 
free water up to 20 µL. Ligation reactions were incubated at 22°C for 4 hours. Ligation reactions were 
dialyzed on 0.025µM nitrocellulose membranes (Merck Millipore, VSWP02500) on de-ionized water 
for 30 minutes prior to transformations. 
Vector (50ng) Variable 
Insert (10:1 molar ratio to vector Variable 
10x T4 Ligase Buffer 2 µL 
T4 DNA Ligase (5 Weiss units/µL) 0.2 µL 
Nuclease free water Up to 20 µL 
Total 50 µL 
2.2.5. E. coli transformations 
E. coli transformations were performed using in-house prepared E. coli DH5α electro-competent cells. 
All steps of preparation of electro-competent cells were carried out on ice. Cultures of E. coli DH5α 
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were grown to O.D.600 ≈ 0.8 in LB broth overnight at 37°C and kept on ice for 10 minutes. Cells were 
harvested by centrifugation at 3000x g for 15 minutes at 4°C and washed by resuspension in a half-
volume of ice-cold water. The suspension was centrifuged at 3000x g for 15 minutes at 4°C following 
which the supernatant was discarded. Washing of cells was carried out three times with the resuspension 
volume being halved with each successive wash. Washed cells were re-suspended in 1/100th the initial 
starting culture volume of ice-cold water. Competent cell aliquots (50 µL) were snap frozen in bath 
containing pure ethanol with dry-ice, and stored at -80°C until required. Transformations were carried 
out as follows. E. coli DH5α electro-competent cells were thawed on ice prior to the addition of 5µL 
dialyzed ligation product, following which the mixture was added to a pre-chilled 0.2cm Gene Pulser 
cuvette (165-2086, Bio-Rad,) and allowed to sit on ice for 30 minutes. Electroporation was carried out 
at 2500V, 25µF and 1000Ω using the Bio-Rad GenePulser Xcell electroporator. Electroporation 
cuvettes were incubated on ice for 2 minutes prior to the addition of 1mL of SOC media for the recovery 
of transformants. The suspension was transferred to a 2mL micro-centrifuge tube and incubated shaking 
at 37°C for 1 hour. A 1:10 dilution and the remaining suspension was then plated LB agar containing 
appropriate selective antibiotic and incubated overnight for growth of transformant colonies. In the case 
of transformation of the candidate pncA mutant library, 500 µL of recovered cells in SOC medium was 
plated on LB agar containing zeocin at the appropriate concentration in 120mm large plates. 
 
2.2.6 Isolation of plasmid DNA 
Plasmid DNA was isolated from E. coli by cell-lysis and spin-column isolation and purification using 
the QIAprep Spin Miniprep Kit (27106, Qiagen, Germany) as per manufacturer’s protocol. Plasmid 
DNA from our E. coli pncA mutant library (pAY230) was isolated using the EndoFree Plasmid Maxi 
Kit (12362, Qiagen, Germany) as per manufacturer’s protocol. 
 
2.2.7. M. tuberculosis transformation 
M. tuberculosis transformations were performed using in-house prepared electro-competent cells which 
were prepared fresh for each transformation. Cultures of M. tuberculosis were grown to O.D.600 ≈ 0.8 
in 7H9 broth at 37°C. Cells were harvested by centrifugation at 3000x g for 15 minutes at 4°C and 
washed by resuspension in a half-volume of 10% glycerol. The suspension was centrifuged at 3000x g 
for 15 minutes at 4°C following which the supernatant was discarded. Washing of cells was carried out 
three times with the resuspension volume being halved with each successive wash. Washed cells were 
re-suspended in 1/10th the initial starting culture volume of 10% glycerol. Transformations were carried 
out as follows. Plasmid DNA (100ng in a 5µL volume) was added to 450µL of freshly prepared 
electrocompetent cells, following which the mixture was added to a 0.2cm Gene Pulser cuvette (Bio-
Rad, 165-2086) and allowed rest for 15 to 30 minutes. Electroporation was carried out at 2500V, 25µF 
and 1000Ω using the Bio-Rad GenePulser Xcell electroporator. 1mL of 7H9 broth was added 
immediately to the cuvette for the recovery of transformants. The suspension was transferred to a 30mL 
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inkwell culture vessel and incubated shaking at 37°C overnight. A 1:10 dilution and the remaining 
suspension was then plated 7H10 agar containing appropriate selective antibiotic and incubated for 
anywhere between two and four weeks for growth of transformant colonies. In the case of 
transformation of the pncA mutant library, 500 µL of recovered cells in 7H9 broth was plated on 7H10 
agar containing hygromycin and zeocin at the appropriate concentrations in 120mm large plates. 
 
2.2.8. Sanger sequencing 
All Sanger sequencing reactions were carried out using standardized conditions using the BigDye 
Terminator v3.1 Cycle Sequencing Kit (4337455, Thermo Fisher Scientific, USA). Reactions were set 
up in 10 µL reactions as follows: 20ng template DNA in the form of purified PCR product, 1µL BigDye 
Terminator 3.1 Ready Reaction Mix, 1x BigDye™ Terminator Sequencing Buffer, 0.32µM sequencing 
primer and water to the 10µL reaction volume. Reactions were incubated at 96°C for 1 minute, followed 
by 25 cycles of 96°C for 10 seconds, 50°C for 5 seconds and 60°C for 4 minutes using a Bio-Rad T100 
Thermocycler. Samples were then held at 4°C until removed.  
DNA (5ng/µL) 4 µL 
Ready Reaction Mix 1 µL 
5x Sequencing buffer 2 µL 
Primer (3.2 µM) 1 µL 
Nuclease free water 2 µL 
Total 50 µL 
 
Sequencing reactions were then purified. To the 10 µL reaction, we added 5 µL of pH 5.2 sodium 
acetate (S7899, Sigma Aldrich, USA) and 50 µL of 100% ethanol. Samples were vortexed vigorously 
and centrifuged at 3500x g for 15 minutes. Following centrifugation, all liquid was removed by turning 
tubes/plates upside down on absorbent paper and centrifuging at 100x g for 1 minute. Immediately, 150 
µL of ice cold 70% ethanol was added to samples, vortexed and 3500x g for 5 minutes. Once again, all 
liquid was removed by turning tubes/plates upside down on absorbent paper and centrifuging at 100x g 
for 1 minute. Samples were then placed uncovered in a Bio-Rad T100 thermocycler at 50°C for 5 
minutes to dry products. Products were then submitted to the Africa Centre Sequencing Core following 
which samples were reconstituted with formamide and run on an ABI Prism 3130 sequencer (Thermo 
Fisher Scientific, USA). Sequence results in the form of ab1 files were imported into Geneious v6 
software (Biomatters Ltd.). Reads were aligned to a reference wild type pncA sequence and mutations 




2.3. Construction of pncA expression vector 
Wild type pncA was PCR amplified as previously described from pAY29 using ANY_P55 and 
ANY_P57 at an annealing temperature of 56°C with a cycling extension time of 1 minute. The 
Mycobacterial Optimized Promoter (MOP) 284 was PCR amplified from pAY1 using ANY_P149 and 
ANY_P150 at an annealing temperature of 58°C with a cycling extension time of 1 minute. Wild type 
pncA was cloned into our Zeocin resistant L5 integrating vector, pAY59 using the ClaI and PciI 
restriction sites to create pAY107. MOP was then cloned into pAY107 using the ClaI and Not I 
restriction sites to create pAY108 (pncA expression vector for complementation). Emerald fluorescent 
protein was PCR amplified from pAY21 using ANY_P147 and ANY_P148 an annealing temperature 
of 58°C with a cycling extension time of 1 minute, and cloned into pAY107 and pAY108 using the Not 
I and Xba I restriction sites to create pAY111 and pAY112 respectively. Expression plasmids pAY108 
and pAY111 were transformed into sAY251 (ΔpncA) to created sAY245 (pncA complement referred 
to as complement) and sAY257 (Vector control) respectively. 
 
Figure 4: Expression vector for pncA expression. Graphical representation of theL5 integrating, zeocin-marked 
mycobacterial expression vector for pncA complementation and generation of pncA mutant library. Full lenght 
pncA was cloned in using ClaI and PciI restriction sites, with the Mycobacterial Optimized Promoter (MOP) 
being cloned using the ClaI and NotI restriction sites to drive pncA expression. Four key sequencing primers have 
also been highlighted. Emerald fluorescent protein was cloned in using the ClaI and PciI restriction sites to 
generate our vector control. 
2.4. Generation of M. tuberculosis pncA mutant library 
The GeneMorph II Random Mutagenesis Kit (200550, Agilent Technologies, USA) was used for 
random PCR mutagenesis with the ANY_P153 and ANY_P154 primers. Reactions were carried out in 
50 µL reactions with either 100, 500 or 1000ng of target template (wild typepncA) added for generation 
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of mutagenesis products. It should be noted that the DNA amount stated is only for the target templateto 
be amplified. The quantity of DNA added to reactions was calculated based on the size of the plasmid 
used for amplification. Reagents were used at the following final concentrations: 1x Mutazyme II 
reaction buffer, 200µM each dNTP, 2.5 ng/µL primer mix, 2.5 units of Mutazyme II DNA polymerase 
and nuclease free water up to the final 50 µL reaction volume. PCR cycling was carried out as follows: 
95°C for 2 minutes as initial denaturation, followed either 10, 15, 20, 25 or 30 cycles (depending on 
input concentration of DNA) of 95°C for 30 seconds, 55°C for 30 seconds and 72°C for 1 minute. Final 
extension was carried out at 72°C for 10 minutes. Specific template DNA concentrations and PCR 
cycles for mutagenesis are listed in supplementary table 5. 
DNA template Variable 
10x Mutazyme II reaction buffer 5 µL 
dNTPs mix (40mM) 1 µL 
250ng/µL primer mix 0.5 µL 
Mutazyme II DNA polymerase 1 µL 
Nuclease free water Up to 50 µL 
Total 50 µL 
 
95°C 2 minutes  
95°C 15 seconds 
x * cycles 
*Variable 
55°C 30 seconds 
72°C 1minute 
72°C 10 minutes  
4°C Hold  
 
Selected mutagenesis products were purified by gel extraction and cloned into pAY112 using the NotI 
and  XbaI restriction sites to generate individual libraries of pncA SNPs. Single colonies from libraries 
were picked for DNA extraction. DNA was then PCR amplified using ANY_P58 and ANY_P59 at a 
cycling annealing temperature of 55°C with a 1 minute cycling extension time, and sequenced (as 
detailed in section 2.2.8.) in order to determine the frequency of mutations within the libraries. 
Approximately 50,000 E. coli clones from the candidate library were harvested by scraping to create 
our pooled pncA SNP library (pAY230). Pooled library plasmid DNA was extracted using EndoFree 
Plasmid Maxi Kit and transformed into sAY251 (ΔpncA). Approximately 34,000 M. tuberculosis clones 
were scraped and pooled to constitute sAY260 (M. tuberculosis pncA mutant library. It is worth noting 
that that if any single SNPs resulted in the formation of a NotI or XbaI site within an amplicon, it is 
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likely that those particular SNPs would be under-represented in our library as any amplicons carrying 
the restriction sites would be truncated during the restriction digest process and lost during the process 
of gel extraction as amplicons of specific size were excised and purified for cloning. Further 
bioinformatics analysis would be required to confirm if any single SNP generated during random 
mutagenesis could result in the formation of either a NotI or XbaI site within a PCR amplicon. 
 
2.5. Pyrazinamide and pyrazinoic acid in vitro growth inhibition assay 
Three titred stocks of each sAYs101 (H37Rv wild type), sAY251 (ΔpncA), sAY245 (pncA 
complement), and sAY257 (vector control), and sAY260 (M. tuberculosis pncA mutant library) were 
thawed and diluted to 100 000 CFU/mL in 7H9 broth. BACTEC MGIT 960 supplemented PZA medium 
(245115 and 245128, Becton Dickonson and company, USA) and BBL MGIT supplemented medium 
(245122 and 245124, Becton Dickonson and company, USA) containing either 0, 1, 4, 20, 100, 500 or 
1000µg/mL pyrazinamide or pyrazinoic acid were inoculated with approximately 50 000 CFU. MGITs 
were loaded in the BACTEC MGIT 960 automated culture system (Becton Dickonson and company, 
USA) and incubated until the predetermined growth threshold was reached or until 42 days had elapsed 
upon which MGITs showing no growth were removed as culture negative and recorded. Time-To-
Positivity (TTP) for each MGIT was recorded and the ratio of TTP of drug containing MGITs over the 
no-drug control were calculated and expressed as mean ± standard deviation in order to determine 
growth inhibition at the various concentrations of drug tested. 
 
2.6. Pyrazinamide and pyrazinoic acid drug susceptibility testing 
Conventional phenotypic drug susceptibility testing was done using the Bactec MGIT 960 PZA medium 
and BBL MGIT medium  with slight modifications in order to determine the MIC (minimum inhibitory 
concentration) of pyrazinamide and pyrazinoic acid. Three titred stocks of each sAY101 (H37Rv wild 
type), sAY251 (ΔpncA) and sAY245 (pncA complement) were thawed, diluted to approximately 50 000 
CFU/mL and 5000 CFU/mL respectively. BACTEC MGIT 960 supplemented PZA medium and BBL 
MGIT supplemented medium containing either 0.04, 0.2, 1, 4, 20, 100 or 1000µg/mL pyrazinamide 
depending on the strain were inoculated with approximately 25 000 CFU (500µL of 50 000 CFU/mL 
dilution). BACTEC MGIT 960 supplemented PZA medium and BBL MGIT supplemented medium 
containing no pyrazinamide (AST control) were inoculated with approximately 2500 CFU (500µL of 
5000 CFU/mL). MGITs were appropriately loaded into 5 place AST carriers and incubated in the 
BACTEC MGIT 960 automated culture system until the AST control reached predetermined growth 
threshold. MGITs were then removed and the growth of each drug containing tube recorded. The lowest 
drug containing tube showing a growth index <100 was considered the MIC. Drug susceptibility testing 




2.7. Real-Time quantitative Polymerase Chain Reaction (RT-qPCR) 
 
RNA extraction, DNase treatment, purification and cDNA synthesis 
Control strains were grown up in triplicate from separate glycerol stocks. RNA was extracted from 25 
ml, mid-log phase (OD600 ≈ 0.5-0.6) cultures as follows. Cultures were centrifuged at 4000x g for 15 
minutes at room temperature. Pelleted cells were suspended in 1 ml of TRIzol (15596026, Thermo 
Fisher Scientific, USA), transferred into 2mL screw-cap micro-centrifuge tubes containing 100 μL of 
0.1 mm sterile zirconia/silica beads (11079101z, Biospec, USA), and incubated for 15 minutes at room 
temperature. Five cycles of 1 min bead-beatingusing a MagnaLyser (Roche, Switzerland) and 1 min 
incubation at -20°C was performed. Phase separation was carried out by the addition of 200 µL of 
chloroform (650498, Sigma Aldrich, USA) followed by vigorous shaking by hand for 15 seconds, 2 
minute incubation at room temperature, and centrifugation at 15000x g for 10 minutes at 4°C. The top 
aqueous layer was transferred to a fresh micro-centrifuge tube and phase separation repeated s above. 
The top aqueous layer was again recovered and transferred to a fresh micro-centrifuge tube, followed 
by the addition of 500 µL ice-cold isopropanol (I9516, Sigma Aldrich, USA). The solution was mixed 
well by inversion and incubated at -20°C for 30 minutes, prior to centrifugation at 15000x g for 10 
minutes at 4°C. After removing the supernatant, 1 mL of ice-cold 75% ethanol was added to the 
resulting pellet, followed by mild vortexing and centrifugation at 15000x g for 10 minutes at 4°C. This 
process was repeated following which the resulting RNA pellet was air-dried at room temperature for 
10 minutes. RNA was eluted in a 50µL DEPC-treated water (750024, Thermo Fisher Scientific, 
USA).Eluted RNA was quantified using a Nanodrop Lite Spectrophotometer (Thermo Fisher Scientific, 
USA) and stored at -80°C in three equal aliquots. A single aliquot for each replicate of each strain was 
thawed on ice and DNase treated as follows. DNase treatment was carried out in a 50 µL volume using 
RNase-free DNase (AM2222, Thermo Fisher Scientific, USA). 
 
RNA 5 µg 
10x reaction buffer 5 µL 
DNase I 5 units (5 µL) 
DEPC-treated water Up to 50 µL 
Total 50 µL 
Reactions were incubated for 30 minutes at 37°C followed by the addition of 5 µL of 50mM EDTA and 
incubation at 65°C for 10 minutes. DNase treated RNA was purified using the RNeasy Mini Kit (74104, 
Qiagen, Germany) as per manufacturer’s protocol and quantified using a Nanodrop Lite 




RNA was reverse transcribed to cDNA in 20µL reaction volumes using the iScript cDNA Synthesis Kit 
(1708891, Bio-Rad, USA) as per manufacturer’s instructions. Reactions were incubated at 25°C for 5 
minutes, 42°C for 30 minutes and 85°C for 5 minutes. The resulting cDNA was quantified as above and 
stored at -80°C in three separate aliquots until ready for Real-Time quantitative PCR. 
Purified DNase treated RNA 250ng 
5x iScript Reaction mix 4 µL 
iScript Reverse Transcriptase 1 µL 
Nuclease free water Up to 20 µL 
Total 20 µL 
 
Real-Time quantitative PCR 
RT-qPCR was performed on CFX 96 Real Time PCR detection system (Bio-Rad, USA) using iTaq 
Universal SYBR Green Supermix (172-5121, Bio-Rad, USA) and KM_P35/KM_P36 and 
sigA_F/sigA_R primers for pncA and sigA, respectively.  
2x iTaq universal SYBR green supermix 5 µL 
Forward primer (10 µM) 1 µL 
Reverse primer (10 µM) 1 µL 
DNA template 1 µL (≈100ng) 
Nuclease free water 2 µL 
Total 10 
 
RT-qPCR cycling conditions were as follows: 
95°C 2 minutes  
95°C 5 seconds 
x 40 cycles 
60°C 30 seconds 
65-95°C High Resolution Melt 5 seconds per temperature 0.5°C increments 
All samples were performed in triplicate, internally normalized to sigA, and the mean fold-change and 





2.8. Sequential in vitro screening of M. tuberculosis pncA mutant library 
Three stocks of sAY260 were thawed and diluted to 100 000 CFU/mL in 7H9 broth. Approximately 
50000 CFU was then inoculated into BACTEC MGIT 960 PZA supplemented medium, containing 
either 0µg/mL PZA (unselected library) or 4, 20, 100 or 5000µg/mL PZA (PZA selected libraries), and 
incubated in the Bactec MGIT 960 automated culture system. Within 24 hours of a MGIT being flagged 
as positive, it was removed and processed with the time-to-positivity (TTP) being recorded. The entire 
8mL culture was centrifuged at 4500x g for 10 minutes. After discarding the supernatant, the bacterial 
pellet was re-suspended in 1mL 7H9 broth, from which 30µL was used to inoculate a new MGIT 
containing the same concentration of PZA. The remaining suspension was transferred to a new micro-
centrifuge tube and centrifuged at 12000x g for 5 minutes. The supernatant was discarded and the 
bacterial pellet stored at -20°C. This process was repeated for 6 rounds of PZA selection. DNA 
extractions of samples from the sequential in vitrolibrary screen were done using the Hain GenoLyse 
kit (51610, Hain Lifesciences, Germany). Briefly, frozen bacterial pellets were thawed out, resuspended 
in 100µL of lysis buffer, and incubated at 95°C for 30 minutes before the addition of 100µL 
neutralization buffer. Samples were centrifuged at 12000x g for 5 minutes and the supernatants 
containing DNA recovered in a fresh 1.5mL micro-centrifuge tube for use as PCR template. 
  
 
Figure 5: Schematic representation of sequential in vitro selection procedure.Our pncA mutant library was 
used to inoculate BACTEC MGIT 960 PZA supplemented medium, containing either 0µg/mL PZA (unselected 
library) or 4, 20, 100 or 5000µg/mL PZA (PZA selected libraries). Upon culture positivity, libraries were 
recovered for sequencing, as well as to inoculate fresh MGITs containing the same concentration of drug to allow 
for sequential enrichment of mutant clone. Selection was repeated for 6 rounds. 
2.9. Screening of M. tuberculosis pncA mutant libraryin vivo 
A culture of sAY260 was grown to an OD600 = 1.071 (approximately 1x108cells/mL). 750µL of culture 
was centrifuged at 12000x g for five minutes, washed by resuspension in 5mL of PBS and 
centrifugation, and finally re-suspended in 15mL of PBS for the tail-vein infections of thirty 6-8 week 
old (≈20g) female BALB/C mice with an expected implantation of approximately 1 000 000 CFU per 
mouse (≈ 100 000 CFU in the spleen). Five mice each were sacrificed on the day after infection (Day -
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3) and the day of treatment initiation (Day 0) to ensure adequate implantation of sufficient bacteria to 
represent the complexity of our library. Upon treatment initiation, mice were randomized into two 
groups with one group of mice receiving 150 mg/kg pyrazinamide (treatment arm), while the second 
group received PBS (mock arm), once daily for five days per week by oral gavage. 
 
Mice were then sacrificed at Day 21 and Day 42 post treatment initiation. At all sacrifice time-points 
sacrifice, spleens of the mice were placed in 2mL of PBS and homogenized using a pestle and mortar. 
The resulting homogenate serial diluted and plated on 7H11 agar containing hygromycin and zeocin, 
with and without200,000 iu/L polymixin B, 10 mg/L amphotericin B, 50 mg/L carbenicillin, and 20 
mg/L trimethoprim (PACT antimicrobial cocktail). Upon growth of colonies (three to four weeks), 
colony counts were carried out for all sacrificial time-points and colonies from plates with adequate 
representation of our library (>100 000 colonies) of the were scraped into 50mL conical tubes and stored 
at -20°C. DNA was extracted using the GTC genomic DNA extraction method (Larsen et al., 2007), 
with the only modifications being a 2nd chloroform separation after separation with GTC solution to 
ensure the removal of phenol from the mixture, and a 2nd ethanol wash prior to air-drying and 
resuspension of the DNA pellet in 1x TE buffer. 
 
Figure 6: Schematic representation of time-line of murine selection model.Mice were infected with our pncA 
mutant library at Day -4 by tail vein injection and sacrificed at Day -3 (day after infection) and Day 0 (treatment 
initiation) to enumerate bacterial burden in the spleens to ensure adequate library representation and to recover 
baseline input libraries. Mice were randomized into two groups, receiving either 150mg/kg pyrazinamide 
(treatment arm) or saline (mock arm). Mice were then sacrificed at Day 21 or Day 42 after treatment to enumerate 
bacterial burden and recover selected/unselected libraries for sequencing. CFU = colony forming units, Rx Start 
= Treatment initiation. 
 
2.10. Library preparation and sequencing 
DNA from screen samples was PCR amplified using ANY_P158 and ANY_P159 with an annealing 
temperature of 60°C and a cycling extension period of 90 seconds, and purified by gel extraction. A 
total of 1ng of DNA from each in vivo sample was utilized for PCR amplification. Since the DNA 
concentration from GenoLyse extracts could not be quantified, 2.5 µL of extract was utilized as DNA 
template for amplification.A total of 200ng of each purified product were vacuumed-dried and 
submitted for sequencing. Sequencing library preparation and sequencing were carried out by Dr. 
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Thomas Ioerger and the Sacchettini lab at Texas A&M University (Texas, USA). Libraries for next 
generation sequencing (NGS) were prepared using standard Illlumina genomic DNA sequencing 
sample preparation protocol (Illumina, Inc.), with barcodes for multiplexing. Shearing was performed 
using a Covaris E220 (Covaris, Inc.). Samples were sequenced in paired-end mode (125+125 bp) on an 
Illumina 2500 sequencer. 
 
2.11. Bioinformatics 
Bioinformatics on sequence libraries and subsequent data analysis resulting in the generation of the list 
of mutations with associated susceptibility predictions were carried out by Dr. Thomas Ioerger and by 
Dr. Adam Yadon. On average 2.9 million pairs of reads were collected for each sample and mapped to 
the M. tuberculosis H37Rv pncA gene the Burroughs-Wheeler Aligner program285. Pairs of reads with 
2 or more mismatches or containing indels (insertions or deletions) were discarded. The number of 
single-nucleotide polymorphisms at each position was tabulated and individual single-nucleotide 
polymorphism frequencies were calculated by dividing the count by the total number of reads covering 
that site in each dataset. The frequency of single-nucleotide polymorphisms from an unselected wild 
type pncA was subtracted from the observed frequencies in each sample. Enrichment or depletion was 
calculated as the log2 mean fold-change for each pyrazinamide selection relative to the no-drug 
selection of the same round or at implantation (day -3) for the sequential in vitro selection and murine 
selection model respectively. Statistical significance was determined using a t-test (two-sided, unequal 
variance). 
 
Single-nucleotide polymorphisms exhibiting ≥2 fold-change (p-value≤0.05, t-test) in two or more in 
vitro selections (any round of drug selection or drug concentrations) or after either 21 or 42 days of 
pyrazinamide treatment in our murine selection model were identified. Single-nucleotide 
polymorphisms identified as both enriched and depleted in a screen were discarded. Mutations were 
then converted to the respective amino acid form and predicted to be either resistance-conferring or 
susceptible-conferringmutations identified either in vitro or during infection in mice. Data from both 
screens were combined after conversion to the amino acid level, with mutations being identified as both 
enriched and depleted in both screens being discarded to provide us with a provisional list of mutations 
with associated predictions. 
2.12. Validation of screen using selected isogenic pncA mutants 
Single colony picks for validation were obtained by streaking out our pncA mutant library onto 7H10 
plates containing selective antibiotics. Two hundred and eleven single colonies were picked and sub-
cultured into 1mL 7H9 broth and 7H10 plates containing selective antibiotics, as well as re-suspended 
in 100µL nuclease free water. Plates and broth were incubated at 37°C to allow outgrowth of the 
mutants, while colonies re-suspended in nuclease-free water were boiled at 95°C for 30 minutes and 
2.5 µL lysate used as template for PCR amplification using primers ANY_P158 and ANY_P159 with 
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an annealing temperature of 60°C and a cycling extension period of 90 seconds. Products were purified 
using the gel extraction and sequenced using ABI Big Dye Terminator Kit and the ABI Prism 3130 
sequencer with primers ANY_P58 and ANY_P59 in order to identify the polymorphism/s carried within 
each mutant clone. After analysis of sequence results, 48 isogenic isolates containing mutations of 
interest were further outgrown from the initial cultures and used to create titres. These 48 isogenic 
mutant isolates then underwent drug susceptibility testing using Bactec MGIT 960 PZA kit as 
previously done for control strains. 
 
2.13. Preliminary comparison of clinical data to screen predictions 
Genotype-to-phenotype data was extracted from the supplementary data from a multicentre study which 
sequenced pncA from pyrazinamide resistant and susceptible isolates whose susceptibility testing was 
carried out using the Bactec MGIT 960 PZA system32. Mutation data for pncA mutations conferring 
pyrazinamide resistance at very high confidence was condensed to amino acid form with the associated 
phenotypes, after removing all indels (insertions and deletions). Mutations associated with both a 
resistant and susceptible phenotype were also removed. Respective pncA mutant genotypes associated 
with pyrazinamide resistance from our provisional screen prediction data and the single clinical dataset 
were then compared to look for overlap.  
 
2.14. Determining mechanisms of resistance to pyrazinamide 
In order to determine the molecular basis of mechanisms of resistance to pyrazinamide, we sought 
quantify PncA and its activity. 
 
2.14.1. Quantitation of PncA 
Due to the lack of an anti-PncA antibody, we utilized a stable isotope labelling and targeted mass-
spectrometry approach in order to carry out relative quantitation of the PncA. For initial development 
and optimization of our method, 13C-labelled lysate alone, as well as 13C-labelled lysates plus lysates 
from our complement and ΔpncA respectively, were digested, purified, run on the mass 
spectrophotometer and analyzed using the methodology described below. 
 
 
2.14.1.1. Growth of isotopically labelled control and isogenic mutants 
The proteome of sAY245 (Comp) was grown to OD600 = 1 in a modified Hartmans-de Bont (HDB) 
medium (recipe provided in appendix) in order to uniformly label the proteome with [13C]. Selected 
isogenic mutants as well as the complement and ΔpncA controls were grown in triplicate to an OD600 = 
0.6 ~ 0.8 in a 30mL volume of standard 7H9 broth, with the addition of the appropriate concentrations 




2.14.1.2. Extraction of cell lysates 
Cell lysates were prepared as follows. Cultures were centrifuged at 3500x g for 15 minutes at 4°C, 
following which pellets were washed three times by resuspension in 10mL of 10% glycerol and 
centrifugation at 3500x g for 15 minutes at 4°C in order to remove Tween 80 and BSA. Washed pellets 
were resuspended in 1mL sterile phosphate buffered saline (PBS) containing Protease inhibitor cocktail 
(11873580001, Roche, Switzerland), and transferred to fresh screw-cap tubes containing 100µL of 
0.1mm sterile zirconia/silica beads (11079101z, Biospec, USA) beads, vortexed and incubated at -20°C 
for 5 minutes. Cells were ruptured by repeated bead-beating at 7000rpm for one minute using a 
MagnaLyser (Roche, Switzerland) and a one minute incubation at -20°C, a total of four times. Sodium 
dodecyl sulphate (SDS) (L4390, Sigma Aldrich, USA) was added to a final concentration of 2%, with 
the samples being vortexed and incubated at 65°C for 30 minutes. Lysates were recovered by twice 
recovering the supernatant of samples after centrifugation at 15000x g for 5 minutes. Lysates were then 
passed 0.2micron Corning Costar SpinX columns (CLS8160, Sigma Aldrich, USA), removed from the 
BSL3 and stored at -80°C. 
 
2.14.1.3. Protein isolation, peptide digest and purification 
13C heavy labelled lysate and lysates from pncA mutants and control strains were mixed 50:50 in a 
200µL volume prior to the addition of 600µL of methanol (34860Sigma Aldrich, USA) and 150µL 
chloroform (650498, Sigma Aldrich, USA).This was briefly vortexed before adding 450µL MilliQ 
water and vortexing again before centrifugation for 1 minute at 16000x g. The upper aqueous layer was 
discarded and 450µL methanol added to the organic phase, vortexed and centrifuged for 2 minutes at 
16000x g. The resulting supernatant was discarded and 100µL of 6M urea buffer (U5378, Sigma 
Aldrich, USA) was added to the precipitate, prior to sonication for 2 minutes. 5µL of 200mM DL-
Dithiothreitol (DTT) (646563, Sigma Aldrich, USA), 20µL of 200mM iodoacetamide (I6125, Sigma 
Aldrich, USA), and 20µL 200mM DTT were added with 30 minute incubation periods at room 
temperature after the addition of each reagent. 775µL MilliQ water was then added to the samples, 
followed by the addition of 20µL of 0.2µg/mL Promega sequencing grade modified Trypsin (V5117, 
Promega, USA) and overnight incubation at room temperature. Reactions were stopped by the addition 
of 10µL concentrated acetic acid (A6283,Sigma Aldrich, USA) to reduce the sample pH <6. Samples 
then underwent column purification using Sep-Pak Vac 6cc 500mg C18 cartridges (WAT043395, 
Waters,USA). Briefly, columns were cleaned and equilibrated by passing through 5mL Acetonitrile 
(34967,Sigma Aldrich, USA), 5mL 65% Acetonitrile with 0.l% Formic Acid (64-18-6, Merck 
Millipore, USA), and 10mL 2% Acetonitrile with 0.l% Formic Acid. Peptide digested samples were 
then added to the column, and washed with 10mL 2% Acetonitrile with 0.l% Formic Acid, before being 
eluted in 2mL 65% Acetonitrile with 0.l% Formic Acid. Samples were completely dried down by 




2.14.1.4. Mass spectrometry and data analysis 
Unique PncA, RpoB, and DnaK peptides (supplemental table 4) were targeted using a Q-Exactive Mass 
Spectrometer coupled to a Dionex RSLC 3000 nano Liquid Chromotograph system (Thermo Fisher 
Scientific, USA), using a 30 minute gradient and mobile phase from 1% acetonitrile and 0.1% formic 
acid to 50% acetonitrile and 0.1% formic acid, with a regeneration phase to clean up and equilibrate the 
column. Separation was carried out on a 15 cm by 75 uM ID fused silica column, backed with 3 uM 
C18 stationary phase, and a flow rate of 0.300 ul min-1. The nano-spray source was operated at a 
capillary temperature of 275°C, an emitter voltage of 1.6 Kv and S-lens voltage of -55 V. A targeted-
MS2 method was employed with an AGC target of 1.0e5 ions, an isolation width of 2 m z-1 and an HCD 
setting of 27. Sample were run on the Mass Spectrophotometer by Dr. John Adamson of the Africa 
Health Research Institute Pharmacology Core. 
 
Spectral traces were quantified using Skyline proteomics software. The area-under-the-curve (AUC) 
for each peptide transition (peptide breakdown product)was exported using the MS1 probe plug-in. Any 
transitions containing a mutation of interest or with an AUC = 0 were discarded. For each sample, the 
quantified light/unlabelled AUC was normalized to the 13C-heavy AUC for each transition. The mean 
ratio of unlabeled to heavy labelled AUC for all PncA peptides was then normalized to the mean ratio 
of unlabeled to heavy labelled AUC for all RpoB or DnaK peptides across all biological replicates. 
Three biological replicates each per mutant and 10 biological replicates for sAY254 (Comp) was 
performed. The fold-change and standard deviations of protein abundance for each mutant is reported 
relative to the isogenic complement control. 
 
2.14.2. Quantitation of pyrazinamidase activity 
A modified quantitative Wayne assay262 was used to determine the enzymatic activity of 
pyrazinamidase by assaying for the production of pyrazinoic acid. 
 
2.14.2.1. POA assay and data analysis 
Cultures for selected mutants of interest as well as our complement and ΔpncA strains were grown in 
triplicate to OD600 = 0.6~0.8, and treated with 500µg/mL pyrazinamide. Aliquots of 500µL were taken 
in sterile screw-cap tubes containing 100µL of 0.1mm sterile zirconia/silica beads beads, immediately 
prior to the addition of pyrazinamide and after 48 hours pyrazinamide treatment. Samples were bead-
beaten 4 times at 7000rpm for 1 minute with 1 minute incubations at -20°C between bead-beating to 
allow for the release of intracellular POA. Samples were then centrifuged at 15000x g for 5 minutes. 
Whole cell lysate (100µL) was then aliquoted into two fresh tubes for each sample, with 900µL of 0.1M 
pH3.4 Glycine-HCl (G2879, Sigma Aldrich, USA) being added to the first tube as a blank. 10µL of 
20% ferrous ammonium sulphate(215406, Sigma Aldrich, USA) was added to the second tube, followed 
by the addition of 890µL 0.1M pH3.4 Glycine-HCl. Absorbances were then read at 460nm 288 (Bio-Rad 
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SmartSpec Plus) with the tube not containing ferrous ammonium sulphate being used to blank the 
spectrophotometer for each sample. Individual absorbance values were normalized to absorbance values 
prior to pyrazinamide treatment and scaled by bulk protein content (described in section 2.14.2.2), and 
pyrazinamidase enzyme levels determined by mass spectrometry. Relative enzymatic activity is 
reported as the mean and standard deviation relative to the isogenic complement control. 
 
2.14.2.2. Bulk protein quantification 
Protein quantification was carried out on whole cell lysates to correct for cell breakage, as per the “test-
tube room temperature” protocol of the Pierce BCA Protein Assay kit (23225, Thermo Fisher Scientific, 
USA), with a minor modification in that a reaction volume of 1mL was used. A standard curve was set 
up using BSA provided with 1x PBS containing 2% SDS as a diluent. Whole cell lysates were diluted 





Chapter 3: Results 
 
3.1. Generation and characterization of pncA mutant library 
In order to comprehensively and systematically screen all potential pncA single nucleotide 
polymorphisms (SNPs), multiple libraries of pncA mutants were constructed using random error-prone 
PCR mutagenesis under different PCR conditions varying the template concentration and PCR cycle 
number in order to maximize the introduction of single SNPs.The technique requires a high template 
concentration which results in all libraries having a significant proportion of wild type sequences. 
Initially the products of five mutagenesis conditions were cloned into our pncA expression vector and 
expressed in E. coli. We then classified the single colony sequences as wild type, containing a single 
SNP, or containing more than one SNP. Results of one round of mutagenesis of these five libraries is 
shown in Figure 7, from which we selected one candidate library.  
 
 
Figure 7: Characterization of pncA mutant library. (a) Distribution of wild type (WT), single SNPs and 2 or 
more SNPs within individual mutant libraries constructed using random error-prone PCR mutagenesis. * indicates 
candidate library selected (b) Mean pncA single nucleotide polymorphism frequency (%) at each nucleotide of 
our M. tuberculosis pncA mutant library in relation to an unmutagenized control 
 
The library with the greatest proportion of single nucleotide mutations, which contained approximately 
48.39% wild typepncA, 32.25% single pncA mutations, and 19.36% pncA containing 2 or more 
mutations (indicated by * in Figure 7a), was then transformed into an H37Rv M. tuberculosisstrain 
where the endogenous pncA locus had been inactivated through insertion of a hygromycin resistance 
cassette (ΔpncA). Additional mutagenesis conditions using different template concentrations and cycle 
numbers (supplementary table 5) were sequenced using PacBio Single Molecule Real Time 
Sequencing, however no other mutagenesis condition produced a more favourable mutation breakdown 
(data not shown) than observed in our candidate library. Transformants were pooled in order to 
constitute the library which then underwent confirmatory deep sequencing which revealed roughly 4.5 
fold higher intragenic pncA SNPs at each nucleotide relative to our unmutagenized wild type control 
strain (Figure 7b). 
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3.2. Development of in vitroscreen 
Due to the challenging nature of pyrazinamide susceptibility testing, we sought to develop and optimize 
a selection screen based on the BD Bactec MGIT 960 PZA system, as this would allow for standardized 
screening using fixed pre-adjusted pH media and culture conditions.  
 
Figure 8: Phenotypic assaying against pyrazinamide and pyrazinoic acid under acid (pH5.9) and standard 
culture conditions to determine growth inhibition.MGITs inoculated with respective strains were assayed 
against varying concentrations of pyrazinamide and pyrazinoic acid under two different culture conditions. Results 
are represented as an average with standard deviation of TTP ratio (time to positivity in drug treated culture 
compared to untreated control) as a measure of growth inhibition. PZA = pyrazinamide, POA = pyrazinoic acid, 
WT = H37Rv wild type control, ΔpncA = H37Rv with pncA insertionally inactivated, Comp = ΔpncA 
complemented with wild type pncA, VC = ΔpncA carrying Emerald fluorescent protein as a vector control, Library 
= ΔpncA carrying our pncA mutant library. 
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As expected our ΔpncA and vector control strains showed high level resistance to pyrazinamide, 
demonstrated by lack of growth inhibition in both acid and standard culture media at all tested 
concentrations (Figure 8). Our complement control showed a greater degree of growth inhibition to 
pyrazinamide compared to the H37Rv wild type strain, with the growth inhibition being more 
pronounced in acidified media than standard culture media for both strains. Complete inhibition of 
growth was observed in the complement strain at both 500µg/mL and 1000 µg/mL in both forms of 
media tested. Growth inhibition to pyrazinoic acid was almost identical across strains with the inhibition 
again being more pronounced in acidic culture media than in standard culture media. Complete 
inhibition of growth was observed at 1000 µg/mL in acidic media. It was interesting to note that our M. 
tuberculosis pncA mutant library showed mild growth inhibition when treated with pyrazinamide at 
higher concentrations in acidified media compatible with it containing a proportion of wild type pncA 
sequences. 
 
Table 1: Drug susceptibility testing results of control strains. Minimum inhibitory concentrations 
(µg/mL) of pyrazinamide and pyrazinoic acid determined under standard pH (pH6.8) and acidic pH (pH 5.9) 
culture conditions using the the Bactec MGIT 960 PZA medium and BBL MGIT medium. PZA = pyrazinamide, 
POA = pyrazinoic acid, WT = H37Rv wild type control, ΔpncA = H37Rv with pncA insertionally inactivated, 
Comp = ΔpncA complemented with wild type pncA. 
 
Drug Media WT ΔpncA Comp 
PZA Acid 20 >1000 1 – 4 
PZA Standard 100 >1000 20 
POA Acid 100 100 100 
POA Standard 500 500 500 
 
 
The observations of our growth inhibition assays was confirmed through susceptibility testing of our 
wild type and complement controls with MIC’s of 20 µg/mL and 1-4 µg/mL respectively in acidified 
media compared to MIC’s of 100 µg/mL and 20 µg/mL respectively in standard culture media (Table 
1), indicating hyper-susceptibility of our complement to pyrazinamide. The ΔpncA strain was highly 
resistant to pyrazinamide with an MIC of >1000µg/mL in both tested media conditions. Pyrazinoic 
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acid MICs were identical across all strains confirming the observations of our growth inhibition assays, 
with a 5-fold lower MIC when tested in acidified media compared to standard culture media.  
 
 
Figure 9: Expression of pncA in wild type H37Rv, ΔpncA and complement.RT-qPCR determination of pncA 
expression levels across control strains reveals 4-fold over-expression of pncA in our complement. Data 
represented as mean with standard deviation (* P-value ≤0.01).WT = H37Rv wild type control, ΔpncA = H37Rv 
with pncA insertionally inactivated, Comp = ΔpncA complemented with wild typepncA. 
 
Real-Time qualitative PCR revealed 4-fold over-expression of pncA in our complement strain relative 
to our H37Rv wild type control and ΔpncA (Figure 9). This explains why we saw a hyper-susceptibility 
phenotype with the complemented stain, since higher expression of pncA would lead to more activation 
of pyrazinamide. 
 
Varying growth inhibition across the full ranges of pyrazinamide tested, as well as the respective MIC’s 
of our complement and ΔpncA, suggested that we could select for resistance conferring mutant clones 
across a wide dynamic range of susceptibilities. As growth inhibition or lack thereof was more 
pronounced in acidified media, we concluded that acidified medium would give us greater enrichment 
of resistance conferring mutants and hence was the ideal medium for in vitro selection. 
 
3.3. Phenotypic screening of pncA mutant libraryin vitro 
Next we sought to enrich for resistance conferring mutants by exposing our pncA mutant library to 
sequential in vitro selection using the Bactec MGIT 960 PZA medium with a range of pyrazinamide 
concentrations.  MGIT tubes were inoculate from titred frozen stocks and grown to positivity under one 
of several concentrations of pyrazinamide. Upon positivity, pyrazinamide-selected libraries were 
harvested and transferred to a second tube containing the same concentration of pyrazinamide and the 
cycle repeated to six rounds of selection. 
 
As expected, cultures showed a progressive reduction in time-to-positivity (TTP) with each subsequent 
selection at all concentrations of pyrazinamide tested (Figure 10). Since TTP is a surrogate read-out for 
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rate of growth of bacteria as MGIT positivity is based on a set-threshold, we believe this to be indicative 
of enrichment for resistance conferring mutant clones, as well as some bacterial adaptation to the acidic 
culture condition which also showed a successive reduction in TTP in the untreated control library. 
Recovered libraries for each selection were then PCR amplified and deep-sequenced using Illumina 
sequencing. 
 
Figure 10: Change in time-to-positivity (TTP) with sequential in vitro selection exposed to different 
concentrations of pyrazinamide. Average time to positivity (TTP) of in vitro selection indicating reduction of 
growth inhibition with sequential selection. Data represented as mean with standard deviation. 
 
3.4. Phenotypic screening of pncA mutant library in vivo 
As in vitro susceptibility to pyrazinamide may not faithfully recapitulate susceptibility in vivo, we 
further screened our pncA library using a murine treatment model. At day -3 (day after infection), we 
observed approximately 5.9 x105 CFU in the spleen of infected mice, which represents over 300-fold 
coverage of the library (Figure 11). Bacterial burden did increase over the course of 42 days after the 
initiation of treatment in the mock (PBS-treated) arm, while showing a moderate decline from day 21 
to day 42 after treatment initiation in the pyrazinamide treated arm, although the difference in bacterial 
burden at day 42 between the pyrazinamide treated and untreated mice was not statistically significant. 
Organ DNA was extracted at each time-point and used as template for PCR amplification of pncA which 




Figure 11: Bacterial burden observed in the spleens of mice infected with our M. tuberculosis pncA mutant 
library.Averagebacterial burden in colony forming units (CFU) observed in spleens of infected mice at pre-
treatment Day -3 (implantation control), Day 0 (treatment initiation), and Day 21 and Day 42 (selection 
timepoints) of either pyrazinamide or mock treatment. Data represented as mean with standard deviation. 
 
3.5. Provisional list of predicted susceptibilities of mutations 
The analysis of the in vitro and in vivo pyrazinamide selected libraries (detailed in the methodology) is 
beyond the scope of this dissertation and was carried out by Dr. Thomas Ioerger and Dr. Adam Yadon. 
In brief, reads from sequenced libraries were aligned to a reference pncA sequence with reads containing 
multiple SNPs or indels (insertions or deletions) being discarded. SNPs at each nucleotide were 
tabulated and used to calculate the mutation frequency by normalizing to total read count at that given 
nucleotide. Mutation frequency from an unmutagenized control was subtracted from each library prior 
to calculating the enrichment or depletion of mutations by comparing fold change in mutation frequency 
of drug selected libraries to respective controls.Mutations were converted to amino acid form with 
phenotype predictions being associated for in vitro and in vivo selections, with data from both screens 
being eventually combined. It is worth noting that fold change comparison  
 
The output of this analysis was a provisional list of mutations at the amino acid level (supplementary 
table 7) which were either enriched (predicted pyrazinamide resistant), depleted (predicted 
pyrazinamide susceptible), or neither enriched nor depleted (unselected or intermediate) during either 
one or both of the phenotypic screens when comparing libraries selected with pyrazinamide treatment 
versus unselected libraries. Of the 1332 possible mutations (including amino acid substitutions, non-
sense mutations resulting in stop codons, and mutations not resulting in an amino acid substitution) in 
pncA, 1197 (89.86%) were adequately represented in our M. tuberculosis pncA mutant library. In total 
we identified 411 mutations that were enriched in either or both of our screens. We also found 357 
mutations that were depleted, and 374 mutations which were neither enriched nor depleted. This meant 
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that we could potentially predict phenotypes for 1142 or 85.74% of all possible mutations at the amino 
acid level. 
 
Figure 12: Breakdown of mutations identified.Venn diagrams comparing overlap of (a) all enriched 
mutations, and (b) all depleted mutations identified through in vitro and in vivo screening. 
 
Of the 411 mutationswhich were enriched in our phenotypic screens, (46.96%) were identified by both 
screens, while 49 (11.92%) and 169 (41.11%) predicted mutations were unique to the in vitro and in 
vivo screens respectively. When looking at mutations that were depleted, 113 (31.66%) were identified 
in both screens, while 125 (35.01%) and 119 (33.33%) were identified uniquely in the in vitro and in 
vivo screens respectively.  
 
When we examine the distribution mutations that were enriched, we observed that these occurred along 
the full length of the gene (Figure 13). When we looked at both the distribution and frequency of 
mutations enriched in our screens (and therefore predicted to confer pyrazinamide resistance) at each 
codon, we found some clustering of mutations around resides predicted to be involved in the enzymatic 
function of PncA. 
 
Figure 13: Distribution of resistance conferring mutations across the pncA gene. Proportion (%) of all 
mutations represented in our library that were enriched in either one or both of our screens for each codon of 
PncA. Predicted linearized structure of PncA is shown above the frequency and distribution graph with key 
functional and structural regions indicated. Mutations predicted to confer resistance are more frequent and cluster 
around residues believed to make up the catalytic triad. 
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3.6. Validation of screen results 
In order to determine if our enriched mutations conferred resistance to pyrazinamide, we randomly 
selected clones from our unselected library, sequence confirmed the isogenic pncA mutation they 
harboured and subjected them to drug susceptibility testing using the Bactec MGIT 960 PZA kit in 
order to determine MIC’s. Of the two hundred and eleven colonies picked and sequenced, we identified 
48 unique SNP containing clones. 
 
All 23(100%) of mutant clones that were classified as enriched by our screens showedan elevated MIC 
atleast five-fold greater (≥ 20 µg/mL) than the isogenic complement control stain which had an MIC 
between 1 and 4 µg/mL, whereas 13 of 14 (92.86%) of clones classified as depleted retained an MIC 
identical to the isogenic complement control stain (supplementary table 6). Strikingly all 11 clones that 
were neither enriched nor depleted in our screens retained an MIC identical to the isogenic complement. 
From these results we concluded that mutations enriched in our screens could be classified as resistance 
conferring mutations and mutations that were depleted classified as susceptible conferring. Mutations 
that were neither enriched nor depleted, we classified as intermediate and concluded that they conferred 
a susceptible phenotype. 
 
3.7. Preliminary comparison to clinical data 
Since our list of genotype to phenotype association is provisional, a fully comprehensive comparison 
between our catalogue of predicted resistance conferring mutations to association data available for 
mutations from pyrazinamide resistant clinical isolates is yet to be done.  We did however undertake a 
smaller preliminary comparison to test our provisional prediction of associated phenotypes-to-
genotypes for pyrazinamide resistance to that from a single clinical dataset. After extracting data from 
the clinical dataset we had selected, we compared the 120pncA mutations (at the amino acid level) 
associated with pyrazinamide resistance at a very high confidence with the 411 predicted resistance 
conferring pncA mutations within our provisional list of predictions.  
 
Figure 14: Preliminary comparison of screen data to mutations associated with pyrazinamide resistance 
from clinical isolates.The 411 predicted resistant conferring pncA mutations from our provisional list of screen 
predictions were compared to a list of 120 pncAmutations associated with pyrazinamide resistance from 
pyrazinamide resistant clinical isolates. 
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Of these 120 mutations, we found 91 mutations (75.83%) in our provisional catalogue of resistance 
conferring mutations (Figure 14), while the remaining 29 mutations associated with resistance in the 
clinical dataset were predicted to be susceptible by our screening methods.On the converse side, 320 
predicted resistance conferring mutations from our provisional catalogue where not identified within 
the pyrazinamide resistant clinical isolates sequenced in the compared dataset. 
 
3.8. Mechanisms of resistance 
Of particular interest to us were mutations predicted to confer resistance which are located outside of 
the regions believed to be essential in the enzymatic activity, leading us to hypothesize two mechanisms 
for pyrazinamide resistance mediated through pncA mutations – abrogation of enzyme function through 
disruption of catalytic domains, and changes in the conformation/structure of the protein which lead to 
reduced abundance or affect functionality without being directly involved in catalytic activity. In order 
to test our hypotheses, we sought to quantify protein abundance and enzyme activity of selected 
mutants. 
 
Since there is no available anti-PncA antibody, quantification by western blotting would require the 
time consuming endeavour of immunization and generation of an antibody. As isogenic mutants were 
already isolated for the validation of our screen and had known phenotypes associated to the mutant 
genotypes, we decided to develop a mass quantitative spectrometry assay for protein quantification. 
 
To accomplish our aim and confirm our hypothesis, we developed a method for the detection of 
unlabelled and 13C stable isotope labelled proteins which would allow for quantification of PncA 
relative to two house-keeping proteins, RpoB and DnaK. First we grew our isogenic complement 
control in the presence of 13C-labelled glycerol as the sole carbon source to ensure heavy labelling of 
the entire proteome. Using an in silico trypsin digest we selected 3 peptides from PncA and single 
peptides from RpoB and DnaK. We then determined if we could simultaneously detect both unlabelled 
as well as 13C-labelled peptides on the Q-Exactive mass spectrometer using our protocol (Figure 15). 
Preliminary experiments showed that the detection of RpoB was more reproducible than DnaK, so we 
then continued only with RpoB as the control protein. 
 
Saturated labelling of protein was clearly shown by the absence of unlabelled PncA and RpoB peptides 
when lysate from our 13C-labelled complement strain was run alone, with 13C-labelled PncA and RpoB 
peptides clearly detectable. Both unlabelled and 13C-labelled RpoB were detected in equivalent amounts 
when lysates from either our complement or ΔpncA strains were combined with 13C-labelled 
complement lysate indicating the suitability of RpoB as a house-keeping control peptide for relative 
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quantification of PncA. As expected unlabelled PncA peptides were detected only in our complement 




Figure 15: Detection of PncA and RpoB peptides through mass spectrophotometry.Spectral tracesof 
unlabelled and 13C-labelled PncA and RpoB peptides in Skyline software. X-axis indicates the peptide retention 
time while Y-axis represents total count. Each coloured line peak represent the total ion count within a retention 
time window for a particular peptide transition (breakdown fragment) of the parent peptide detected by mass 




Relative PncA abundance for isogenic mutants with either confirmed resistant or susceptible 
phenotypes was then determined using the method we had developed using the area under the curve 
(AUC) for each peptide transition for relative quantification of peptides. In brief, unlabelled peptide 
transitions were normalized to 13C-labelled peptide transitions for each peptide. The mean ratio of AUC 
for light and heavy labelled peptides for PncA were then normalized to the mean ratio of AUC for RpoB 
light and heavy labelled peptides. Protein abundance was calculated relative to our isogenic 
complement. 
 
In strong support of our hypothesis that pncA mutations not affecting residues linked to the active site 
of PncA resulted in reduced abundance of the enzyme, 16 of the 22 pyrazinamide resistant isogenic 
pncA mutants we testedhad significantly lower pyrazinamidase levels (Figure 16) relative to our 
complement strain. In contrast all but one of our mutants susceptible to pyrazinamide showed PncA 
levels comparable to our complement control. It is intersting to note that three additional pyrazinamide 
resistant isogenic mutants (V7L, D8E, and G97D) which showed significantly lower pyrazinamidase 
levels are in close proximity to proposed catalytic sites suggesting that active site mutations may have 
a destabilizing effect on the protein structure. 
 
When we looked at the location of the remaining three pyrazinamide resistant isogenic mutants with 
wild type protein abundance (D8N, C138G, and C138S) on PncA, we found they were all located at the 
catalytic triad, suggesting they may cause resistance by disrupting the active site rather than disrupting 
protein stability and abundance. To test this hypothesis we used a modified Wayne’s assay for the 
detection of pyrazinoic acid produced through the activation of pyrazinamide, which is a reliable proxy 
for enzymatic activity. 
 
 
Figure 16: Relative abundance of PncA in clones harbouring mutations in pncA.PncA abundance normalized 
to RpoB and relative to our isogenic complement strain was determined using mass spectrometry in selected 
isogenic isolates harbouring single mutations in pncA and having varying susceptibility phenotypes. Data 
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represented as mean abundance and standard deviation relative to complement. * P-value ≤ 0.05 (t-test, two-
sided). † corresponds to clones tested for enzymatic activity (Figure 17). 
We found all three of the phenotypically confirmed pyrazinamide resistant mutants with complement-
equivalent PncA levels showed significant reduction in the catalytic conversion of pyrazinamide to 
pyrazinoic acid (Figure 17) and therefore reduced enzymatic activity. Three pyrazinamide susceptible 
mutants with complement-equivalent PncA abundance also had complement-equivalent enzyme 
activity as measure by pyrazinoic acid production. 
 
Figure 17:  Relative pyrazinamidase (PncA) activity.PncA enzyme activity of selected isogenic mutants was 
carried out using a modified Wayne’s assay. RelativeActivity refers to the amount of POA generated in a 48 hour 
time-period as measured by the absorbance at 460nm after the addition of ferrous ammonium sulphate in a 
respective pncA mutant clone compared to that of the isogenic complement strain. Individual absorbance values 
were normalized to absorbance values prior to pyrazinamide treatment and scaled by bulk protein content 
(described in section 2.14.2.2), and pyrazinamidase enzyme levels determined by mass spectrometry. Relative 
enzymatic activity is reported as the mean and standard deviation relative to the isogenic complement control. * 





Chapter 4: Discussion 
 
The emergence of resistance to pyrazinamide jeopardizes its use both in current and future treatment 
regimens for tuberculosis. Given the pitfalls of current phenotypic drug diagnostic testing as well the 
vital role of pyrazinamide in tuberculosis chemotherapy, the development and introduction of a 
genotypic assay for detection of pyrazinamide resistance is a high priority for TB control programmes. 
It has been previously illustrated that mutations in pncA, which codes for the activator of pyrazinamide, 
can occur along the full length of the gene and is the primary mechanism of resistance to pyrazinamide 
28,29,207. The development of a genotypic based assay for detection of pyrazinamide resistance is hindered 
by the lack of knowledge of the full spectrum of the specific resistance conferring mutations, since 
mutations occur in pncA which do not confer pyrazinamide resistance by standard drug susceptibility 
methods34,220. 
 
Current knowledge of the mutations believed to confer resistance have been reliant on identifying 
pyrazinamide resistant isolates and deducing the specific mutations within pncA associated with the 
resistant phenotype by sequencing 29,32. The identification of these pyrazinamide resistant isolates is 
based on conventional drug susceptibility testing and it has been observed that some mutations associate 
with both pyrazinamide resistant and susceptible phenotypes in clinical isolates 24,32,33. This  observation 
is probably due to the shortcomings associated with testing methods, and may be complicated by the 
genetic background of these isolates 
 
Our work details a screen to define the full repertoire of pncA mutations that confer resistance to 
pyrazinamide in an isogenic background which could be utilized as a reference for genotypic based 
diagnostic tools. Using two independent screening methods, we generated a provisional list of 411 
mutations predicted to confer resistance. In addition we have provisionally identified 357 mutations 
predicted to be susceptible to pyrazinamide with a further 374 mutations being classified as 
intermediate. It is plausible that these mutations which were neither enriched nor depleted may result 
in phenotype that sits on a borderline of the critical concentration used for susceptibility testing, 
however we conclude that they confer a susceptible phenotype. It is worth reiterating that additional 
data analysis is currently underway which may alter the final predictions of mutations represented in 
our mutant library. 
 
The use of an isogenic background is major strength in our study in that it allows us to isolate and 
specifically predict phenotypes of pncA mutations, while eliminating the inherent variability in genetic 
background which may be a confounding factor in clinical isolates. It should be noted that sequencing 
of pncA may not predict all clinical pyrazinamide resistance, as mutations in rpsA168 and panD163,165 
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have also been implicated in conferring resistance. However variants in these genes likely account for 
a minority of pyrazinamide resistant cases since few mutations have been reported clinically 168,220,222. 
This is in stark contrast to mutations in pncA which are reported to be harboured in between 70 to 97% 
of pyrazinamide resistant cases 24,29,31-33,191,195-197,200,214-218,220, however these may be underestimates 
when taking into account the limited reported sequence data and the pitfalls of drug susceptibility 
testing.  
 
Given the random nature of the error-prone mutagenesis, our library did contain clones with wild 
typepncA and multiple mutations in pncA. Thus predictions of the resistance or susceptibility to 
pyrazinamide of pncA mutants was based on statistical analysis of pooled mutation abundance under 
the different screening conditions, rather than direct testing of individual mutants which would be 
extremely cumbersome and laborious. As such, there certainly will be false negative and, and to a lesser 
extent, false positive predictions though we do not have enough data to estimate this at present. Despite 
this, the high correlation between screen predictions and susceptibility results carried out through 
conventional drug susceptibility testing of isogenic pncA mutants (100% and 92.86% for resistant and 
susceptible predictions respectively) would suggest that our results are robust and reliable, particularly 
for resistance predictions. 
 
A striking observation in our data analysis were the differences in resistance conferring mutations 
identified in vitro vs in vivo. The majority of mutations found to be resistant in vitro were also found to 
be resistant in our in vivo murine treatment model while the converse was not true in that a high 
proportion of mutations identified as resistant in vivo were not selected through in vitro screening. These 
results suggests that selection was stronger in vivo that in vitro. This was surprising as the duration of 
exposure to pyrazinamide was similar, but in vitro, bacteria would have been in the presence of higher 
and continuous concentrations of the drug. Our in vitro screening methodology is based on an artificial 
sequential selection in the MGIT system in which bacterial growth is logarithmic and pyrazinamide is 
believed to have only modest in vitro killing efficacy against actively replicating M. tuberculosis 21,117. 
Although the mechanism of action of pyrazinamide has not been unequivocally defined, in vivo 
selection may reproduce conditions that enhance drug efficacy which would account for greater 
selection of enriched mutants. The role of the immune system in our in vivo screening is unknown but 
may have also contributed to stronger enrichment of resistance conferring mutant clones. 
 
Our murine treatment model does not perfectly replicate infection in a human model. For our in vivo 
screen, we utilized a high-dose infection in order to adequately represent our mutant library which is 
dissimilar to human infection.Lesions are markedly different from those that affect drug penetration 286. 
In addition, treatment of tuberculosis in humans is based on combinatory therapy 88,89 rather than 
monotherapy used in our screen. Mutations selected using monotherapy might not affect treatment 
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outcome in combination therapy. Nevertheless, conclusions derived from pyrazinamide treatment in a 
murine model may be closer to those observed in the treatment of human tuberculosis compared to in 
vitro models.  
 
We are however confident of the outcome of our screens due to the high degree of selection of stop 
codons which result in loss of function observed in both screens, the substantial overlap in mutations 
observed in our independent screening, as well as the results of phenotypic drug susceptibility testing 
of isogenic mutants. Our findings highlight the inherent limitations of clinical drug susceptibility 
testing. Understanding the mechanism of action of pyrazinamide in vivo would enable the development 
of a more reliable phenotypic test that more faithfully replicates the critical factors that account for drug 
efficacy in vivo. 
 
The role of an acidic extracellular environment and its impact on the efficacy of pyrazinamide has been 
greatly debated over the course of many decades. Although it was initially suggested that pyrazinamide 
required an acid environment to be active anti-tuberculosis agent 65,107,116,119,122,123, recent evidence has 
begun to uncouple this relationship. Consisting with previous findings 128,139, we observed that acidified 
media was not a prerequisite for pyrazinamide activity in vitro. Although susceptibility to pyrazinamide 
and growth inhibition were more pronounced when media was acidic, we observed that over-expression 
of pncA negated the requirement for acidity. We found our complement strain in standard culture media 
was equally susceptible to pyrazinamide as our H37Rv wild type control in acidified media. This 
overexpression of pncA in our complement strain resulted in hyper-susceptibility in acidified media. 
Taken together the results suggests that the in vitro activity of pyrazinamide is limited by drug 
activation. The hyper-susceptibility phenotype is both a strength and a limitation. While it widens the 
dynamic range of susceptibility within which we can select mutant, MICs obtained for our isogenic 
mutants cannot be directly compared to any available data from clinical isolates. 
 
We observed equivalent susceptibility to pyrazinoic acid across our H37Rv, complement and ΔpncA 
strains, with a fall in MIC in acidic media, indicating that the role of acid in the action of pyrazinamide 
is independent of its activation by pyrazinamidase. It could be that susceptibility to pyrazinamide is not 
directly dependent on an external acidic environment environment, but rather that an acidic environment 
may induce a stress response which in turn renders M. tuberculosis more susceptible to pyrazinamide. 
More experiments are needed to understand the optimal conditions for pyrazinamide killing in vitro 
which will help in improving phenotypic drug susceptibility testing. 
 
In our study we were able to show that reduction of pyrazinamidase abundance is a molecular basis for 
pyrazinamide resistance for many mutations and probably explains the widespread distribution of drug 
resistance conferring mutations throughout pncA. We were also able to show selective disruption of 
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enzymatic function212 without significant reductions in protein levels is a mechanism of resistance for 
substitutions at certain codons. The precise biological mechanisms by which these mutations may cause 
reduced abundance of the protein is yet to be elucidated, however it remains plausible that these 
mutations may affect transcriptional or translational efficiency or result in post-translational 
degradation of the protein due to structural deformities. It has been shown previously that expression 
of pncA can vary in pyrazinamide resistant strains harbouring pncA intragenic or promoter mutations 
201, however additional experimentation is required to concretely determine at what point in protein 
metabolism the low-abundance associated substitutions act.We did find a single mutation (V157E) with 
a discordant proteomic result relative to phenotypic susceptibility. However it was classified as 
intermediate and it may be an example of a resistance conferring mutation with an MIC close to the 
breakpoint that is not reliably identified using conventional susceptibility testing. 
 
In keeping with aim of this study, we were successful in generating a comprehensive pncA mutant 
library, as observed by the representation of 89.86% of possible pncA intragenic mutations at the amino 
acid level. Through phenotypic screening, we are provisionally able to predict the susceptibilities of 
85.74% of intragenic pncA mutations, with 411 mutations predicted to confer pyrazinamide resistance. 
As our list of resistance conferring mutations generated to date is provisional, we have not yet done a 
comprehensive formal comparison with clinically selected mutations from previous studies. This type 
of comparison is problematic because studies from different laboratories have used different phenotypic 
methods to evaluate susceptibilities and the differing backgrounds of clinical isolates. Nevertheless, a 
preliminary comparison of the results from a single prospective multicentre study from WHO reference 
laboratories 32 to our list of enriched mutations, showed a reasonable degree of agreement (75.83%) for 
mutations associated with pyrazinamide resistance. We anticipate that this congruence will improve 
with the conclusion of our additional data analysis and a more comprehensive comparative analysis 
against representative data sets. 
 
Random PCR mutagenesis and phenotypic screening of isogenic mutant libraries represents a powerful 
tool for defining novel resistance conferring mutations yet to be determined for other anti-tuberculosis 
drugs. In addition to validating the strengths of PCR mutagenesis and phenotypic screening of isogenic 
mutant libraries, we have also contributed further knowledge to our understanding of pyrazinamide 
activity. The serendipitous observation of hyper-susceptibility to pyrazinamide and the abrogation of 
an extracellular acidic through over-expression of pncA suggests that this over-expression could be a 
useful tool to study the elusive mode of action of pyrazinamide as it would allow for the assessment of 
mode of action independent of extracellular acidic conditions. We have also optimized a technique that 





In closing, our provisional list of mutations and associated predicted phenotypes represents a step 
towards a clinically applicable algorithm for interpreting pncA sequences. With the conclusion of the 
additional data analysis of our phenotypic screens we anticipate we will be able to rule in and rule out 
patients for successful pyrazinamide therapy. We believe our screens were close to saturation as the 
vast majority of stop codons were enriched but ongoing analysis and comparison with clinical studies 
should be able to refine our predictions and lead ultimately to a reference list and rapid genotypic based 







M. tuberculosis cultivation media 
 
7H9 Broth (1 Liter) 
4.9g Middlebrook 7H9 powder (271310, Difco, BD, USA) 
0.2% Glycerol 
0.05% Tween 80 
Water up to 900 mL 
100 mL Middlebrook OADC Enrichment supplement (212240, BBL, BD, USA)  
 
Filter sterilized using Corning 0.22µm filter sterilization units and stored at 2-8°C. 
 
 
7H10 Agar (500 mL) 
9.5g Middlebrook 7H10 powder (262710, Difco, BD, USA) 
0.5% Glycerol 
Water up to 450 mL 
 
Autoclave sterilized at 121°C for 15 minutes. 
Cooled to 55°C in waterbath. 
50 mL Middlebrook OADC Enrichment supplement (212240, BBL, BD, USA). 
Appropriate antibiotic added if necessary. 
Poured and allowed to set at room temperature until solid, then stored at 2-8°C. 
 
7H11 Agar 
10.5g Middlebrook 7H10 powder (283810, Difco, BD, USA) 
0.5% Glycerol 
Water up to 450 mL 
 
Autoclave sterilized at 121°C for 15 minutes. 
Cooled to 55°C in waterbath. 
50 mL Middlebrook OADC Enrichment supplement (212240, BBL, BD, USA). 
Appropriate antibiotic added if necessary. 





Modified Hartmans-de Bont (HDB) medium 
3.4 µM EDTA 
49 µM MgCl2•6H2O 
0.7 µM CaCl2•2H2O 
0.08 µM NaMoO4•2H2O 
0.17 µM CoCl2•6H2O 
0.62 µM MnCl2•2H2O 
0.7 µM ZnSO4•7H2O 
1.8 µM FeSO4•7H2O, 0.08 µM CuSO4•5H2O 
890 µM K2HPO4 
708 µM NaH2PO4 
15 mM (NH4)2SO4 
27.4 mM glycerol-13C3 






E. coli cultivation media 
 
LB Broth (500 mL) 
10g LB Lennox broth (L3022, Sigma Aldrich, USA) 
 10g/L Tryptone 
 5g/L Yeast Extract 
 5g/L NaCl 
500 mL water 
 
Autoclave sterilized at 121°C for 15 minutes. 
Allow to cool and store at room temperature. 
 
LB Agar (500 mL) 
10g LB Lennox broth (L3022, Sigma Aldrich, USA) 
 10g/L Tryptone 
 5g/L Yeast Extract 
 5g/L NaCl 
7.5g Agar (A1296, Sigma Aldrich, USA) 
500 mL water 
 
Autoclave sterilized at 121°C for 15 minutes. 
Cooled to 55°C in waterbath. 
Appropriate antibiotic added if necessary. 




0.5% yeast extract 
10 mM NaCl 
2.5 mM KCl 
10 mM MgCl2 
10 mM MgSO4 





Supplementary table 1: Strains 
 
Strain Lab Number Description Resistance marker Source 
E. coli DH5α sAY97 E. coli strain used for propagation of plasmids  Rubin Lab 
H37Rv sAY101 ATCC 27294 laboratory reference strain  Our lab 
H37RvΔpncA sAY251 H37Rv with pncA insertionally inactivated by a Hygromycin resistance cassette Hygromycin 
202 
Complement sAY245 ΔpncA containing L5 integrated wild typepncAconstitutively expressed of the MOP (pAY108) Hygromycin, Zeocin Our work 








Supplementary table 2: Plasmids 
 
Plasmid Description Resistance marker Source 
pAY1 pJEB402 L5 integrating plasmid containing constitutive mycobacterial optimizted promoter (MOP) Kanamycin Rubin Lab 
pAY21 pUC57 plasmid containing Emerald fluorescent protein Ampicillin Rubin Lab 
pAY29 pBlueScriptSK plasmid containing wild typepncA Ampicillin Rubin Lab 
pAY59 L5 integrating Gateway expression vector with Zeocin resistance marker Zeocin Rubin Lab 
pAY107 ZeoR, L5 integrating vector containing wild typepncA Zeocin Our work 
pAY108 ZeoR, L5 integrating vector with wild typepncA constitutively expressed from the MOP  Zeocin Our work 
pAY111 ZeoR, L5 integrating vector with Emerald fluorescent protein Zeocin Our work 
pAY112 ZeoR, L5 integrating vector with Emerald fluorescent protein constitutively expressed by the MOP Zeocin Our work 
pAY230 ZeoR, L5 integrating vector with MOP expressed pncA mutagenesis library Zeocin Our work 
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Supplementary table3: DNA oligonucleotide primers 
 

















Supplementary table 4: Proteomic peptides for mass spectrometry 
 












Supplementary table 5: Summary of PCR mutagenesis conditions 
 
Library ID DNA template (ng) PCR cycles 
A 100 20 
B 100 25 
C 100 30 
D 500 20 
E 500 25 
F 500 30 
G 1000 20 
H 1000 30 
I 25 15 
J 50 10 
K 50 15 
L 75 15 
M 100 15 
N 150 20 





Supplementary Table 6: Drug susceptibility testing results of isogenic pncA mutants. 
Minimum inhibitory concentration (MIC in µg/mL) were determined using the Bactec MGIT 960 PZA 
medium. Provisional in vitro and in vivo screen, as well as combined classifications are presented. E = 
Enriched, D = Depleted, U = Unselected 
 
Mutation in vitro in vivo Combined MIC (µg/mL) 
Comp (WT) NA NA 
 
1 - 4 
ΔpncA NA NA 
 
>500 
S74S U U U 1 
D136D D D D 1 
V109V D D D 1 
S18S D D D 4 
A134A D D D 4 
G108G D U D 4 
V93V D D D 4 
I6I U U U 4 
V131V U U U 4 
D8D U U U 4 
H43L U D D 1 
G55R U U U 1 
S104N U U U 1 
C72S U D D 4 
V7I D U D 4 
D40E D U D 4 
V147L U D D 4 
E144K D U D 4 
V9M D U D 4 
V157E U U U 4 
F81I U U U 4 
64 
 
Mutation in vitro in vivo Combined MIC (µg/mL) 
S67W U U U 4 
Q122R U U U 4 
R2G U U U 4 
I133T D U D 20 
D63G E E E 20 
E15V E U E 20 
R2W E E E 20 
V155M U E E 20 
D129N U E E 20 
P62L U E E 20 
G97D E E E 100 
V7L E E E 100 
D8E E E E 500 
C14Y U E E 500 
L85P E E E 500 
D136Y E E E >500 
D8N E E E >500 
V7F E E E >500 
Q10H E E E >500 
G101* E E E >500 
Q10* E E E >500 
C138G E E E >500 
G132A E E E >500 
H57D E E E >500 
C138S E E E >500 
L120Q U E E >500 




Supplementary Table 7: Provisional catalogue of associated phenotypes to mutations represented 
in our M. tuberculosispncA mutant library 
 
Resulting mutation in vitro prediction in vivo prediction Catalogue 
M1I Resistant Resistant Resistant 
M1L Resistant Resistant Resistant 
M1V Neutral Neutral Cautiously Susceptible 
R2G Neutral Neutral Cautiously Susceptible 
R2L Neutral Resistant Resistant 
R2Q Susceptible Susceptible Susceptible 
R2R Susceptible Susceptible Susceptible 
R2W Resistant Resistant Resistant 
A3A Resistant Resistant Resistant 
A3E Resistant Resistant Resistant 
A3G Resistant Neutral Resistant 
A3S Neutral Neutral Cautiously Susceptible 
A3T Neutral Resistant Resistant 
A3V Susceptible Susceptible Susceptible 
L4* Resistant Resistant Resistant 
L4F Neutral Resistant Resistant 
L4L Neutral Susceptible Susceptible 
L4M Susceptible Neutral Susceptible 
L4S Neutral Resistant Resistant 
L4V Neutral Neutral Cautiously Susceptible 
L4W Resistant Neutral Resistant 
I5F Resistant Resistant Resistant 
I5I Susceptible Susceptible Susceptible 
I5M Neutral Resistant Resistant 
I5N Resistant Resistant Resistant 
I5T Resistant Resistant Resistant 
I5V Susceptible Neutral Susceptible 
I6F Resistant Resistant Resistant 
I6I Neutral Neutral Cautiously Susceptible 
I6L Neutral Neutral Cautiously Susceptible 
I6M Neutral Resistant Resistant 
I6N Neutral Neutral Cautiously Susceptible 
I6S Neutral Neutral Cautiously Susceptible 
I6T Neutral Resistant Resistant 
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I6V Neutral Neutral Cautiously Susceptible 
V7A Neutral Resistant Resistant 
V7D Resistant Resistant Resistant 
V7F Resistant Resistant Resistant 
V7G Neutral Neutral Cautiously Susceptible 
V7I Susceptible Neutral Susceptible 
V7L Resistant Resistant Resistant 
V7V Neutral Susceptible Susceptible 
D8A Neutral Resistant Resistant 
D8D Neutral Neutral Cautiously Susceptible 
D8E Resistant Resistant Resistant 
D8G Resistant Resistant Resistant 
D8H Resistant Resistant Resistant 
D8N Resistant Resistant Resistant 
D8V Resistant Resistant Resistant 
D8Y Resistant Resistant Resistant 
V9A Neutral Resistant Resistant 
V9M Susceptible Neutral Susceptible 
V9V Resistant Resistant Resistant 
Q10* Resistant Resistant Resistant 
Q10E Neutral Resistant Resistant 
Q10H Resistant Resistant Resistant 
Q10K Neutral Neutral Cautiously Susceptible 
Q10L Resistant Resistant Resistant 
Q10P Neutral Neutral Cautiously Susceptible 
Q10R Resistant Resistant Resistant 
N11D Neutral Neutral Cautiously Susceptible 
N11H Neutral Susceptible Susceptible 
N11I Susceptible Neutral Susceptible 
N11K Neutral Neutral Cautiously Susceptible 
N11N Susceptible Neutral Susceptible 
N11S Susceptible Neutral Susceptible 
N11T Neutral Neutral Cautiously Susceptible 
N11Y Susceptible Neutral Susceptible 
D12D Susceptible Neutral Susceptible 
D12E Resistant Resistant Resistant 
D12G Neutral Resistant Resistant 
D12H Neutral Neutral Cautiously Susceptible 
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D12N Resistant Resistant Resistant 
D12V Neutral Neutral Cautiously Susceptible 
D12Y Neutral Resistant Resistant 
F13C Neutral Neutral Cautiously Susceptible 
F13F Susceptible Susceptible Susceptible 
F13I Resistant Neutral Resistant 
F13L Neutral Neutral Cautiously Susceptible 
F13S Neutral Neutral Cautiously Susceptible 
F13V Resistant Resistant Resistant 
F13Y Neutral Resistant Resistant 
C14* Resistant Resistant Resistant 
C14C Neutral Neutral Cautiously Susceptible 
C14F Neutral Susceptible Susceptible 
C14R Resistant Resistant Resistant 
C14S Resistant Neutral Resistant 
C14W Neutral Neutral Cautiously Susceptible 
C14Y Neutral Resistant Resistant 
E15* Resistant Resistant Resistant 
E15D Susceptible Neutral Susceptible 
E15E Neutral Neutral Cautiously Susceptible 
E15G Neutral Resistant Resistant 
E15K Susceptible Susceptible Susceptible 
E15Q Neutral Susceptible Susceptible 
E15V Resistant Neutral Resistant 
G16C Neutral Resistant Resistant 
G16D Neutral Neutral Cautiously Susceptible 
G16G Neutral Resistant Resistant 
G16R Resistant Resistant Resistant 
G16S Neutral Neutral Cautiously Susceptible 
G16V Neutral Neutral Cautiously Susceptible 
G17A Neutral Resistant Resistant 
G17C Neutral Resistant Resistant 
G17D Neutral Resistant Resistant 
G17G Susceptible Neutral Susceptible 
G17S Neutral Neutral Cautiously Susceptible 
S18* Resistant Resistant Resistant 
S18A Neutral Neutral Cautiously Susceptible 
S18L Neutral Resistant Resistant 
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S18P Neutral Neutral Cautiously Susceptible 
S18S Susceptible Susceptible Susceptible 
S18T Neutral Susceptible Susceptible 
S18W Neutral Resistant Resistant 
L19L Neutral Neutral Cautiously Susceptible 
L19M Neutral Resistant Resistant 
L19P Resistant Resistant Resistant 
L19Q Resistant Neutral Resistant 
L19R Neutral Neutral Cautiously Susceptible 
L19V Neutral Susceptible Susceptible 
A20A Susceptible Susceptible Susceptible 
A20E Neutral Susceptible Susceptible 
A20G Neutral Neutral Cautiously Susceptible 
A20S Susceptible Susceptible Susceptible 
A20T Susceptible Neutral Susceptible 
A20V Susceptible Neutral Susceptible 
V21A Neutral Resistant Resistant 
V21E Resistant Resistant Resistant 
V21I Neutral Neutral Cautiously Susceptible 
V21L Neutral Susceptible Susceptible 
V21V Resistant Neutral Resistant 
T22A Neutral Susceptible Susceptible 
T22N Neutral Neutral Cautiously Susceptible 
T22S Neutral Neutral Cautiously Susceptible 
T22T Neutral Neutral Cautiously Susceptible 
G23A Neutral Susceptible Susceptible 
G23D Neutral Neutral Cautiously Susceptible 
G23G Neutral Susceptible Susceptible 
G23R Neutral Susceptible Susceptible 
G23S Neutral Neutral Cautiously Susceptible 
G23V Neutral Neutral Cautiously Susceptible 
G24C Resistant Neutral Resistant 
G24D Resistant Resistant Resistant 
G24G Susceptible Neutral Susceptible 
G24R Neutral Neutral Cautiously Susceptible 
G24S Neutral Neutral Cautiously Susceptible 
G24V Neutral Resistant Resistant 
A25A Neutral Resistant Resistant 
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A25D Neutral Neutral Cautiously Susceptible 
A25P Neutral Neutral Cautiously Susceptible 
A25S Neutral Neutral Cautiously Susceptible 
A25T Susceptible Susceptible Susceptible 
A25V Susceptible Susceptible Susceptible 
A26A Susceptible Susceptible Susceptible 
A26G Neutral Neutral Cautiously Susceptible 
A26P Susceptible Neutral Susceptible 
A26S Neutral Susceptible Susceptible 
A26T Susceptible Susceptible Susceptible 
A26V Resistant Neutral Resistant 
L27L Susceptible Susceptible Susceptible 
L27M Neutral Resistant Resistant 
L27P Resistant Resistant Resistant 
L27Q Neutral Resistant Resistant 
L27R Susceptible Neutral Susceptible 
L27V Neutral Susceptible Susceptible 
A28A Susceptible Susceptible Susceptible 
A28D Neutral Neutral Cautiously Susceptible 
A28G Neutral Susceptible Susceptible 
A28P Neutral Resistant Resistant 
A28S Neutral Resistant Resistant 
A28T Neutral Neutral Cautiously Susceptible 
A28V Neutral Neutral Cautiously Susceptible 
R29C Resistant Neutral Resistant 
R29G Neutral Susceptible Susceptible 
R29H Neutral Neutral Cautiously Susceptible 
R29L Neutral Neutral Cautiously Susceptible 
R29P Neutral Resistant Resistant 
R29R Susceptible Susceptible Susceptible 
R29S Neutral Susceptible Susceptible 
A30A Neutral Resistant Resistant 
A30D Susceptible Susceptible Susceptible 
A30P Resistant Resistant Resistant 
A30T Susceptible Susceptible Susceptible 
A30V Resistant Resistant Resistant 
I31F Resistant Resistant Resistant 
I31I Susceptible Neutral Susceptible 
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I31M Neutral Neutral Cautiously Susceptible 
I31N Resistant Resistant Resistant 
I31T Neutral Neutral Cautiously Susceptible 
I31V Neutral Resistant Resistant 
S32C Neutral Neutral Cautiously Susceptible 
S32G Susceptible Neutral Susceptible 
S32I Neutral Resistant Resistant 
S32N Resistant Neutral Resistant 
S32S Neutral Neutral Cautiously Susceptible 
S32T Susceptible Susceptible Susceptible 
D33A Susceptible Susceptible Susceptible 
D33D Susceptible Susceptible Susceptible 
D33E Neutral Neutral Cautiously Susceptible 
D33G Neutral Neutral Cautiously Susceptible 
D33H Neutral Neutral Cautiously Susceptible 
D33N Susceptible Neutral Susceptible 
D33V Neutral Neutral Cautiously Susceptible 
D33Y Neutral Neutral Cautiously Susceptible 
Y34* Neutral Neutral Cautiously Susceptible 
Y34C Neutral Resistant Resistant 
Y34F Neutral Susceptible Susceptible 
Y34H Neutral Susceptible Susceptible 
Y34N Neutral Neutral Cautiously Susceptible 
Y34S Neutral Neutral Cautiously Susceptible 
Y34Y Resistant Resistant Resistant 
L35L Susceptible Neutral Susceptible 
L35M Neutral Neutral Cautiously Susceptible 
L35P Neutral Resistant Resistant 
L35Q Neutral Resistant Resistant 
L35R Neutral Resistant Resistant 
L35V Neutral Susceptible Susceptible 
A36A Susceptible Susceptible Susceptible 
A36G Neutral Neutral Cautiously Susceptible 
A36P Susceptible Neutral Susceptible 
A36S Resistant Resistant Resistant 
A36T Resistant Neutral Resistant 
A36V Susceptible Susceptible Susceptible 
E37* Resistant Resistant Resistant 
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E37A Neutral Neutral Cautiously Susceptible 
E37D Susceptible Neutral Susceptible 
E37E Neutral Neutral Cautiously Susceptible 
E37G Neutral Neutral Cautiously Susceptible 
E37K Neutral Resistant Resistant 
E37Q Neutral Neutral Cautiously Susceptible 
E37V Resistant Neutral Resistant 
A38A Neutral Neutral Cautiously Susceptible 
A38E Neutral Neutral Cautiously Susceptible 
A38G Resistant Neutral Resistant 
A38S Resistant Neutral Resistant 
A38T Susceptible Neutral Susceptible 
A38V Susceptible Susceptible Susceptible 
A39A Neutral Susceptible Susceptible 
A39E Neutral Neutral Cautiously Susceptible 
A39G Susceptible Susceptible Susceptible 
A39P Neutral Neutral Cautiously Susceptible 
A39S Susceptible Neutral Susceptible 
A39T Neutral Neutral Cautiously Susceptible 
A39V Susceptible Neutral Susceptible 
D40D Susceptible Neutral Susceptible 
D40E Susceptible Neutral Susceptible 
D40G Neutral Resistant Resistant 
D40H Resistant Resistant Resistant 
D40N Neutral Neutral Cautiously Susceptible 
D40V Neutral Neutral Cautiously Susceptible 
D40Y Susceptible Neutral Susceptible 
Y41* Resistant Resistant Resistant 
Y41F Neutral Neutral Cautiously Susceptible 
Y41H Resistant Neutral Resistant 
Y41N Neutral Neutral Cautiously Susceptible 
Y41S Neutral Neutral Cautiously Susceptible 
Y41Y Neutral Resistant Resistant 
H42D Neutral Resistant Resistant 
H42H Neutral Neutral Cautiously Susceptible 
H42L Susceptible Susceptible Susceptible 
H42N Resistant Resistant Resistant 
H42Q Resistant Resistant Resistant 
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H42R Neutral Susceptible Susceptible 
H42Y Neutral Neutral Cautiously Susceptible 
H43H Neutral Neutral Cautiously Susceptible 
H43L Neutral Susceptible Susceptible 
H43N Neutral Neutral Cautiously Susceptible 
H43P Neutral Resistant Resistant 
H43R Susceptible Neutral Susceptible 
H43Y Susceptible Neutral Susceptible 
V44A Neutral Resistant Resistant 
V44D Resistant Resistant Resistant 
V44F Neutral Neutral Cautiously Susceptible 
V44I Susceptible Susceptible Susceptible 
V44L Neutral Susceptible Susceptible 
V45A Neutral Susceptible Susceptible 
V45E Resistant Resistant Resistant 
V45M Neutral Resistant Resistant 
V45V Neutral Neutral Cautiously Susceptible 
A46A Resistant Neutral Resistant 
A46E Neutral Resistant Resistant 
A46P Resistant Resistant Resistant 
A46S Susceptible Neutral Susceptible 
A46T Neutral Resistant Resistant 
A46V Resistant Resistant Resistant 
T47A Neutral Neutral Cautiously Susceptible 
T47I Resistant Resistant Resistant 
T47P Neutral Neutral Cautiously Susceptible 
T47T Susceptible Neutral Susceptible 
K48* Resistant Resistant Resistant 
K48E Resistant Resistant Resistant 
K48K Neutral Neutral Cautiously Susceptible 
K48N Resistant Resistant Resistant 
K48Q Neutral Susceptible Susceptible 
K48R Neutral Neutral Cautiously Susceptible 
K48T Neutral Resistant Resistant 
D49A Neutral Neutral Cautiously Susceptible 
D49D Neutral Susceptible Susceptible 
D49E Neutral Resistant Resistant 
D49G Resistant Resistant Resistant 
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D49H Resistant Neutral Resistant 
D49N Resistant Resistant Resistant 
D49V Resistant Resistant Resistant 
D49Y Neutral Resistant Resistant 
F50F Resistant Resistant Resistant 
F50I Neutral Neutral Cautiously Susceptible 
F50L Neutral Resistant Resistant 
F50S Resistant Resistant Resistant 
F50V Neutral Neutral Cautiously Susceptible 
F50Y Susceptible Susceptible Cautiously Susceptible 
H51D Neutral Resistant Resistant 
H51H Susceptible Neutral Susceptible 
H51L Neutral Resistant Resistant 
H51N Neutral Resistant Resistant 
H51Q Neutral Neutral Cautiously Susceptible 
H51R Neutral Resistant Resistant 
H51Y Resistant Resistant Resistant 
I52F Neutral Neutral Cautiously Susceptible 
I52I Neutral Neutral Cautiously Susceptible 
I52L Neutral Neutral Cautiously Susceptible 
I52M Neutral Susceptible Susceptible 
I52N Neutral Susceptible Susceptible 
I52S Neutral Neutral Cautiously Susceptible 
I52T Resistant Neutral Resistant 
I52V Susceptible Neutral Susceptible 
D53D Neutral Susceptible Susceptible 
D53E Neutral Neutral Cautiously Susceptible 
D53N Susceptible Susceptible Susceptible 
D53V Neutral Neutral Cautiously Susceptible 
D53Y Neutral Neutral Cautiously Susceptible 
P54L Resistant Resistant Resistant 
P54P Susceptible Neutral Susceptible 
P54Q Neutral Resistant Resistant 
P54R Neutral Neutral Cautiously Susceptible 
P54S Resistant Resistant Resistant 
P54T Resistant Resistant Resistant 
G55C Neutral Neutral Cautiously Susceptible 
G55D Neutral Neutral Cautiously Susceptible 
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G55G Neutral Susceptible Susceptible 
G55R Neutral Neutral Cautiously Susceptible 
G55S Susceptible Neutral Susceptible 
G55V Neutral Susceptible Susceptible 
D56A Neutral Susceptible Susceptible 
D56E Neutral Susceptible Susceptible 
D56G Neutral Neutral Cautiously Susceptible 
D56H Neutral Neutral Cautiously Susceptible 
D56N Neutral Susceptible Susceptible 
D56V Neutral Neutral Cautiously Susceptible 
D56Y Neutral Neutral Cautiously Susceptible 
H57D Resistant Resistant Resistant 
H57H Susceptible Susceptible Susceptible 
H57L Neutral Resistant Resistant 
H57N Resistant Resistant Resistant 
H57P Neutral Neutral Cautiously Susceptible 
H57Q Resistant Resistant Resistant 
H57R Resistant Resistant Resistant 
H57Y Neutral Resistant Resistant 
F58C Neutral Neutral Cautiously Susceptible 
F58F Neutral Resistant Resistant 
F58I Neutral Neutral Cautiously Susceptible 
F58L Resistant Resistant Resistant 
F58S Resistant Resistant Resistant 
F58Y Neutral Neutral Cautiously Susceptible 
S59C Neutral Neutral Cautiously Susceptible 
S59F Neutral Resistant Resistant 
S59P Neutral Resistant Resistant 
S59S Susceptible Neutral Susceptible 
S59T Neutral Neutral Cautiously Susceptible 
S59Y Neutral Neutral Cautiously Susceptible 
G60A Neutral Neutral Cautiously Susceptible 
G60C Neutral Susceptible Susceptible 
G60D Susceptible Susceptible Susceptible 
G60G Susceptible Neutral Susceptible 
G60R Neutral Neutral Cautiously Susceptible 
G60S Susceptible Neutral Susceptible 
G60V Susceptible Susceptible Susceptible 
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T61A Neutral Susceptible Susceptible 
T61I Susceptible Neutral Susceptible 
T61K Neutral Susceptible Susceptible 
T61S Neutral Neutral Cautiously Susceptible 
T61T Neutral Resistant Resistant 
P62A Neutral Neutral Cautiously Susceptible 
P62L Neutral Resistant Resistant 
P62Q Neutral Resistant Resistant 
P62R Neutral Resistant Resistant 
P62S Neutral Resistant Resistant 
P62T Neutral Neutral Cautiously Susceptible 
D63D Susceptible Neutral Susceptible 
D63E Neutral Resistant Resistant 
D63G Resistant Resistant Resistant 
D63H Neutral Resistant Resistant 
D63N Susceptible Neutral Susceptible 
D63V Neutral Resistant Resistant 
D63Y Neutral Resistant Resistant 
Y64* Resistant Resistant Resistant 
Y64C Neutral Neutral Cautiously Susceptible 
Y64D Neutral Resistant Resistant 
Y64F Neutral Resistant Resistant 
Y64H Resistant Neutral Resistant 
Y64N Neutral Susceptible Susceptible 
Y64Y Neutral Neutral Cautiously Susceptible 
S65C Susceptible Susceptible Susceptible 
S65F Resistant Neutral Resistant 
S65P Resistant Resistant Resistant 
S65S Neutral Resistant Resistant 
S65T Susceptible Neutral Susceptible 
S65Y Neutral Neutral Cautiously Susceptible 
S66* Resistant Resistant Resistant 
S66L Susceptible Neutral Susceptible 
S66S Susceptible Susceptible Susceptible 
S66T Neutral Susceptible Susceptible 
S66W Neutral Neutral Cautiously Susceptible 
S67* Neutral Resistant Resistant 
S67A Neutral Neutral Cautiously Susceptible 
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S67L Neutral Neutral Cautiously Susceptible 
S67P Neutral Resistant Resistant 
S67S Neutral Neutral Cautiously Susceptible 
S67T Neutral Susceptible Susceptible 
S67W Neutral Neutral Cautiously Susceptible 
W68* Resistant Resistant Resistant 
W68C Resistant Resistant Resistant 
W68G Resistant Neutral Resistant 
W68L Resistant Resistant Resistant 
W68R Resistant Resistant Resistant 
P69A Neutral Neutral Cautiously Susceptible 
P69L Neutral Resistant Resistant 
P69P Susceptible Susceptible Susceptible 
P69Q Neutral Neutral Cautiously Susceptible 
P69S Resistant Resistant Resistant 
P69T Neutral Neutral Cautiously Susceptible 
P70A Neutral Neutral Cautiously Susceptible 
P70L Neutral Neutral Cautiously Susceptible 
P70P Neutral Resistant Resistant 
P70Q Neutral Susceptible Susceptible 
P70R Susceptible Neutral Susceptible 
P70S Resistant Resistant Resistant 
P70T Neutral Neutral Cautiously Susceptible 
H71D Neutral Resistant Resistant 
H71H Resistant Neutral Resistant 
H71L Resistant Resistant Resistant 
H71N Neutral Neutral Cautiously Susceptible 
H71P Resistant Neutral Resistant 
H71Q Resistant Resistant Resistant 
H71R Resistant Resistant Resistant 
H71Y Resistant Resistant Resistant 
C72* Resistant Resistant Resistant 
C72C Neutral Susceptible Susceptible 
C72F Resistant Resistant Resistant 
C72R Resistant Resistant Resistant 
C72S Neutral Susceptible Susceptible 
C72W Resistant Resistant Resistant 
C72Y Resistant Resistant Resistant 
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V73A Neutral Neutral Cautiously Susceptible 
V73D Neutral Resistant Resistant 
V73F Neutral Resistant Resistant 
V73I Susceptible Susceptible Susceptible 
V73L Susceptible Neutral Susceptible 
V73V Susceptible Neutral Susceptible 
S74C Resistant Neutral Resistant 
S74G Susceptible Susceptible Susceptible 
S74I Neutral Susceptible Susceptible 
S74N Neutral Neutral Cautiously Susceptible 
S74R Susceptible Neutral Susceptible 
S74S Neutral Neutral Cautiously Susceptible 
G75A Neutral Neutral Cautiously Susceptible 
G75C Susceptible Neutral Susceptible 
G75D Neutral Susceptible Susceptible 
G75G Neutral Susceptible Susceptible 
G75R Neutral Neutral Cautiously Susceptible 
G75V Resistant Resistant Resistant 
T76A Neutral Neutral Cautiously Susceptible 
T76I Neutral Resistant Resistant 
T76N Susceptible Neutral Susceptible 
T76S Neutral Neutral Cautiously Susceptible 
T76T Neutral Susceptible Susceptible 
P77H Neutral Neutral Cautiously Susceptible 
P77L Neutral Susceptible Susceptible 
P77P Susceptible Susceptible Susceptible 
P77S Neutral Neutral Cautiously Susceptible 
P77T Neutral Neutral Cautiously Susceptible 
G78C Resistant Resistant Resistant 
G78D Resistant Resistant Resistant 
G78G Susceptible Susceptible Susceptible 
G78R Neutral Resistant Resistant 
G78S Neutral Neutral Cautiously Susceptible 
G78V Resistant Resistant Resistant 
A79A Susceptible Neutral Susceptible 
A79E Neutral Neutral Cautiously Susceptible 
A79P Resistant Resistant Resistant 
A79S Susceptible Neutral Susceptible 
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A79T Neutral Susceptible Susceptible 
A79V Susceptible Neutral Susceptible 
D80D Susceptible Susceptible Susceptible 
D80G Neutral Neutral Cautiously Susceptible 
D80H Resistant Resistant Resistant 
D80V Susceptible Neutral Susceptible 
D80Y Neutral Neutral Cautiously Susceptible 
F81F Neutral Neutral Cautiously Susceptible 
F81I Neutral Neutral Cautiously Susceptible 
F81L Neutral Neutral Cautiously Susceptible 
F81S Resistant Resistant Resistant 
F81V Neutral Neutral Cautiously Susceptible 
H82D Neutral Neutral Cautiously Susceptible 
H82H Neutral Neutral Cautiously Susceptible 
H82L Neutral Resistant Resistant 
H82N Neutral Neutral Cautiously Susceptible 
H82Q Susceptible Neutral Susceptible 
H82Y Neutral Neutral Cautiously Susceptible 
P83A Neutral Neutral Cautiously Susceptible 
P83H Neutral Neutral Cautiously Susceptible 
P83L Neutral Resistant Resistant 
P83P Susceptible Susceptible Susceptible 
P83R Neutral Neutral Cautiously Susceptible 
P83S Neutral Susceptible Susceptible 
P83T Neutral Neutral Cautiously Susceptible 
S84C Susceptible Neutral Susceptible 
S84G Neutral Susceptible Susceptible 
S84I Susceptible Susceptible Susceptible 
S84N Neutral Susceptible Susceptible 
S84R Neutral Susceptible Susceptible 
S84S Susceptible Susceptible Susceptible 
S84T Neutral Neutral Cautiously Susceptible 
L85L Neutral Susceptible Susceptible 
L85M Neutral Resistant Resistant 
L85P Resistant Resistant Resistant 
L85Q Resistant Resistant Resistant 
L85R Resistant Resistant Resistant 
L85V Neutral Susceptible Susceptible 
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D86A Susceptible Neutral Susceptible 
D86D Neutral Neutral Cautiously Susceptible 
D86E Susceptible Susceptible Susceptible 
D86G Susceptible Susceptible Susceptible 
D86N Neutral Susceptible Susceptible 
D86V Resistant Resistant Resistant 
D86Y Neutral Resistant Resistant 
T87A Susceptible Neutral Susceptible 
T87K Neutral Neutral Cautiously Susceptible 
T87M Neutral Neutral Cautiously Susceptible 
T87R Neutral Susceptible Susceptible 
T87S Neutral Neutral Cautiously Susceptible 
S88* Resistant Resistant Resistant 
S88A Susceptible Neutral Susceptible 
S88L Neutral Neutral Cautiously Susceptible 
S88P Neutral Neutral Cautiously Susceptible 
S88S Susceptible Neutral Susceptible 
S88T Neutral Neutral Cautiously Susceptible 
A89A Susceptible Susceptible Susceptible 
A89E Neutral Neutral Cautiously Susceptible 
A89G Neutral Neutral Cautiously Susceptible 
A89P Susceptible Neutral Susceptible 
A89S Neutral Susceptible Susceptible 
A89T Susceptible Neutral Susceptible 
A89V Resistant Resistant Resistant 
I90I Susceptible Neutral Susceptible 
I90M Neutral Resistant Resistant 
I90N Neutral Neutral Cautiously Susceptible 
I90T Neutral Neutral Cautiously Susceptible 
I90V Neutral Neutral Cautiously Susceptible 
E91* Resistant Neutral Resistant 
E91D Susceptible Neutral Susceptible 
E91E Susceptible Neutral Susceptible 
E91G Neutral Neutral Cautiously Susceptible 
E91K Neutral Neutral Cautiously Susceptible 
E91V Resistant Resistant Resistant 
A92A Resistant Neutral Resistant 
A92E Neutral Resistant Resistant 
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A92P Neutral Neutral Cautiously Susceptible 
A92S Neutral Susceptible Susceptible 
A92T Neutral Resistant Resistant 
A92V Susceptible Neutral Susceptible 
V93A Neutral Neutral Cautiously Susceptible 
V93E Neutral Resistant Resistant 
V93L Neutral Neutral Cautiously Susceptible 
V93M Resistant Neutral Resistant 
V93V Susceptible Susceptible Susceptible 
F94C Resistant Neutral Resistant 
F94F Resistant Resistant Resistant 
F94I Neutral Neutral Cautiously Susceptible 
F94L Resistant Resistant Resistant 
F94S Resistant Resistant Resistant 
F94Y Neutral Neutral Cautiously Susceptible 
Y95* Resistant Resistant Resistant 
Y95C Neutral Neutral Cautiously Susceptible 
Y95F Neutral Resistant Resistant 
Y95H Susceptible Neutral Susceptible 
Y95N Neutral Neutral Cautiously Susceptible 
Y95Y Neutral Neutral Cautiously Susceptible 
K96* Resistant Resistant Resistant 
K96E Resistant Resistant Resistant 
K96K Susceptible Susceptible Susceptible 
K96M Resistant Resistant Resistant 
K96N Resistant Resistant Resistant 
K96Q Resistant Resistant Resistant 
K96R Resistant Resistant Resistant 
K96T Neutral Resistant Resistant 
G97A Neutral Neutral Cautiously Susceptible 
G97C Resistant Resistant Resistant 
G97D Resistant Resistant Resistant 
G97G Neutral Neutral Cautiously Susceptible 
G97R Neutral Neutral Cautiously Susceptible 
G97S Resistant Resistant Resistant 
G97V Neutral Neutral Cautiously Susceptible 
A98A Susceptible Susceptible Susceptible 
A98D Neutral Neutral Cautiously Susceptible 
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A98P Neutral Neutral Cautiously Susceptible 
A98S Neutral Neutral Cautiously Susceptible 
A98T Neutral Neutral Cautiously Susceptible 
A98V Neutral Neutral Cautiously Susceptible 
Y99* Resistant Resistant Resistant 
Y99C Neutral Neutral Cautiously Susceptible 
Y99D Neutral Susceptible Susceptible 
Y99F Susceptible Susceptible Susceptible 
Y99H Neutral Neutral Cautiously Susceptible 
Y99N Neutral Susceptible Susceptible 
Y99Y Neutral Neutral Cautiously Susceptible 
T100A Neutral Susceptible Susceptible 
T100I Susceptible Neutral Susceptible 
T100N Neutral Neutral Cautiously Susceptible 
T100P Neutral Neutral Cautiously Susceptible 
T100S Neutral Neutral Cautiously Susceptible 
T100T Susceptible Susceptible Susceptible 
G101* Resistant Resistant Resistant 
G101E Resistant Resistant Resistant 
G101G Neutral Susceptible Susceptible 
G101R Susceptible Neutral Susceptible 
G101V Neutral Neutral Cautiously Susceptible 
A102E Susceptible Neutral Susceptible 
A102G Neutral Neutral Cautiously Susceptible 
A102P Neutral Resistant Resistant 
A102S Susceptible Neutral Susceptible 
A102T Resistant Resistant Resistant 
Y103* Neutral Resistant Resistant 
Y103C Susceptible Neutral Susceptible 
Y103F Neutral Neutral Cautiously Susceptible 
Y103H Neutral Neutral Cautiously Susceptible 
Y103N Neutral Neutral Cautiously Susceptible 
Y103S Neutral Neutral Cautiously Susceptible 
Y103Y Resistant Neutral Resistant 
S104C Resistant Resistant Resistant 
S104G Neutral Resistant Resistant 
S104I Neutral Resistant Resistant 
S104N Neutral Neutral Cautiously Susceptible 
82 
 
S104R Resistant Resistant Resistant 
S104S Susceptible Susceptible Susceptible 
G105A Susceptible Neutral Susceptible 
G105C Susceptible Neutral Susceptible 
G105D Resistant Resistant Resistant 
G105G Susceptible Susceptible Susceptible 
G105R Neutral Resistant Resistant 
G105S Susceptible Neutral Susceptible 
G105V Neutral Resistant Resistant 
F106F Susceptible Neutral Susceptible 
F106I Resistant Resistant Resistant 
F106S Neutral Resistant Resistant 
F106V Neutral Neutral Cautiously Susceptible 
F106Y Resistant Resistant Resistant 
E107* Neutral Resistant Resistant 
E107D Susceptible Susceptible Susceptible 
E107E Neutral Neutral Cautiously Susceptible 
E107G Neutral Susceptible Susceptible 
E107K Susceptible Neutral Susceptible 
E107Q Susceptible Neutral Susceptible 
E107V Susceptible Neutral Susceptible 
G108* Resistant Resistant Resistant 
G108E Resistant Resistant Resistant 
G108G Susceptible Neutral Susceptible 
G108R Resistant Resistant Resistant 
G108V Neutral Neutral Cautiously Susceptible 
V109A Neutral Neutral Cautiously Susceptible 
V109D Neutral Neutral Cautiously Susceptible 
V109F Susceptible Neutral Susceptible 
V109G Neutral Susceptible Susceptible 
V109L Resistant Neutral Resistant 
V109V Susceptible Susceptible Susceptible 
D110D Neutral Neutral Cautiously Susceptible 
D110G Neutral Susceptible Susceptible 
D110H Neutral Resistant Resistant 
D110N Neutral Resistant Resistant 
E111* Resistant Resistant Resistant 
E111A Neutral Susceptible Susceptible 
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E111D Susceptible Neutral Susceptible 
E111E Neutral Neutral Cautiously Susceptible 
E111G Neutral Neutral Cautiously Susceptible 
E111K Susceptible Susceptible Susceptible 
E111Q Neutral Neutral Cautiously Susceptible 
N112D Neutral Susceptible Susceptible 
N112H Neutral Susceptible Susceptible 
N112I Neutral Resistant Resistant 
N112K Neutral Susceptible Susceptible 
N112N Susceptible Susceptible Susceptible 
N112S Resistant Neutral Resistant 
N112T Neutral Neutral Cautiously Susceptible 
N112Y Neutral Neutral Cautiously Susceptible 
G113A Susceptible Neutral Susceptible 
G113C Neutral Neutral Cautiously Susceptible 
G113D Neutral Neutral Cautiously Susceptible 
G113G Susceptible Neutral Susceptible 
G113R Susceptible Susceptible Susceptible 
G113S Neutral Neutral Cautiously Susceptible 
G113V Susceptible Susceptible Susceptible 
T114A Neutral Neutral Cautiously Susceptible 
T114M Neutral Neutral Cautiously Susceptible 
T114P Neutral Neutral Cautiously Susceptible 
T114S Neutral Neutral Cautiously Susceptible 
P115A Resistant Resistant Resistant 
P115L Susceptible Susceptible Susceptible 
P115P Neutral Resistant Resistant 
P115Q Neutral Neutral Cautiously Susceptible 
P115R Neutral Resistant Resistant 
P115S Neutral Neutral Cautiously Susceptible 
P115T Neutral Neutral Cautiously Susceptible 
L116L Susceptible Susceptible Susceptible 
L116M Susceptible Neutral Susceptible 
L116P Neutral Resistant Resistant 
L116Q Resistant Resistant Resistant 
L116R Neutral Resistant Resistant 
L116V Neutral Resistant Resistant 
L117L Susceptible Susceptible Susceptible 
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L117M Susceptible Neutral Susceptible 
L117P Susceptible Neutral Susceptible 
L117Q Neutral Neutral Cautiously Susceptible 
L117R Neutral Neutral Cautiously Susceptible 
L117V Susceptible Susceptible Susceptible 
N118D Neutral Neutral Cautiously Susceptible 
N118I Neutral Neutral Cautiously Susceptible 
N118K Neutral Neutral Cautiously Susceptible 
N118N Neutral Neutral Cautiously Susceptible 
N118S Neutral Susceptible Susceptible 
N118Y Neutral Neutral Cautiously Susceptible 
W119* Resistant Resistant Resistant 
W119C Neutral Neutral Cautiously Susceptible 
W119G Neutral Neutral Cautiously Susceptible 
W119L Neutral Resistant Resistant 
W119R Resistant Resistant Resistant 
L120M Susceptible Neutral Susceptible 
L120P Resistant Resistant Resistant 
L120Q Neutral Resistant Resistant 
L120R Neutral Resistant Resistant 
L120V Neutral Neutral Cautiously Susceptible 
R121G Neutral Neutral Cautiously Susceptible 
R121L Susceptible Susceptible Susceptible 
R121P Neutral Resistant Resistant 
R121Q Resistant Neutral Resistant 
R121R Susceptible Susceptible Susceptible 
R121W Neutral Neutral Cautiously Susceptible 
Q122* Resistant Resistant Resistant 
Q122E Neutral Neutral Cautiously Susceptible 
Q122H Neutral Neutral Cautiously Susceptible 
Q122K Resistant Neutral Resistant 
Q122L Neutral Susceptible Susceptible 
Q122Q Neutral Neutral Cautiously Susceptible 
Q122R Neutral Neutral Cautiously Susceptible 
R123C Neutral Neutral Cautiously Susceptible 
R123G Neutral Susceptible Susceptible 
R123H Susceptible Susceptible Susceptible 
R123L Susceptible Susceptible Susceptible 
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R123P Neutral Neutral Cautiously Susceptible 
R123R Neutral Neutral Cautiously Susceptible 
R123S Neutral Neutral Cautiously Susceptible 
G124A Susceptible Susceptible Susceptible 
G124C Neutral Susceptible Susceptible 
G124D Neutral Susceptible Susceptible 
G124G Susceptible Neutral Susceptible 
G124V Susceptible Neutral Susceptible 
V125A Resistant Resistant Resistant 
V125D Neutral Resistant Resistant 
V125F Neutral Resistant Resistant 
V125G Neutral Neutral Cautiously Susceptible 
V125I Susceptible Neutral Susceptible 
V125L Neutral Susceptible Susceptible 
V125V Resistant Neutral Resistant 
D126D Susceptible Neutral Susceptible 
D126E Neutral Neutral Cautiously Susceptible 
D126G Neutral Neutral Cautiously Susceptible 
D126H Neutral Susceptible Susceptible 
D126N Susceptible Susceptible Susceptible 
D126V Susceptible Neutral Susceptible 
D126Y Neutral Susceptible Susceptible 
E127* Neutral Neutral Cautiously Susceptible 
E127E Neutral Susceptible Susceptible 
E127G Susceptible Susceptible Susceptible 
E127K Neutral Susceptible Susceptible 
E127V Neutral Neutral Cautiously Susceptible 
V128A Neutral Resistant Resistant 
V128D Neutral Neutral Cautiously Susceptible 
V128F Neutral Neutral Cautiously Susceptible 
V128G Neutral Resistant Resistant 
V128I Susceptible Neutral Susceptible 
V128L Neutral Neutral Cautiously Susceptible 
V128V Susceptible Susceptible Susceptible 
D129D Neutral Susceptible Susceptible 
D129E Neutral Resistant Resistant 
D129G Neutral Neutral Cautiously Susceptible 
D129H Susceptible Neutral Susceptible 
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D129N Neutral Resistant Resistant 
D129V Susceptible Neutral Susceptible 
D129Y Neutral Resistant Resistant 
V130A Neutral Resistant Resistant 
V130E Resistant Resistant Resistant 
V130L Susceptible Susceptible Susceptible 
V130V Susceptible Susceptible Susceptible 
V131A Susceptible Susceptible Susceptible 
V131D Resistant Resistant Resistant 
V131F Resistant Resistant Resistant 
V131G Neutral Neutral Cautiously Susceptible 
V131I Neutral Neutral Cautiously Susceptible 
V131L Susceptible Neutral Susceptible 
V131V Neutral Neutral Cautiously Susceptible 
G132A Resistant Resistant Resistant 
G132C Resistant Resistant Resistant 
G132D Resistant Resistant Resistant 
G132G Neutral Resistant Resistant 
G132R Resistant Resistant Resistant 
G132S Resistant Resistant Resistant 
G132V Neutral Resistant Resistant 
I133F Resistant Resistant Resistant 
I133I Neutral Neutral Cautiously Susceptible 
I133M Susceptible Susceptible Susceptible 
I133N Resistant Resistant Resistant 
I133S Neutral Resistant Resistant 
I133T Susceptible Neutral Susceptible 
I133V Neutral Susceptible Susceptible 
A134A Susceptible Susceptible Susceptible 
A134D Neutral Neutral Cautiously Susceptible 
A134G Neutral Resistant Resistant 
A134P Resistant Neutral Resistant 
A134S Susceptible Susceptible Susceptible 
A134T Resistant Resistant Resistant 
A134V Resistant Resistant Resistant 
T135A Neutral Neutral Cautiously Susceptible 
T135I Resistant Neutral Resistant 
T135N Neutral Resistant Resistant 
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T135P Neutral Resistant Resistant 
T135S Susceptible Neutral Susceptible 
T135T Neutral Susceptible Susceptible 
D136D Susceptible Susceptible Susceptible 
D136E Neutral Neutral Cautiously Susceptible 
D136G Neutral Neutral Cautiously Susceptible 
D136H Neutral Resistant Resistant 
D136N Susceptible Neutral Susceptible 
D136V Resistant Resistant Resistant 
D136Y Resistant Resistant Resistant 
H137D Neutral Neutral Cautiously Susceptible 
H137H Neutral Susceptible Susceptible 
H137L Neutral Neutral Cautiously Susceptible 
H137N Neutral Resistant Resistant 
H137P Resistant Resistant Resistant 
H137Q Neutral Resistant Resistant 
H137R Neutral Neutral Cautiously Susceptible 
H137Y Neutral Neutral Cautiously Susceptible 
C138* Resistant Resistant Resistant 
C138C Neutral Neutral Cautiously Susceptible 
C138F Neutral Resistant Resistant 
C138G Resistant Resistant Resistant 
C138R Resistant Resistant Resistant 
C138S Resistant Resistant Resistant 
C138W Neutral Neutral Cautiously Susceptible 
C138Y Resistant Resistant Resistant 
V139A Resistant Resistant Resistant 
V139E Resistant Resistant Resistant 
V139G Neutral Resistant Resistant 
V139L Susceptible Neutral Susceptible 
V139M Resistant Resistant Resistant 
V139V Susceptible Neutral Susceptible 
R140C Neutral Neutral Cautiously Susceptible 
R140G Neutral Resistant Resistant 
R140L Susceptible Susceptible Susceptible 
R140P Resistant Resistant Resistant 
R140R Susceptible Susceptible Susceptible 
R140S Susceptible Susceptible Susceptible 
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Q141* Resistant Resistant Resistant 
Q141E Neutral Susceptible Susceptible 
Q141H Resistant Neutral Resistant 
Q141K Neutral Neutral Cautiously Susceptible 
Q141L Susceptible Susceptible Susceptible 
Q141Q Neutral Neutral Cautiously Susceptible 
Q141R Susceptible Susceptible Susceptible 
T142A Resistant Resistant Resistant 
T142K Resistant Resistant Resistant 
T142M Resistant Resistant Resistant 
T142P Neutral Neutral Cautiously Susceptible 
T142R Resistant Resistant Resistant 
T142S Neutral Neutral Cautiously Susceptible 
T142T Resistant Neutral Resistant 
A143A Neutral Susceptible Susceptible 
A143D Neutral Neutral Cautiously Susceptible 
A143G Susceptible Neutral Susceptible 
A143P Neutral Neutral Cautiously Susceptible 
A143S Neutral Resistant Resistant 
A143T Neutral Neutral Cautiously Susceptible 
A143V Neutral Neutral Cautiously Susceptible 
E144* Neutral Resistant Resistant 
E144D Susceptible Susceptible Susceptible 
E144E Neutral Neutral Cautiously Susceptible 
E144G Neutral Susceptible Susceptible 
E144K Susceptible Neutral Susceptible 
E144Q Neutral Neutral Cautiously Susceptible 
D145D Susceptible Susceptible Susceptible 
D145E Neutral Resistant Resistant 
D145G Susceptible Susceptible Susceptible 
D145N Neutral Susceptible Susceptible 
D145V Neutral Resistant Resistant 
D145Y Neutral Neutral Cautiously Susceptible 
A146A Neutral Susceptible Susceptible 
A146E Neutral Neutral Cautiously Susceptible 
A146P Neutral Neutral Cautiously Susceptible 
A146S Resistant Neutral Resistant 
A146T Resistant Resistant Resistant 
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A146V Resistant Resistant Resistant 
V147A Resistant Resistant Resistant 
V147I Neutral Neutral Cautiously Susceptible 
V147L Neutral Susceptible Susceptible 
V147V Susceptible Susceptible Susceptible 
R148C Neutral Neutral Cautiously Susceptible 
R148G Susceptible Neutral Susceptible 
R148H Susceptible Neutral Susceptible 
R148L Neutral Neutral Cautiously Susceptible 
R148P Neutral Resistant Resistant 
R148R Susceptible Susceptible Susceptible 
R148S Susceptible Susceptible Susceptible 
N149D Susceptible Neutral Susceptible 
N149H Neutral Susceptible Susceptible 
N149I Neutral Neutral Cautiously Susceptible 
N149N Neutral Susceptible Susceptible 
N149S Susceptible Neutral Susceptible 
N149Y Resistant Resistant Resistant 
G150A Neutral Neutral Cautiously Susceptible 
G150C Neutral Neutral Cautiously Susceptible 
G150D Neutral Resistant Resistant 
G150G Resistant Resistant Resistant 
G150S Neutral Neutral Cautiously Susceptible 
G150V Neutral Neutral Cautiously Susceptible 
L151* Resistant Resistant Resistant 
L151F Neutral Susceptible Susceptible 
L151M Neutral Neutral Cautiously Susceptible 
L151S Neutral Resistant Resistant 
L151V Neutral Neutral Cautiously Susceptible 
L151W Neutral Neutral Cautiously Susceptible 
A152A Susceptible Susceptible Susceptible 
A152D Neutral Resistant Resistant 
A152G Susceptible Neutral Susceptible 
A152P Neutral Susceptible Susceptible 
A152S Neutral Neutral Cautiously Susceptible 
A152T Resistant Neutral Resistant 
A152V Resistant Neutral Resistant 
T153A Susceptible Susceptible Susceptible 
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T153I Neutral Neutral Cautiously Susceptible 
T153N Neutral Neutral Cautiously Susceptible 
T153T Susceptible Susceptible Susceptible 
R154G Susceptible Neutral Susceptible 
R154K Neutral Neutral Cautiously Susceptible 
R154M Resistant Resistant Resistant 
R154R Susceptible Susceptible Susceptible 
R154S Neutral Susceptible Susceptible 
R154T Neutral Susceptible Susceptible 
R154W Neutral Resistant Resistant 
V155A Neutral Neutral Cautiously Susceptible 
V155E Neutral Neutral Cautiously Susceptible 
V155L Neutral Neutral Cautiously Susceptible 
V155M Neutral Resistant Resistant 
V155V Neutral Neutral Cautiously Susceptible 
L156L Susceptible Susceptible Susceptible 
L156M Neutral Susceptible Susceptible 
L156P Neutral Neutral Cautiously Susceptible 
L156Q Neutral Neutral Cautiously Susceptible 
L156R Resistant Resistant Resistant 
V157A Neutral Resistant Resistant 
V157E Neutral Neutral Cautiously Susceptible 
V157G Neutral Neutral Cautiously Susceptible 
V157L Susceptible Susceptible Susceptible 
V157M Susceptible Neutral Susceptible 
V157V Susceptible Neutral Susceptible 
D158D Neutral Neutral Cautiously Susceptible 
D158E Susceptible Susceptible Susceptible 
D158G Neutral Resistant Resistant 
D158N Susceptible Susceptible Susceptible 
D158V Resistant Resistant Resistant 
L159L Neutral Susceptible Susceptible 
L159M Susceptible Neutral Susceptible 
L159P Resistant Resistant Resistant 
L159Q Neutral Resistant Resistant 
L159R Susceptible Neutral Susceptible 
L159V Resistant Resistant Resistant 
T160A Neutral Resistant Resistant 
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T160I Neutral Neutral Cautiously Susceptible 
T160K Resistant Resistant Resistant 
T160R Resistant Resistant Resistant 
T160S Neutral Susceptible Susceptible 
T160T Neutral Susceptible Susceptible 
A161A Neutral Neutral Cautiously Susceptible 
A161E Neutral Neutral Cautiously Susceptible 
A161P Neutral Neutral Cautiously Susceptible 
A161S Susceptible Neutral Susceptible 
A161T Neutral Susceptible Susceptible 
A161V Neutral Neutral Cautiously Susceptible 
G162A Resistant Neutral Resistant 
G162C Neutral Susceptible Susceptible 
G162D Resistant Resistant Resistant 
G162G Resistant Resistant Resistant 
G162R Neutral Resistant Resistant 
G162S Neutral Resistant Resistant 
G162V Neutral Resistant Resistant 
V163A Neutral Neutral Cautiously Susceptible 
V163G Neutral Neutral Cautiously Susceptible 
V163L Neutral Neutral Cautiously Susceptible 
V163M Susceptible Susceptible Susceptible 
V163V Neutral Susceptible Susceptible 
S164* Resistant Resistant Resistant 
S164A Neutral Neutral Cautiously Susceptible 
S164L Neutral Neutral Cautiously Susceptible 
S164P Resistant Resistant Resistant 
S164S Neutral Susceptible Susceptible 
S164W Neutral Neutral Cautiously Susceptible 
A165A Susceptible Susceptible Susceptible 
A165D Neutral Resistant Resistant 
A165G Susceptible Neutral Susceptible 
A165S Neutral Neutral Cautiously Susceptible 
A165T Susceptible Neutral Susceptible 
A165V Neutral Neutral Cautiously Susceptible 
D166D Susceptible Susceptible Susceptible 
D166E Resistant Neutral Resistant 
D166G Neutral Neutral Cautiously Susceptible 
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D166H Susceptible Neutral Susceptible 
D166N Neutral Neutral Cautiously Susceptible 
D166V Neutral Susceptible Susceptible 
D166Y Neutral Resistant Resistant 
T167A Neutral Neutral Cautiously Susceptible 
T167I Neutral Resistant Resistant 
T167N Neutral Neutral Cautiously Susceptible 
T167S Neutral Neutral Cautiously Susceptible 
T167T Susceptible Neutral Susceptible 
T168A Neutral Neutral Cautiously Susceptible 
T168N Neutral Resistant Resistant 
T168P Neutral Resistant Resistant 
T168S Neutral Neutral Cautiously Susceptible 
T168T Susceptible Susceptible Susceptible 
V169A Neutral Neutral Cautiously Susceptible 
V169D Neutral Neutral Cautiously Susceptible 
V169F Susceptible Neutral Susceptible 
V169I Susceptible Susceptible Susceptible 
V169L Neutral Susceptible Susceptible 
V169V Susceptible Neutral Susceptible 
A170A Resistant Resistant Resistant 
A170D Neutral Neutral Cautiously Susceptible 
A170P Neutral Neutral Cautiously Susceptible 
A170S Resistant Neutral Resistant 
A170T Susceptible Neutral Susceptible 
A170V Resistant Neutral Resistant 
A171A Neutral Neutral Cautiously Susceptible 
A171E Neutral Neutral Cautiously Susceptible 
A171G Neutral Neutral Cautiously Susceptible 
A171P Neutral Neutral Cautiously Susceptible 
A171S Neutral Neutral Cautiously Susceptible 
A171T Resistant Resistant Resistant 
L172L Neutral Neutral Cautiously Susceptible 
L172P Resistant Resistant Resistant 
L172Q Neutral Neutral Cautiously Susceptible 
E173* Neutral Resistant Resistant 
E173D Neutral Susceptible Susceptible 
E173E Neutral Neutral Cautiously Susceptible 
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E173G Resistant Resistant Resistant 
E173K Susceptible Susceptible Susceptible 
E173V Neutral Susceptible Susceptible 
E174A Neutral Neutral Cautiously Susceptible 
E174D Neutral Neutral Cautiously Susceptible 
E174E Neutral Neutral Cautiously Susceptible 
E174G Resistant Resistant Resistant 
E174K Neutral Neutral Cautiously Susceptible 
E174Q Neutral Neutral Cautiously Susceptible 
E174V Neutral Neutral Cautiously Susceptible 
M175I Resistant Neutral Resistant 
M175K Resistant Resistant Resistant 
M175L Susceptible Susceptible Susceptible 
M175R Neutral Neutral Cautiously Susceptible 
M175T Resistant Resistant Resistant 
M175V Resistant Resistant Resistant 
R176C Neutral Resistant Resistant 
R176G Neutral Neutral Cautiously Susceptible 
R176H Neutral Resistant Resistant 
R176L Neutral Neutral Cautiously Susceptible 
R176P Neutral Neutral Cautiously Susceptible 
R176R Susceptible Neutral Susceptible 
R176S Neutral Neutral Cautiously Susceptible 
T177A Neutral Neutral Cautiously Susceptible 
T177I Neutral Susceptible Susceptible 
T177N Neutral Susceptible Susceptible 
T177S Neutral Susceptible Susceptible 
T177T Resistant Resistant Resistant 
A178A Susceptible Susceptible Susceptible 
A178D Neutral Susceptible Susceptible 
A178P Neutral Neutral Cautiously Susceptible 
A178S Neutral Neutral Cautiously Susceptible 
A178T Neutral Resistant Resistant 
A178V Neutral Susceptible Susceptible 
S179C Susceptible Susceptible Susceptible 
S179G Neutral Resistant Resistant 
S179I Susceptible Susceptible Susceptible 
S179N Resistant Resistant Resistant 
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S179R Susceptible Susceptible Susceptible 
S179S Resistant Resistant Resistant 
V180A Neutral Resistant Resistant 
V180D Neutral Resistant Resistant 
V180F Neutral Resistant Resistant 
V180I Neutral Neutral Cautiously Susceptible 
V180L Neutral Neutral Cautiously Susceptible 
V180V Susceptible Susceptible Susceptible 
E181* Neutral Resistant Resistant 
E181A Neutral Neutral Cautiously Susceptible 
E181D Susceptible Susceptible Susceptible 
E181E Neutral Resistant Resistant 
E181G Neutral Neutral Cautiously Susceptible 
E181K Resistant Neutral Resistant 
E181V Neutral Neutral Cautiously Susceptible 
L182* Neutral Neutral Cautiously Susceptible 
L182F Neutral Neutral Cautiously Susceptible 
L182M Susceptible Neutral Susceptible 
L182S Neutral Resistant Resistant 
V183A Neutral Susceptible Susceptible 
V183D Neutral Neutral Cautiously Susceptible 
V183F Neutral Neutral Cautiously Susceptible 
V183I Susceptible Susceptible Susceptible 
V183L Resistant Neutral Resistant 
V183V Neutral Neutral Cautiously Susceptible 
C184* Neutral Neutral Cautiously Susceptible 
C184C Neutral Resistant Resistant 
C184F Neutral Neutral Cautiously Susceptible 
C184S Neutral Resistant Resistant 
C184W Neutral Neutral Cautiously Susceptible 
C184Y Susceptible Neutral Susceptible 
S185C Neutral Neutral Cautiously Susceptible 
S185G Neutral Susceptible Susceptible 
S185I Neutral Neutral Cautiously Susceptible 
S185N Neutral Neutral Cautiously Susceptible 
S185R Susceptible Susceptible Susceptible 
S185S Neutral Neutral Cautiously Susceptible 
S185T Neutral Neutral Cautiously Susceptible 
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S186F Neutral Resistant Resistant 
S186P Neutral Susceptible Susceptible 
S186Y Neutral Neutral Cautiously Susceptible 
*187* Neutral Neutral Cautiously Susceptible 
*187W Susceptible Susceptible Susceptible 








1. WHO. WHO Global Tuberculosis Report, (WHO press, Geneva, Switzerland, 2015). 
2. Dawson, R. et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-
824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, 
open-label, partly randomised trial in patients with drug-susceptible or drug-resistant 
pulmonary tuberculosis. Lancet385, 1738-47 (2015). 
3. Zumla, A.I. et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, 
advances, and future prospects. Lancet Infect Dis14, 327-40 (2014). 
4. Chang, K.C. et al. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-
resistant tuberculosis. Antimicrob Agents Chemother56, 5465-75 (2012). 
5. Grosset, J. The sterilizing value of rifampicin and pyrazinamide in experimental short-course 
chemotherapy. Bull Int Union Tuberc53, 5-12 (1978). 
6. Snider, D.E., Jr., Rogowski, J., Zierski, M., Bek, E. & Long, M.W. Successful intermittent 
treatment of smear-positive pulmonary tuberculosis in six months: a cooperative study in 
Poland. Am Rev Respir Dis125, 265-7 (1982). 
7. Mitchison, D.A. The action of antituberculosis drugs in short-course chemotherapy. 
Tubercle66, 219-225 (1985). 
8. Fox, W., Ellard, G.A. & Mitchison, D.A. Studies on the treatment of tuberculosis undertaken 
by the British Medical Research Council tuberculosis units, 1946-1986, with relevant 
subsequent publications. Int J Tuberc Lung Dis3, S231-79 (1999). 
9. Zhang, Y. & Mitchison, D.A. The curious characteristics of pyrazinamide: a review. Int J 
Tuberc Lung Dis7, 6-21 (2003). 
10. WHO. Guideline for surveillance of drug resistance in tuberculosis 5th edition, (WHO press, 
Geneva, Switzerland, 2015). 
11. Telenti, A. et al. Detection of rifampicin-resistance mutations in Mycobacterium 
tuberculosis. Lancet341, 647-50 (1993). 
12. Musser, J.M. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin 
Microbiol Rev8, 496-514 (1995). 
13. Fluit, A.C., Visser, M.R. & Schmitz, F.J. Molecular detection of antimicrobial resistance. Clin 
Microbiol Rev14, 836-71, table of contents (2001). 
14. Mani, C., Selvakumar, N., Narayanan, S. & Narayanan, P.R. Mutations in the rpoB gene of 
multidrug-resistant Mycobacterium tuberculosis clinical isolates from India. J Clin 
Microbiol39, 2987-90 (2001). 
15. Cavusoglu, C., Hilmioglu, S., Guneri, S. & Bilgic, A. Characterization of rpoB mutations in 
rifampin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey by DNA 
sequencing and line probe assay. J Clin Microbiol40, 4435-8 (2002). 
16. Garcia de Viedma, D. Rapid detection of resistance in Mycobacterium tuberculosis: a review 
discussing molecular approaches. Clin Microbiol Infect9, 349-59 (2003). 
17. Nikolayevsky, V. et al. Detection of mutations associated with isoniazid and rifampin 
resistance in Mycobacterium tuberculosis isolates from Samara Region, Russian Federation. J 
Clin Microbiol42, 4498-502 (2004). 
18. Zhang, M. et al. Detection of mutations associated with isoniazid resistance in 
Mycobacterium tuberculosis isolates from China. J Clin Microbiol43, 5477-82 (2005). 
19. Hewlett, D., Jr., Horn, D.L. & Alfalla, C. Drug-resistant tuberculosis: inconsistent results of 
pyrazinamide susceptibility testing. JAMA273, 916-7 (1995). 
20. Miller, M.A., Thibert, L., Desjardins, F., Siddiqi, S.H. & Dascal, A. Testing of susceptibility of 
Mycobacterium tuberculosis to pyrazinamide: Comparison of Bactec method with 
pyrazinamidase assay. Journal of Clinical Microbiology33, 2468-2470 (1995). 
97 
 
21. Zhang, Y., Permar, S. & Sun, Z. Conditions that may affect the results of susceptibility testing 
of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol51, 42-49 (2002). 
22. Chang, K.C., Yew, W.W. & Zhang, Y. Pyrazinamide susceptibility testing in Mycobacterium 
tuberculosis: a systematic review with meta-analyses. Antimicrob Agents Chemother55, 
4499-505 (2011). 
23. Hoffner, S. et al. Proficiency of drug susceptibility testing of Mycobacterium tuberculosis 
against pyrazinamide: the Swedish experience. Int J Tuberc Lung Dis17, 1486-90 (2013). 
24. Whitfield, M.G. et al. A Global Perspective on Pyrazinamide Resistance: Systematic Review 
and Meta-Analysis. PLoS One10, e0133869 (2015). 
25. WHO. Guidelines for surveillance of drug resistance in tuberculosis 4th edition, (WHO press, 
Geneva, Switzerland, 2009). 
26. WHO. Guidelines for the programmatic management of drug-resistant tuberculosis. World 
Health Organization. , (WHO press, Geneva, Switzerland, 2011). 
27. WHO. WHO treatment guidelines for drug-resistant tuberculosis. 2016 Update., (WHO press, 
Geneva, Switzerland, 2016). 
28. Scorpio, A. & Zhang, Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, 
cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nature 
Medicine2, 662-667 (1996). 
29. Scorpio, A. et al. Characterization of pncA mutations of pyrazinamide-resistant 
Mycobacterium tuberculosis. Antimicrob Agents Chemother41, 540-543 (1997). 
30. Lemaitre, N., Sougakoff, W., Truffot-Pernot, C. & Jarlier, V. Characterization of new 
mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification 
of conserved regions important for the catalytic activity of pyrazinamidase pncA. Antimicrob 
Agents Chemother43, 1761-1763 (1999). 
31. Stoffels, K., Mathys, V., Fauville-Dufaux, M., Wintjens, R. & Bifani, P. Systematic analysis of 
pyrazinamide-resistant spontaneous mutants and clinical isolates of Mycobacterium 
tuberculosis. Antimicrob Agents Chemother56, 5186-93 (2012). 
32. Miotto, P. et al. Mycobacterium tuberculosis Pyrazinamide Resistance Determinants: a 
Multicenter Study. mBio5, e01819-14-e01819-14 (2014). 
33. Ramirez-Busby, S.M. & Valafar, F. A Systematic Review of Mutations in Pyrazinamidase 
Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis Clinical Isolates. 
Antimicrob Agents Chemother (2015). 
34. Whitfield, M.G. et al. Mycobacterium tuberculosis pncApolymorphisms that do not confer 
pyrazinamide resistance at a breakpoint concentration of 100 μg/ml in MGIT. Journal of 
Clinical Microbiology, JCM.01001-15 (2015). 
35. Denkin, S., Volokhov, D., Chizhikov, V. & Zhang, Y. Microarray-based pncA genotyping of 
pyrazinamide-resistant strains of Mycobacterium tuberculosis. J Med Microbiol54, 1127-31 
(2005). 
36. Sekiguchi, J. et al. Development and evaluation of a line probe assay for rapid identification 
of pncA mutations in pyrazinamide-resistant mycobacterium tuberculosis strains. J Clin 
Microbiol45, 2802-7 (2007). 
37. Streicher, E. et al. Rapid sequencing of the M. tuberculosis pncA gene for detection of 
pyrazinamide susceptibility.pdf>. J Clin Microbiol52, 4056-4057 (2014). 
38. Kunkel, T.A. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc 
Natl Acad Sci U S A82, 488-92 (1985). 
39. van Kessel, J.C. & Hatfull, G.F. Recombineering in Mycobacterium tuberculosis. Nat 
Methods4, 147-52 (2007). 




41. van Kessel, J.C. & Hatfull, G.F. Efficient point mutagenesis in mycobacteria using single-
stranded DNA recombineering: characterization of antimycobacterial drug targets. Mol 
Microbiol67, 1094-107 (2008). 
42. Campagna, M., Calix, A. & Hauser, G. Observations on the combined use of pyrazinamide 
(Aldinamide) and isoniazid in the treatment of pulmonary tuberculosis; a clinical study. Am 
Rev Tuberc69, 334-50 (1954). 
43. United States Public Health Service, U. Hepatic toxicity of pyrazinamide used with isoniazid 
in tuberculous patients. United States Public Health Service. American Review of Respiratory 
Disease80, 371 (1959). 
44. A controlled comparison of four regimens of streptomycin plus pyrazinamide in the 
retreatment of pulmonary tuberculosis. Tubercle50, 81-114 (1969). 
45. Fox, W. Whither short-course chemotherapy? Br J Dis Chest75, 331-57 (1981). 
46. Zhang, Y., Shi, W., Zhang, W. & Mitchison, D. Mechanisms of Pyrazinamide Action and 
Resistance. Microbiology Spectrum2(2014). 
47. Mendez, S. et al. The antituberculosis drug pyrazinamide affects the course of cutaneous 
leishmaniasis in vivo and increases activation of macrophages and dendritic cells. Antimicrob 
Agents Chemother53, 5114-21 (2009). 
48. Dalmer, O., Walter, E. & Firma, E. Merck in Darmstadt. Verfahren zur Herstellung von 
Abkömmlingen der Pyrazinmonocarbonsäure. Patentiert im Deutschen Reiche vom 8. Juli 
1934 ab. Germany patent 632 257 Klasse 12 p Gruppe 6 M 127990 IV a/12 p. (1936). 
49. Chlorine, V. Action de l’amide nicotinique sur les bacilles du genre Mycobacterium. CR Acad 
Sci (Paris)220, 150-151 (1945). 
50. McKenzie, D., Malone, L. & et al. The effect of nicotinic acid amide on experimental 
tuberculosis of white mice. J Lab Clin Med33, 1249-53 (1948). 
51. Dessau, F.I., Burger, F., Yeager, R.L. & Kulish, M. A method for the determination of in vitro 
sensitivity of tubercle bacilli to pyrazinamide (aldinamide). Am Rev Tuberc65, 635-6 (1952). 
52. Dessau, F.I., Yeager, R.L., Burger, F.J. & Williams, J.H. Pyrazinamide (aldinamide) in 
experimental tuberculosis of the guinea pig. Am Rev Tuberc65, 519-22 (1952). 
53. Malone, L. et al. The effect of pyrazinamide (aldinamide) on experimental tuberculosis in 
mice. Am Rev Tuberc65, 511-8 (1952). 
54. Solotorovsky, M. et al. Pyrazinoic acid amide: an agent active against experimental murine 
tuberculosis. Proc Soc Exp Biol Med79, 563-5 (1952). 
55. Yeager, R.L., Munroe, W.G. & Dessau, F.I. Pyrazinamide (aldinamide) in the treatment of 
pulmonary tuberculosis. Am Rev Tuberc65, 523-46 (1952). 
56. McDermott, W. et al. Pyrazinamide-isoniazid in tuberculosis. Am Rev Tuberc69, 319-33 
(1954). 
57. Muschenheim, C. et al. Pyrazinamide-isoniazid in tuberculosis. I. Results in 58 patients with 
pulmonary lesions one year after the start of therapy. Am Rev Tuberc70, 743-7 (1954). 
58. Schwartz, W.S. & Moyer, R.E. The chemotherapy of pulmonary tuberculosis with 
pyrazinamide used alone and in combination with streptomycin, para-aminosalicylic acid, or 
isoniazid. Am Rev Tuberc70, 413-22 (1954). 
59. Jindani, A., Aber, V.R., Edwards, E.A. & Mitchison, D.A. The early bactericidal activity of drugs 
in patients with pulmonary tuberculosis. Am Rev Respir Dis121, 939-49 (1980). 
60. Stehr, M., Elamin, A.A. & Singh, M. Pyrazinamide: the importance of uncovering the 
mechanisms of action in mycobacteria. Expert Rev Anti Infect Ther13, 593-603 (2015). 
61. McCune, R.M., Jr., McDermott, W. & Tompsett, R. The fate of Mycobacterium tuberculosis in 
mouse tissues as determined by the microbial enumeration technique. II. The conversion of 
tuberculous infection to the latent state by the administration of pyrazinamide and a 
companion drug. J Exp Med104, 763-802 (1956). 
62. McCune, R.M., Jr. & Tompsett, R. Fate of Mycobacterium tuberculosis in mouse tissues as 
determined by the microbial enumeration technique. I. The persistence of drug-susceptible 
99 
 
tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J Exp Med104, 737-62 
(1956). 
63. McCune, R.M., Feldmann, F.M., Lambert, H.P. & McDermott, W. Microbial persistence. I. The 
capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med123, 445-68 
(1966). 
64. McCune, R.M., Feldmann, F.M. & McDermott, W. Microbial persistence. II. Characteristics of 
the sterile state of tubercle bacilli. J Exp Med123, 469-86 (1966). 
65. Dickinson, J.M. & Mitchison, D.A. Observations in vitro on the suitability of pyrazinamide for 
intermittent chemotherapy of tuberculosis. Tubercle51(1970). 
66. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment 
of pulmonary tuberculosis. Lancet1, 1079-85 (1972). 
67. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for 
treatment of pulmonary tuberculosis. Second report. Lancet1, 1331-8 (1973). 
68. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for 
treatment of pulmonary tuberculosis. Lancet2, 1100-6 (1974). 
69. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for 
treatment of pulmonary tuberculosis. Third report. East African-British Medical Research 
Councils. Lancet2, 237-40 (1974). 
70. Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin 
plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. The results up to 
30 months. Am Rev Respir Dis115, 727-35 (1977). 
71. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary 
tuberculosis. First report of 4th study. East African and British Medical Research Councils. 
Lancet2, 334-8 (1978). 
72. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of 
pulmonary tuberculosis: the results up to 30 months. Tubercle62, 95-102 (1981). 
73. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary 
tuberculosis. Second report of the 4th study. East African/British Medical Research Councils 
Study. Am Rev Respir Dis123, 165-70 (1981). 
74. A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: 
results during the 24 months after the end of chemotherapy. British Thoracic Association. 
Am Rev Respir Dis126, 460-2 (1982). 
75. A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results 
during the 36 months after the end of chemotherapy and beyond. British Thoracic Society. 
Br J Dis Chest78, 330-6 (1984). 
76. Clinical trial of three 6-month regimens of chemotherapy given intermittently in the 
continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis 
Service/British Medical Research Council. Am Rev Respir Dis132, 374-8 (1985). 
77. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 
8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical 
Research Council Fifth Collaborative Study. Tubercle67, 5-15 (1986). 
78. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for 
pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council. Am Rev 
Respir Dis136, 1339-42 (1987). 
79. Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given 
intermittently in the continuation phase in the treatment of pulmonary tuberculosis. 
Singapore Tuberculosis Service/British Medical Research Council. Am Rev Respir Dis137, 
1147-50 (1988). 
80. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly 
regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined 
100 
 
preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest 
Service/British Medical Research Council. Am Rev Respir Dis143, 700-6 (1991). 
81. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary 
tuberculosis: the results up to 24 months. Tubercle60, 201-10 (1979). 
82. Somner, A.R. Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the 
British Thoracic Association (first report). Lancet1, 1182-3 (1981). 
83. Snider, D.E., Graczyk, J., Bek, E. & Rogowski, J. Supervised six-months treatment of newly 
diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and 
without streptomycin. Am Rev Respir Dis130, 1091-4 (1984). 
84. Snider, D.E., Jr. et al. Standard therapy for tuberculosis 1985. Chest87, 117S-124S (1985). 
85. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a 
controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. 
Singapore Tuberculosis Service/British Medical Research Council. Am Rev Respir Dis143, 707-
12 (1991). 
86. Grosset, J., Truffot, C., Fermanian, J. & Lecoeur, H. [Sterilizing activity of the main drugs on 
the mouse experimental tuberculosis (author's transl)]. Pathol Biol (Paris)30, 444-8 (1982). 
87. Lalande, V., Truffot-Pernot, C., Paccaly-Moulin, A., Grosset, J. & Ji, B. Powerful bactericidal 
activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob 
Agents Chemother37, 407-13 (1993). 
88. WHO. Treatment of tuberculosis: Guidelines for national programmes., (WHO press, Geneva, 
Switzerland, 2003). 
89. WHO. Treatment of tuberculosis guidelines, (WHO press, Geneva, Switzerland, 2010). 
90. Mitnick, C. et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, 
Peru. N Engl J Med348, 119-28 (2003). 
91. Van Deun, A., Salim, M.A., Das, A.P., Bastian, I. & Portaels, F. Results of a standardised 
regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis8, 560-7 
(2004). 
92. Van Deun, A. et al. Short, highly effective, and inexpensive standardized treatment of 
multidrug-resistant tuberculosis. Am J Respir Crit Care Med182, 684-92 (2010). 
93. Aung, K.J. et al. Successful '9-month Bangladesh regimen' for multidrug-resistant 
tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis18, 1180-7 (2014). 
94. Kuaban, C. et al. High effectiveness of a 12-month regimen for MDR-TB patients in 
Cameroon. Int J Tuberc Lung Dis19, 517-24 (2015). 
95. Ibrahim, M. et al. Synergistic activity of R207910 combined with pyrazinamide against 
murine tuberculosis. Antimicrob Agents Chemother51, 1011-5 (2007). 
96. Rustomjee, R. et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline 
TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother52, 2831-5 
(2008). 
97. Ibrahim, M., Truffot-Pernot, C., Andries, K., Jarlier, V. & Veziris, N. Sterilizing activity of 
R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir 
Crit Care Med180, 553-7 (2009). 
98. Veziris, N. et al. A once-weekly R207910-containing regimen exceeds activity of the standard 
daily regimen in murine tuberculosis. Am J Respir Crit Care Med179, 75-9 (2009). 
99. Tasneen, R. et al. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a 
murine model of tuberculosis. Antimicrob Agents Chemother55, 5485-92 (2011). 
100. Diacon, A.H. et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and 
moxifloxacin combinations: a randomised trial. Lancet380, 986-93 (2012). 
101. Diacon, A.H. et al. Bactericidal activity of pyrazinamide and clofazimine alone and in 




102. Nuermberger, E. et al. Powerful bactericidal and sterilizing activity of a regimen containing 
PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob 
Agents Chemother52, 1522-4 (2008). 
103. Tasneen, R., Tyagi, S., Williams, K., Grosset, J. & Nuermberger, E. Enhanced bactericidal 
activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of 
tuberculosis. Antimicrob Agents Chemother52, 3664-8 (2008). 
104. Rosenthal, I.M. et al. Daily dosing of rifapentine cures tuberculosis in three months or less in 
the murine model. PLoS Med4, e344 (2007). 
105. Tyagi, S. et al. Clofazimine shortens the duration of the first-line treatment regimen for 
experimental chemotherapy of tuberculosis. Proc Natl Acad Sci U S A112, 869-74 (2015). 
106. Andries, K. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium 
tuberculosis. Science307, 223-7 (2005). 
107. Zhang, Y., Scorpio, A., Nikaido, H. & Sun, Z. Role of acid pH and deficient efflux pf pyrazinoic 
acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. Journal of 
Bacteriology181, 2044-2049 (1999). 
108. Zhang, Y., Wade, M.M., Scorpio, A., Zhang, H. & Sun, Z. Mode of action of pyrazinamide: 
disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic 
acid. J Antimicrob Chemother52, 790-5 (2003). 
109. Raynaud, C. et al. Mechanisms of pyrazinamide resistance in mycobacteria: importance of 
lack of uptake in addition to lack of pyrazinamidase activity. Microbiology145, 1359-1367 
(1999). 
110. Bonicke, R. & Lisboa, B.P. [Type differentiation of tuberculosis bacteria with the aid of the 
nicotinamidase test]. Tuberkulosearzt13, 377-84 (1959). 
111. Toida, I. Metabolism of pyrazinamide. Pyrazinamide deamidase of animal tissues. Am Rev 
Respir Dis107, 630-8 (1973). 
112. Via, L.E. et al. Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, 
Resistance, and Therapeutic Alternatives. ACS Infect Dis1, 203-214 (2015). 
113. Foster, J.W. & Moat, A.G. Nicotinamide adenine dinucleotide biosynthesis and pyridine 
nucleotide cycle metabolism in microbial systems. Microbiol Rev44, 83-105 (1980). 
114. Kasarov, L.B. & Moat, A.G. Metabolism of nicotinamide adenine dinucleotide in human and 
bovine strainsof Mycobacterium tuberculosis. J Bacteriol110, 600-3 (1972). 
115. Boshoff, H.I. et al. Biosynthesis and recycling of nicotinamide cofactors in mycobacterium 
tuberculosis. An essential role for NAD in nonreplicating bacilli. J Biol Chem283, 19329-41 
(2008). 
116. Heifets, L.B. & Lindholm-Levy, P.J. Is pyrazinamide bactericidal against Mycobacterium 
tuberculosis? Am Rev Respir Dis141, 250-252 (1990). 
117. Hu, Y., Coates, A.R. & Mitchison, D.A. Sterilising action of pyrazinamide in models of dormant 
and rifampicin-tolerant Mycobacterium tuberculosis. Int J Tuberc Lung Dis10, 317-22 (2006). 
118. Pullan, S.T. et al. The effect of growth rate on pyrazinamide activity in Mycobacterium 
tuberculosis - insights for early bactericidal activity? BMC Infect Dis16, 205 (2016). 
119. McDermott, W. & Tompsett, R. Activation of pyrazinamide and nicotinamide in acid 
environments in vitro. American Review of Tuberculosis70, 748-754 (1954). 
120. Stottmeier, K.D., Beam, R.E. & Kubica, G.P. Determination of drug susceptibility of 
mycobacteria to pyrazinamide in 7H10 agar. Am Rev Respir Dis95, 1072-1075 (1967). 
121. Heifets, L. Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med 
Microbiol51, 11-2 (2002). 
122. Salfinger, M., Crowle, A.J. & Reller, L.B. Pyrazinamide and pyrazinoic acid activity against 
tubercle bacilli in cultured human macrophages and in the BACTEC system. J Infect Dis162, 
201-7 (1990). 
123. Heifets, L. & Lindholm-Levy, P. Pyrazinamide sterilizing activity in vitro against semidormant 
Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis145, 1223-5 (1992). 
102 
 
124. Tarshis, M.S. & Weed, W.A., Jr. Lack of significant in vitro sensitivity of Mycobacterium 
tuberculosis to pyrazinamide on three different solid media. Am Rev Tuberc67, 391-5 (1953). 
125. Steenken, W., Jr. & Wolinsky, E. The antituberculous activity of pyrazinamide in vitro and in 
the guinea pig. Am Rev Tuberc70, 367-9 (1954). 
126. Crowle, A.J., Sbarbaro, J.A. & May, M.H. Inhibition by pyrazinamide of tubercle bacilli within 
cultured human macrophages. Am Rev Respir Dis134, 1052-5 (1986). 
127. Salfinger, M. & Heifets, L.B. Determination of pyrazinamide MICs for Mycobacterium 
tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother32, 
1002-1004 (1988). 
128. Peterson, N.D., Rosen, B.C., Dillon, N.A. & Baughn, A.D. Uncoupling Environmental pH and 
Intrabacterial Acidification from Pyrazinamide Susceptibility in Mycobacterium tuberculosis. 
Antimicrob Agents Chemother59, 7320-6 (2015). 
129. Zhang, H. et al. Characterization of Mycobacterium tuberculosis 
nicotinamidase/pyrazinamidase. FEBS J275, 753-62 (2008). 
130. Wade, M.M. & Zhang, Y. Anaerobic incubation conditions enhance pyrazinamide activity 
against Mycobacterium tuberculosis. J Med Microbiol53, 769-73 (2004). 
131. Huang, Q. et al. Nutrient-starved incubation conditions enhance pyrazinamide activity 
against Mycobacterium tuberculosis. Chemotherapy53, 338-43 (2007). 
132. Coleman, D., Waddell, S.J. & Mitchison, D.A. Effects of low incubation temperatures on the 
bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother66, 146-50 (2011). 
133. den Hertog, A.L. et al. Pyrazinamide Is Active against Mycobacterium tuberculosis Cultures at 
Neutral pH and Low Temperature. Antimicrob Agents Chemother60, 4956-60 (2016). 
134. Wade, M.M. & Zhang, Y. Effects of weak acids, UV and proton motive force inhibitors on 
pyrazinamide activity against Mycobacterium tuberculosis in vitro. J Antimicrob 
Chemother58, 936-41 (2006). 
135. Gu, P., Constantino, L. & Zhang, Y. Enhancement of the antituberculosis activity of weak 
acids by inhibitors of energy metabolism but not by anaerobiosis suggests that weak acids 
act differently from the front-line tuberculosis drug pyrazinamide. J Med Microbiol57, 1129-
34 (2008). 
136. Byrne, S.T., Denkin, S.M. & Zhang, Y. Aspirin and ibuprofen enhance pyrazinamide treatment 
of murine tuberculosis. J Antimicrob Chemother59, 313-6 (2007). 
137. Sheen, P. et al. Role of metal ions on the activity of Mycobacterium tuberculosis 
pyrazinamidase. Am J Trop Med Hyg87, 153-61 (2012). 
138. Somoskovi, A., Wade, M.M., Sun, Z. & Zhang, Y. Iron enhances the antituberculous activity of 
pyrazinamide. J Antimicrob Chemother53, 192-6 (2004). 
139. Baughn, A.D. et al. Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide 
resistance reveal a potential resistance-proofing strategy. Antimicrob Agents Chemother54, 
5323-8 (2010). 
140. Mackaness, G.B. The intracellular activation of pyrazinamide and nicotinamide. Am Rev 
Tuberc74, 718-28 (1956). 
141. Carlone, N.A., Acocella, G., Cuffini, A.M. & Forno-Pizzoglio, M. Killing of macrophage-
ingested mycobacteria by rifampicin, pyrazinamide, and pyrazinoic acid alone and in 
combination. Am Rev Respir Dis132, 1274-7 (1985). 
142. Dhillon, J. & Mitchison, D.A. Activity and penetration of antituberculosis drugs in mouse 
peritoneal macrophages infected with Mycobacterium microti OV254. Antimicrob Agents 
Chemother33, 1255-9 (1989). 
143. Rastogi, N., Potar, M.C. & David, H.L. Pyrazinamide is not effective against intracellularly 
growing Mycobacterium tuberculosis. Antimicrob Agents Chemother32, 287 (1988). 
144. Sbarbaro, J.A., Iseman, M.D. & Crowle, A.J. The combined effect of rifampin and 
pyrazinamide within the human macrophage. Am Rev Respir Dis146, 1448-51 (1992). 
103 
 
145. Sbarbaro, J.A., Iseman, M.D. & Crowle, A.J. Combined effect of pyrazinamide and ofloxacin 
within the human macrophage. Tuber Lung Dis77, 491-5 (1996). 
146. Heifets, L., Higgins, M. & Simon, B. Pyrazinamide is not active against Mycobacterium 
tuberculosis residing in cultured human monocyte-derived macrophages. Int J Tuberc Lung 
Dis4, 491-5 (2000). 
147. Crowle, A.J. & May, M.H. Inhibition of tubercle bacilli in cultured human macrophages by 
chloroquine used alone and in combination with streptomycin, isoniazid, pyrazinamide, and 
two metabolites of vitamin D3. Antimicrob Agents Chemother34, 2217-22 (1990). 
148. Armstrong, J.A. & Hart, P.D. Response of cultured macrophages to Mycobacterium 
tuberculosis, with observations on fusion of lysosomes with phagosomes. J Exp Med134, 
713-40 (1971). 
149. MacMicking, J.D., Taylor, G.A. & McKinney, J.D. Immune control of tuberculosis by IFN-
gamma-inducible LRG-47. Science302, 654-9 (2003). 
150. Crowle, A.J., Dahl, R., Ross, E. & May, M.H. Evidence that vesicles containing living, virulent 
Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are 
not acidic. Infect Immun59, 1823-31 (1991). 
151. Sturgill-Koszycki, S. et al. Lack of acidification in Mycobacterium phagosomes produced by 
exclusion of the vesicular proton-ATPase. Science263, 678-81 (1994). 
152. Botha, F.J. et al. Early bactericidal activity of ethambutol, pyrazinamide and the fixed 
combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary 
tuberculosis. S Afr Med J86, 155-8 (1996). 
153. Mitchison, D.A. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc 
Lung Dis4, 796-806 (2000). 
154. Sirgel, F.A. et al. A multicentre study of the early bactericidal activity of anti-tuberculosis 
drugs. J Antimicrob Chemother45, 859-70 (2000). 
155. Brindle, R., Odhiambo, J. & Mitchison, D. Serial counts of Mycobacterium tuberculosis in 
sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in 
treating pulmonary tuberculosis. BMC Pulm Med1, 2 (2001). 
156. Jindani, A., Dore, C.J. & Mitchison, D.A. Bactericidal and sterilizing activities of 
antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med167, 1348-54 
(2003). 
157. Diacon, A.H. & Donald, P.R. The early bactericidal activity of antituberculosis drugs. Expert 
Rev Anti Infect Ther12, 223-37 (2014). 
158. Almeida, D.V. et al. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide 
combination in a mouse model of tuberculosis. Antimicrob Agents Chemother53, 4178-84 
(2009). 
159. Almeida, D.V. et al. Revisiting Anti-tuberculosis Activity of Pyrazinamide in Mice. Mycobact 
Dis4, 145 (2014). 
160. Boshoff, H.I., Mizrahi, V. & Barry, C.E. Effects of Pyrazinamide on Fatty Acid Synthesis by 
Whole Mycobacterial Cells and Purified Fatty Acid Synthase I. Journal of Bacteriology184, 
2167-2172 (2002). 
161. Singh, P. et al. The paradox of pyrazinamide: An update on the molecular mechanisms of 
pyrazinamide resistance in Mycobacteria. J Commun Dis38, 288-298 (2006). 
162. Dillon, N.A., Peterson, N.D., Rosen, B.C. & Baughn, A.D. Pantothenate and pantetheine 
antagonize the antitubercular activity of pyrazinamide. Antimicrob Agents Chemother58, 
7258-63 (2014). 
163. Zhang, S. et al. Mutations in panD encoding aspartate decarboxylase are associated with 




164. Sharma, R., Kothapalli, R., Van Dongen, A.M. & Swaminathan, K. Chemoinformatic 
identification of novel inhibitors against Mycobacterium tuberculosis L-aspartate alpha-
decarboxylase. PLoS One7, e33521 (2012). 
165. Shi, W. et al. Aspartate decarboxylase (PanD) as a new target of pyrazinamide in 
Mycobacterium tuberculosis. Emerg Microbes Infect3, e58 (2014). 
166. Gopal, P. et al. Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention 
of Coenzyme A Depletion and Loss of Virulence Factor Synthesis. ACS Infect Dis2, 616-626 
(2016). 
167. Pandey, B. et al. Molecular principles behind pyrazinamide resistance due to mutations in 
panD gene in Mycobacterium tuberculosis. Gene581, 31-42 (2016). 
168. Shi, W. et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. 
Science333, 1630-1632 (2011). 
169. Keiler, K.C. Biology of trans-translation. Annu Rev Microbiol62, 133-51 (2008). 
170. Li, J., Ji, L., Shi, W., Xie, J. & Zhang, Y. Trans-translation mediates tolerance to multiple 
antibiotics and stresses in Escherichia coli. J Antimicrob Chemother68, 2477-81 (2013). 
171. Yang, J. et al. Structural basis for targeting the ribosomal protein S1 of Mycobacterium 
tuberculosis by pyrazinamide. Mol Microbiol95, 791-803 (2015). 
172. Personne, Y. & Parish, T. Mycobacterium tuberculosis possesses an unusual tmRNA rescue 
system. Tuberculosis (Edinb)94, 34-42 (2014). 
173. Lu, P. et al. Pyrazinoic acid decreases the proton motive force, respiratory ATP synthesis 
activity, and cellular ATP levels. Antimicrob Agents Chemother55, 5354-7 (2011). 
174. Kim, H., Shibayama, K., Rimbara, E. & Mori, S. Biochemical characterization of quinolinic acid 
phosphoribosyltransferase from Mycobacterium tuberculosis H37Rv and inhibition of its 
activity by pyrazinamide. PLoS One9, e100062 (2014). 
175. Zimhony, O., Cox, J.S., Welch, J.T., Vilcheze, C. & Jacobs, W.R., Jr. Pyrazinamide inhibits the 
eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med6, 
1043-7 (2000). 
176. Konno, K., Nagayama, H. & Oka, S. Nicotinamidase in Mycobacteria: a method for 
distinguishing bovine type tubercle bacilli from other Mycobacteria. Nature184(Suppl 22), 
1743-4 (1959). 
177. Konno, K., Feldmann, F.M. & McDermott, W. Pyrazinamide susceptibility and amidase 
activity of tubercle bacilli. Am Rev Respir Dis95, 461-469 (1967). 
178. Ngo, S.C. et al. Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by 
pyrazinamide analogs. Antimicrob Agents Chemother51, 2430-5 (2007). 
179. Zimhony, O., Vilcheze, C., Arai, M., Welch, J.T. & Jacobs, W.R., Jr. Pyrazinoic acid and its n-
propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli. Antimicrob Agents 
Chemother51, 752-4 (2007). 
180. Sayahi, H., Zimhony, O., Jacobs, W.R., Jr., Shekhtman, A. & Welch, J.T. Pyrazinamide, but not 
pyrazinoic acid, is a competitive inhibitor of NADPH binding to Mycobacterium tuberculosis 
fatty acid synthase I. Bioorg Med Chem Lett21, 4804-7 (2011). 
181. Sayahi, H. et al. Analogs of the antituberculous agent pyrazinamide are competitive 
inhibitors of NADPH binding to M. tuberculosis fatty acid synthase I. Chem Biodivers9, 2582-
96 (2012). 
182. Ellard, G.A. Absorption, metabolism and excretion of pyrazinamide in man. Tubercle50, 144-
58 (1969). 
183. Manca, C. et al. Host targeted activity of pyrazinamide in Mycobacterium tuberculosis 
infection. PLoS One8, e74082 (2013). 
184. Kim, J.J. et al. Host cell autophagy activated by antibiotics is required for their effective 
antimycobacterial drug action. Cell Host Microbe11, 457-68 (2012). 
105 
 
185. Shenai, S., Rodrigues, C., Sadani, M., Sukhadia, N. & Mehta, A. Comparison of phenotypic 
and genotypic methods for pyrazinamide susceptibility testing. Indian J Tuberc56, 82-90 
(2009). 
186. Kim, H.J. et al. Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis 
isolated from patients in South Korea. Int J Tuberc Lung Dis16, 98-103 (2012). 
187. Pierre-Audigier, C. et al. Fluoroquinolone and pyrazinamide resistance in multidrug-resistant 
tuberculosis. Int J Tuberc Lung Dis16, 221-3, i-ii (2012). 
188. Zhang, Y., Heym, B., Allen, B., Young, D. & Cole, S. The catalase-peroxidase gene and 
isoniazid resistance of Mycobacterium tuberculosis. Nature358, 591-3 (1992). 
189. Zhang, Y. Genetic basis of isoniazid resistance of Mycobacterium tuberculosis. Res 
Microbiol144, 143-9 (1993). 
190. Zhang, Y., Garbe, T. & Young, D. Transformation with katG restores isoniazid-sensitivity in 
Mycobacterium tuberculosis isolates resistant to a range of drug concentrations. Mol 
Microbiol8, 521-4 (1993). 
191. Zhang, Y. & Yew, W.W. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J 
Tuberc Lung Dis13, 1320-30 (2009). 
192. McClatchy, J.K., Tsang, A.Y. & Cernich, M.S. Use of pyrazinamidase activity on 
Mycobacterium tuberculosis as a rapid method for determination of pyrazinamide 
susceptibility. Antimicrob Agents Chemother20, 556-7 (1981). 
193. Butler, W.R. & Kilburn, J.O. Susceptibility of Mycobacterium tuberculosis to pyrazinamide 
and its relationship to pyrazinamidase activity. Antimicrobial Agents and Chemotherapy24, 
600-601 (1983). 
194. Trivedi, S.S. & Desai, S.G. Pyrazinamidase activity of Mycobacterium tuberculosis--a test of 
sensitivity to pyrazinamide. Tubercle68, 221-4 (1987). 
195. Mestdagh, M. et al. Relationship between pyrazinamide resistance, loss of pyrazinamidase 
activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of 
Mycobacterium tuberculosisAntimicrob Agents Chemother43, 2317-2319 (1999). 
196. Sreevatsan, S., Pan, X., Zhang, Y., Kreiswirth, B.N. & Musser, J.M. Mutations associated with 
pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. 
Antimicrob Agents Chemother41, 636-640 (1997). 
197. Hirano, K., Takahashi, M., Kazumi, Y., Fukasawa, Y. & Abe, C. Mutation in pncA is a major 
mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tubercle and Lung 
Disease78, 117-122 (1998). 
198. Cheng, S.J., Thibert, L., Sanchez, T., Heifets, L. & Zhang, Y. pncA Mutations as a major 
mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: Spread of a 
monoresistant strain in Quebec, Canada. Antimicrob Agents Chemother44, 528-532 (2000). 
199. Lee, K.W., Lee, J.-M. & Jung, K.-S. Characterization of pncA mutations of pyrazinamide 
resistance Mycobacterium tuberculosis in Korea. J Korean Med Sci16, 537-543 (2001). 
200. Park, S.K. et al.pncA Mutations in clinical Mycobacterium tuberculosis isolates from Korea. 
BMC Infect Dis1(2001). 
201. Sheen, P. et al. pncA gene expression and prediction factors on pyrazinamide resistance in 
Mycobacterium tuberculosis. Tuberculosis (Edinb)93, 515-22 (2013). 
202. Boshoff, H.I. & Mizrahi, V. Expression of Mycobacterium smegmatis pyrazinamidase in 
Mycobacterium tuberculosis confers hypersensitivity to pyrazinamide and related amides. 
Journal of Bacteriology182, 5479-5485 (2000). 
203. Sassetti, C.M., Boyd, D.H. & Rubin, E.J. Genes required for mycobacterial growth defined by 
high density mutagenesis. Mol Microbiol48, 77-84 (2003). 
204. Sassetti, C.M. & Rubin, E.J. Genetic requirements for mycobacterial survival during infection. 
Proc Natl Acad Sci U S A100, 12989-94 (2003). 
205. Griffin, J.E. et al. High-resolution phenotypic profiling defines genes essential for 
mycobacterial growth and cholesterol catabolism. PLoS Pathog7, e1002251 (2011). 
106 
 
206. Zhang, Y.J. et al. Global assessment of genomic regions required for growth in 
Mycobacterium tuberculosis. PLoS Pathog8, e1002946 (2012). 
207. Sandgren, A. et al. Tuberculosis drug resistance mutation database. PLoS Med6, e2 (2009). 
208. Pym, A.S., Saint-Joanis, B. & Cole, S.T. Effect of katG mutations on the virulence of 
Mycobacterium tuberculosis and the implication for transmission in humans. Infect 
Immun70, 4955-60 (2002). 
209. Du, X. et al. Crystal structure and mechanism of catalysis of a pyrazinamidase from 
Pyrococcus horikoshii. Biochemistry40, 14166-72 (2001). 
210. Lemaitre, N., Callebaut, I., Frenois, F., Jarlier, V. & Sougakoff, W. Study of the structure-
activity relationships for the pyrazinamidase (PncA) from Mycobacterium tuberculosis. 
Biochem J353, 453-8 (2001). 
211. Fyfe, P.K., Rao, V.A., Zemla, A., Cameron, S. & Hunter, W.N. Specificity and mechanism of 
Acinetobacter baumanii nicotinamidase: implications for activation of the front-line 
tuberculosis drug pyrazinamide. Angew Chem Int Ed Engl48, 9176-9 (2009). 
212. Petrella, S. et al. Crystal structure of the pyrazinamidase of Mycobacterium tuberculosis: 
insights into natural and acquired resistance to pyrazinamide. PLoS One6, e15785 (2011). 
213. Quiliano, M. et al. Structure-Activity relationship in mutated pyrazinamidases from 
Mycobacterium tuberculosis. Bioinformation6, 335-9 (2011). 
214. Morlock, G.P. et al. Phenotypic Characterization of pncA Mutants of Mycobacterium 
tuberculosis. Antimicrobial Agents and Chemotherapy44, 2291-2295 (2000). 
215. Huang, T.S. et al. Correlation between Pyrazinamide Activity and pncA Mutations in 
Mycobacterium tuberculosis Isolates in Taiwan. Antimicrobial Agents and Chemotherapy47, 
3672-3673 (2003). 
216. Louw, G.E. et al. Frequency and implication of pyrazinamide resistance in managing 
previously treated tuberculosis patients. Int J Tuberc Lung Dis10, 802-807 (2006). 
217. Jureen, P., Werngren, J., Toro, J.C. & Hoffner, S. Pyrazinamide resistance and pncA gene 
mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother52, 1852-4 (2008). 
218. Mphahlele, M. et al. Pyrazinamide resistance among South African multidrug-resistant 
Mycobacterium tuberculosis isolates. J Clin Microbiol46, 3459-64 (2008). 
219. Zhang, H. et al. Mutations found in the pncA gene of Mycobacterium tuberculosis in clinical 
pyrazinamide-resistant isolates from a local region of China. Journal of International Medical 
Research37, 1430-1435 (2009). 
220. Gu, Y. et al. Pyrazinamide resistance among multidrug-resistant tuberculosis clinical isolates 
in a national referral center of China and its correlations with pncA, rpsA, and panD gene 
mutations. Diagn Microbiol Infect Dis84, 207-11 (2016). 
221. Sheen, P. et al. Effect of pyrazinamidase activity on pyrazinamide resistance in 
Mycobacterium tuberculosis. Tuberculosis (Edinb)89, 109-13 (2009). 
222. Simons, S.O., Mulder, A., van Ingen, J., Boeree, M.J. & van Soolingen, D. Role of rpsA gene 
sequencing in diagnosis of pyrazinamide resistance. J Clin Microbiol51, 382 (2013). 
223. Tan, Y. et al. Role of pncA and rpsA gene sequencing in detection of pyrazinamide resistance 
in Mycobacterium tuberculosis isolates from southern China. J Clin Microbiol52, 291-7 
(2014). 
224. Akhmetova, A. et al. Mutations in the pncA and rpsA genes among 77 Mycobacterium 
tuberculosis isolates in Kazakhstan. Int J Tuberc Lung Dis19, 179-184 (2015). 
225. Alexander, D.C. et al. Gene sequencing for routine verification of pyrazinamide resistance in 
Mycobacterium tuberculosis: a role for pncA but not rpsA. J Clin Microbiol50, 3726-8 (2012). 
226. Bhuju, S. et al. Mycobacterium tuberculosis isolates from Rio de Janeiro reveal unusually low 
correlation between pyrazinamide resistance and mutations in the pncA gene. Infect Genet 
Evol19, 1-6 (2013). 
107 
 
227. Feuerriegel, S., Koser, C.U., Richter, E. & Niemann, S. Mycobacterium canettii is intrinsically 
resistant to both pyrazinamide and pyrazinoic acid. J Antimicrob Chemother68, 1439-40 
(2013). 
228. Somoskovi, A. et al. Sequencing of the pncA gene in members of the Mycobacterium 
tuberculosis complex has important diagnostic applications: Identification of a species-
specific pncA mutation in "Mycobacterium canettii" and the reliable and rapid predictor of 
pyrazinamide resistance. J Clin Microbiol45, 595-9 (2007). 
229. Azad, A.K., Sirakova, T.D., Fernandes, N.D. & Kolattukudy, P.E. Gene knockout reveals a novel 
gene cluster for the synthesis of a class of cell wall lipids unique to pathogenic mycobacteria. 
J Biol Chem272, 16741-5 (1997). 
230. Azad, A.K., Sirakova, T.D., Rogers, L.M. & Kolattukudy, P.E. Targeted replacement of the 
mycocerosic acid synthase gene in Mycobacterium bovis BCG produces a mutant that lacks 
mycosides. Proc Natl Acad Sci U S A93, 4787-92 (1996). 
231. Camacho, L.R., Ensergueix, D., Perez, E., Gicquel, B. & Guilhot, C. Identification of a virulence 
gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis. 
Mol Microbiol34, 257-67 (1999). 
232. Cox, J.S., Chen, B., McNeil, M. & Jacobs, W.R., Jr. Complex lipid determines tissue-specific 
replication of Mycobacterium tuberculosis in mice. Nature402, 79-83 (1999). 
233. Ali, A. et al. Whole genome sequencing based characterization of extensively drug-resistant 
Mycobacterium tuberculosis isolates from Pakistan. PLoS One10, e0117771 (2015). 
234. Chernyaeva, E.N. et al. Genome-wide Mycobacterium tuberculosis variation (GMTV) 
database: a new tool for integrating sequence variations and epidemiology. BMC 
Genomics15, 308 (2014). 
235. Boshoff, H.I. & Mizrahi, V. Purification, Gene Cloning, Targeted Knockout, Overexpression 
and Biochemical characterization of the major pyrazinamidase from Mycobacterium 
smegmatis. Journal of Bacteriology180, 5809-5814 (1998). 
236. Guo, M., Sun, Z. & Zhang, Y. Mycobacterium smegmatis has 2 pyrazinamidase enzymes, PncA 
and PzaA. Journal of Bacteriology182, 3881-3884 (2000). 
237. Kim, S.J. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur 
Respir J25, 564-9 (2005). 
238. Chedore, P., Bertucci, L., Wolfe, J., Sharma, M. & Jamieson, F. Potential for erroneous results 
indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of 
Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol48, 300-1 (2010). 
239. Davies, A.P., Billington, O.J., McHugh, T.D., Mitchison, D.A. & Gillespie, S.H. Comparison of 
phenotypic and genotypic methods for pyrazinamide susceptibility testing with 
Mycobacterium tuberculosis. Journal of Clinical Microbiology38, 3686-3688 (2000). 
240. Middlebrook, G., Cohn, M.L., Dye, W.E., Russell, W.F., Jr. & Levy, D. Acta Tuberc. 
Scand.38(1960). 
241. Marx, J. (London, 1964). 
242. Stottmeier, D. & Atay, N. [Comparison of Culture and Biochemical Methods for the 
Differentiation of Mycobacterium Tuberculosis and Mycobacterium Bovis with Special 
Reference to Strains with High Isoniazid Resistance]. Beitr Klin Tuberk Spezif 
Tuberkuloseforsch128, 166-77 (1964). 
243. Tripathy, S.P., Mitchison, D.A., Nair, N.G., Radhakrishna, S. & Subbammal, S. A comparison of 
various measures of sensitivity of M. tubercolosis to pyrazinamide. Tubercle51, 375-88 
(1970). 
244. Tummon, R. Growth inhibition of Mycobacterium tuberculosis by oleate in acidified medium. 
Med Lab Technol32, 229-232 (1975). 
245. Butler, W.R. & Kilburn, J.O. Improved method for testing susceptibility of Mycobacterium 
tuberculosis to pyrazinamide. Journal of Clinical Microbiology16, 1106-1109 (1982). 
108 
 
246. Kubica, G.P. et al.Laboratory methods for clinical and public health : mycobacteriology, (U.S. 
Dept. of Health, Education, and Welfare, Public Health Service, Bureau of Disease Prevention 
and Environmental Control, National Communicable Disease Center ; For sale by the Supt. of 
Docs., U.S. G.P.O., Atlanta, Ga.; Washington, D.C., 1967). 
247. Heifets, L. & Sanchez, T. New agar medium for testing susceptibility of Mycobacterium 
tuberculosis to pyrazinamide. J Clin Microbiol38, 1498-501 (2000). 
248. Canetti, G. et al. Mycobacteria: Laboratory Methods for Testing Drug Sensitivity and 
Resistance. Bull World Health Organ29, 565-78 (1963). 
249. CLSI. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; 
Approved Standard – Second Edition. CLSI document M24-A2. Wayne, PA: Clinical and 
Laboratory Standards Institute (2003). 
250. WHO. Policy guidance on drug susceptibility testing (DST) of second-line antituberculosis 
drugs, (WHO ress, Geneva, Switzerland, 2008). 
251. Pfyffer, G.E., Palicova, F. & Rusch-Gerdes, S. Testing of susceptibility of Mycobacterium 
tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system. J Clin 
Microbiol40, 1670-4 (2002). 
252. Kontos, F. et al. Multicenter evaluation of the fully automated Bactec MGIT 960 system for 
susceptibility testing of Mycobacterium tuberculosis to pyrazinamide: comparison with the 
radiometric Bactec 460TB system. J Microbiol Methods55, 331-3 (2003). 
253. Piersimoni, C., Olivieri, A., Benacchio, L. & Scarparo, C. Current perspectives on drug 
susceptibility testing of Mycobacterium tuberculosis complex: the automated 
nonradiometric systems. J Clin Microbiol44, 20-8 (2006). 
254. Dormandy, J. et al. Discrepant results between pyrazinamide susceptibility testing by the 
reference BACTEC 460TB method and pncA DNA sequencing in patients infected with 
multidrug-resistant W-Beijing Mycobacterium tuberculosis strains. Chest131, 497-501 
(2007). 
255. Cunha, J. Pyrazinamide susceptibility testing in all isolates of the Mycobacterium 
tuberculosis complex - a critical analysis. Rev Port Pneumol18, 188-9 (2012). 
256. Simons, S.O. et al. Validation of pncA gene sequencing in combination with the 
mycobacterial growth indicator tube method to test susceptibility of Mycobacterium 
tuberculosis to pyrazinamide. J Clin Microbiol50, 428-34 (2012). 
257. Piersimoni, C. et al. Prevention of false resistance results obtained in testing the 
susceptibility of Mycobacterium tuberculosis to pyrazinamide with the Bactec MGIT 960 
system using a reduced inoculum. J Clin Microbiol51, 291-4 (2013). 
258. Scarparo, C., Ricordi, P., Ruggiero, G. & Piccoli, P. Evaluation of the fully automated BACTEC 
MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide, 
streptomycin, isoniazid, rifampin, and ethambutol and comparison with the radiometric 
BACTEC 460TB method. J Clin Microbiol42, 1109-14 (2004). 
259. Miller, M.A., Thibert, L., Desjardins, F., Siddiqi, S.H. & Dascal, A. Growth inhibition of 
Mycobacterium tuberculosis by polyoxyethylene stearate present in the BACTEC 
pyrazinamide susceptibility test. J Clin Microbiol34, 84-6 (1996). 
260. Sharma, B., Pal, N., Malhotra, B., Vyas, L. & Rishi, S. Comparison of MGIT 960 & 
pyrazinamidase activity assay for pyrazinamide susceptibility testing of Mycobacterium 
tuberculosis. Indian Journal of Medical Research132, 72-76 (2010). 
261. Werngren, J. et al. Reevaluation of the critical concentration for drug susceptibility testing of 
Mycobacterium tuberculosis against pyrazinamide using wild type MIC distributions and 
pncA gene sequencing. Antimicrob Agents Chemother56, 1253-7 (2012). 
262. Wayne, L.G. Simple pyrazinamidase and urease tests for routine identification of 
mycobacteria. Am Rev Respir Dis109, 147-51 (1974). 
263. Meinzen, C. et al. A quantitative adaptation of the Wayne test for pyrazinamide resistance. 
Tuberculosis (Edinb)99, 41-6 (2016). 
109 
 
264. Palomino, J.C. Nonconventional and new methods in the diagnosis of tuberculosis: feasibility 
and applicability in the field. Eur Respir J26, 339-50 (2005). 
265. Fredricks, B.A. et al. Rapid pyrazinamide susceptibility testing of Mycobacterium tuberculosis 
by flow cytometry. J Microbiol Methods67, 266-72 (2006). 
266. Campanerut, P.A. et al. Rapid detection of resistance to pyrazinamide in Mycobacterium 
tuberculosis using the resazurin microtitre assay. J Antimicrob Chemother66, 1044-6 (2011). 
267. Leite, C.Q., Beretta, A.L., Anno, I.S. & Telles, M.A. Standardization of broth microdilution 
method for Mycobacterium tuberculosis. Mem Inst Oswaldo Cruz95, 127-9 (2000). 
268. Zhou, M. et al. Rapid colorimetric testing for pyrazinamide susceptibility of M. tuberculosis 
by a PCR-based in-vitro synthesized pyrazinamidase method. PLoS One6, e27654 (2011). 
269. Li, H. et al. Rapid detection of Mycobacterium tuberculosis and pyrazinamide susceptibility 
related to pncA mutations in sputum specimens through an integrated gene-to-protein 
function approach Journal of Clinical Microbiology52, 260-267 (2014). 
270. Martin, A. et al. A new rapid and simple colorimetric method to detect pyrazinamide 
resistance in Mycobacterium tuberculosis using nicotinamide. J Antimicrob Chemother58, 
327-31 (2006). 
271. Mirabal, N.C. et al. Evaluation of colorimetric methods using nicotinamide for rapid 
detection of pyrazinamide resistance in Mycobacterium tuberculosis. J Clin Microbiol48, 
2729-33 (2010). 
272. Lawn, S.D. & Nicol, M.P. Xpert(R) MTB/RIF assay: development, evaluation and 
implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin 
resistance. Future Microbiol6, 1067-82 (2011). 
273. Banerjee, A. et al. inhA, a gene encoding a target for isoniazid and ethionamide in 
Mycobacterium tuberculosis. Science263, 227-30 (1994). 
274. Miesel, L., Rozwarski, D.A., Sacchettini, J.C. & Jacobs, W.R., Jr. Mechanisms for isoniazid 
action and resistance. Novartis Found Symp217, 209-20; discussion 220-1 (1998). 
275. Rozwarski, D.A., Grant, G.A., Barton, D.H., Jacobs, W.R., Jr. & Sacchettini, J.C. Modification of 
the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science279, 98-
102 (1998). 
276. Hillemann, D., Rusch-Gerdes, S. & Richter, E. Evaluation of the GenoType MTBDRplus assay 
for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and 
clinical specimens. J Clin Microbiol45, 2635-40 (2007). 
277. Anek-Vorapong, R. et al. Validation of the GenoType MTBDRplus assay for detection of MDR-
TB in a public health laboratory in Thailand. BMC Infect Dis10, 123 (2010). 
278. Yadav, R.N. et al. Comparative evaluation of GenoType MTBDRplus line probe assay with 
solid culture method in early diagnosis of multidrug resistant tuberculosis (MDR-TB) at a 
tertiary care centre in India. PLoS One8, e72036 (2013). 
279. Prabhu, S.S. et al. Rapid detection of pncA mutations in pyrazinamide-resistant 
Mycobacterium tuberculosis clinical isolates. European Journal of Applied Sciences1, 20-25 
(2009). 
280. Choi, J.H. et al. Clinical efficacy of direct DNA sequencing analysis on sputum specimens for 
early detection of drug-resistant Mycobacterium tuberculosis in a clinical setting. Chest137, 
393-400 (2010). 
281. Maningi, N.E. et al. Improved Detection by Next-Generation Sequencing of Pyrazinamide 
Resistance in Mycobacterium tuberculosis Isolates. J Clin Microbiol53, 3779-83 (2015). 
282. Martinez, E., Holmes, N., Jelfs, P. & Sintchenko, V. Genome sequencing reveals novel 
deletions associated with secondary resistance to pyrazinamide in MDR Mycobacterium 
tuberculosis. J Antimicrob Chemother (2015). 
283. Alexander, D.C. et al. Reply to "role of rpsA gene sequencing in diagnosis of pyrazinamide 
resistance". J Clin Microbiol51, 383 (2013). 
110 
 
284. Hickey, M.J. et al. Luciferase in vivo expression technology: use of recombinant 
mycobacterial reporter strains to evaluate antimycobacterial activity in mice. Antimicrob 
Agents Chemother40, 400-7 (1996). 
285. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. 
Bioinformatics25, 1754-60 (2009). 
286. Dartois, V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. 
Nat Rev Microbiol12, 159-67 (2014). 
287.        Vilcheze, C., Weinrick, B., Wong, K., Chen, B., and Jacobs Jr, W.R., NAD+auxotrophy is 
                bacteriocidal for the tubercle bacilli. Molecular Microbiology 76, 365-377 (2010). 
288.        Allen, W.S., Aronovic, S.M., Brancone, L.M., and Williams, J.H. Determination of the 
               Pyrazinamide content of Blood and Urine.Analytical Chemistry 25,895-897 (1953).  
 
